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RIASSUNTO: 
Lo studio della biologia molecolare comporta la dissezione dei sistemi biologici per 
individuare e isolare le singole molecole, delle quali si determinano le proprietà, 
cercando di dedurre dalla loro funzione e dalle loro caratteristiche il ruolo all’interno 
delle cellule. 
Una volta definita la funzione di una singola molecola, ad essa si affiancano reti di 
relazione interazione-struttura-funzione, al fine di descrivere le interconnessioni che 
caratterizzano un sistema biologico. 
E’ noto però che i sistemi biologici sono complessi e il loro funzionamento dipende, in 
massima parte, dalle interazioni multiple che i singoli componenti stabiliscono tra loro 
in un determinato momento e in un dato contesto. 
Dunque, questo approccio, definito di tipo riduzionistico, risulta essere poco utile in 
campi della biologia i cui fini ultimi consistono nella comprensione dell’evoluzione 
spaziale e temporale degli interattori molecolari. 
Da questa osservazione emerge la necessità di guardare al “mondo cellula” con un 
nuovo approccio che miri a studiare gli organismi viventi in quanto sistemi che si 
evolvono nel tempo, ossia nell’interazione dinamica della parti di cui sono composti. 
A tale necessità è chiamata a dare risposta una  nuova branca della Biologia, definita 
Biologia dei Sistemi. 
La Biologia dei sistemi parte dalla conoscenza dei geni e delle proteine presenti nel 
coso del tempo in un organismo e utilizza tecniche di trascrittomica, metabolomica e 
proteomica per valutare i cambiamenti dinamici derivati da una perturbazione del 
sistema stesso. Tale disciplina utilizza ampiamente gli approcci della teoria dei 
sistemi, della bioinformatica e della matematica-statistica con l’obiettivo di creare un 
modello sempre più completo del funzionamento dei sistemi biologici. 
Al contrario della biologia molecolare,che si focalizza sulle macromolecole 
biologiche, con particolare attenzione agli acidi nucleici e alle proteine, la Biologia dei 
Sistemi non si occupa del singolo meccanismo molecolare bensì delle interazioni 
dinamiche tra le varie molecole per formare nel corso del tempo un sistema. 
L’aspetto dinamico, e cioè la forte dipendenza dal tempo dei programmi di 
formazione di strutture e processi biologici, è l’aspetto che fortemente caratterizza la 
biologia dei sistemi rispetto al resto delle scienze “omiche”. 
La novità che ha consentito l’inizio e lo sviluppo della biologia dei sistemi è 
l’introduzione di tecnologie high-throughput che permettono di studiare 
contemporaneamente una enorme varietà di molecole (mRNA, proteine, lipidi, 
metaboliti) coinvolte nei processi biologici e integrare i dati provenienti da diversi 
esperimenti in una visione unitaria. 
Le caratteristiche che le tecnologie high-throughput devono possedere affinché 
possano essere integrate in un progetto di biologia dei sistemi sono: rapidità di 
esecuzione, simultaneità di esperimenti, elevato numero di dati derivanti 
dall’esperimento stesso. 
Queste caratteristiche sono proprie della tecnologia Laser-ChIP attualmente in 
sviluppo nell’ambito della linea di ricerca “sviluppo di una sorgente laser ultra-breve 
per lo studio delle modifiche epigenetiche”. 
L’obiettivo principale della linea di ricerca “sviluppo di una sorgente laser ultra-breve 
per lo studio delle modifiche epigenetiche” è consistito nella messa a punto e nella 
successiva creazione di una piattaforma sperimentale che, tramite l’utilizzazione di 
una sorgente laser, sia in grado di indurre reazioni di crosslink tra DNA e proteine 
all’interno di cellule vive per studiare l’evoluzione nel tempo e nello spazio tanto del 
macchinario trascrizionale, tanto del codice epigenetico. 
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La necessità di tale apparecchiatura e tecnologia origina dal fatto che il rapido 
sviluppo della ricerca applicata nel settore “Biologia dei Sistemi” ha attualmente 
raggiunto un livello critico dal punto di vista tecnologico, poiché i metodi chimici 
convenzionali per l’induzione di legami covalenti tra DNA e fattori trascrizionali come 
passaggi preliminari di esperimenti di immunoprecipitazione della cromatina (ChIP, 
NChIP e XChIP) presentano una serie di limitazioni tecniche intrinseche per quanto 
riguarda la selettività, la sensibilità, la precisione, l’efficienza, la dinamica delle 
interazioni, il mascheramento e la modifica di alcuni epitopi. 
Tale tecnologia Laser dunque si pone come valida alternativa ai suddetti metodi 
tradizionali poichè è in grado di indurre legami tra DNA e proteine in intervalli di 
tempo molto brevi e con efficienza di reazione abbastanza elevata. 
L’idea che anima tale progetto è l’osservazione, confermata sia da dati sperimentali 
che in evidenze presenti in letteratura, che una sorgente laser UV ultrabreve è in 
grado di eccitare gli stati elettronici delle basi azotate che compongono il DNA  e  dei 
residui laterali amminoacidici delle proteine che legano il DNA stesso. 
Una volta assorbita energia, il sistema DNA-proteina rilassa verso lo stato 
fondamentale tramite le formazione di un legame covalente (1-7). 
La creazione di tale legame, ottenuto mediante una metodica “foto-fisica”, apre un 
ventaglio di possibilità per quanto riguarda studi di interazione in “real time” e la 
decifrazione di rapidi “cross-talk”tra fattori trascrizionali, enhancer, modulatori 
epigenetici e DNA. 
La messa a punto della metodica Laser-ChIP ha previsto la definizione e la 
costruzione di una nuova sorgente laser, le cui caratteristiche meglio si coniugano 
alla tipologia di esperimenti high-through-put. In particolare la sorgente laser dedicata 
al progetto di ricerca produce impulsi di durata minore di 170 fs ad una lunghezza 
d’onda portante di 1030 nm con una eccellente qualità del fascio e una potenza 
media di 4 W nel range di frequenza di ripetizione di 50-350 kHz con una energia 
pari a ~0.7 mJ . Il sistema è dotato di cristalli generatori di armoniche che permettono 
di ottenere anche impulsi di circa 0.4 mJ a 515 nm, nel centro della banda visibile, e 
di circa 0.15 mJ a 260 nm, nell’UV. La durata degli impulsi nel verde e nell’UV si 
riduce a circa 120 fs. 
Tale sorgente laser è implementata di un sistema in grado di generare impulsi “ a 
doppio colore” nello spettro dell’UV e del visibile per ridurre la probabilità di indurre 
danni al DNA e in generale al sistema cellulare in analisi. Tramite l’utilizzo di tale 
dispositivo viene infatti ridotta la quantità di fotoni altamente energetici che viene 
fornita al sistema nel quale si vuole indurre il crosslink. 
La scelta di questo sistema laser impulsato è dettata dal fatto che ha caratteristiche 
di unicità tali da soddisfare i due requisiti essenziali per ottenere un crosslink DNA-
proteina in modo rapido, altamente efficiente e che comporti un ridotto danno al 
DNA: un alto rapporto energia/impulso (alta intensità) e  un’alta e variabile frequenza 
di ripetizione.   
Il primo passo per confermare la possibilità di indurre un crosslink tra DNA e proteine 
con una sorgente Laser ultrabreve e per determinare il quali condizioni operative tale 
induzione di crosslink è ottimizzata, è stato la creazione di una linea cellulare in 
grado di esprimere la proteina di fusione ERα-GFP. ERα è un fattore trascrizionale il 
cui legame a particolari regioni del DNA (ERE, Estrogen Responsive Element) causa 
l’attivazione trascrizionale dei geni responsivi all’estrogeno. La presenza della Green 
Fluorescence Protein (GFP) consente di poter seguire in tempo reale l’avvenuto 
crosslink in cellule vive per mezzo di misure di fluorescenza. L’utilizzazione di queste 
cellule e la successiva messa a punto del protocollo di purificazione della cromatina 
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ha consentito di eseguire un numero elevato di esperimenti in un intervallo di tempo 
molto breve e, dunque, ha consentito di ricavare alcune informazioni importanti 
riguardanti il modo in cui una radiazione luminosa (in particolare di tipo UV Laser) 
interagisce con le cellule, gettando le basi per la comprensione del meccanismo che 
sottende all’induzione del cross-link stesso. 
Nelle condizioni operative definite con questa tecnica sono stati effettuati esperimenti 
di immunoprecipitazione della cromatina (L-ChIP). 
I risultati ottenuti hanno mostrato l’effettiva presenza di crosslink e, in aggiunta, 
hanno evidenziato il differente comportamento che singole proteine e regioni geniche 
hanno rispetto all’induzione di legami stabili ottenuta mediante una sorgente UV 
Laser. 
Il primo vantaggio riscontrato dall’utilizzo della luce laser come induttore di crosslink 
è stato la progressiva diminuzione dei tempi di irraggiamento (che coincidono con i 
tempi di induzione dei legami stabili) che, al momento, sono di circa 1 minuto (contro 
i 15 minuti normalmente richiesti per l’induzione del crosslink ottenuta mediante 
trattamento delle cellule con formaldeide). 
Questa diminuzione del tempo richiesto per la formazione di legami covalenti, 
consente di poter studiare interazioni tra proteine e DNA di un ordine di grandezza 
più rapide, nonché la presenza e la variazione nel tempo di particolari modifiche 
epigenetiche reversibili a carico della proteine istoniche 
Inizialmente l’attenzione è stata focalizzata su tre distinte combinazioni di repetition 
rate e energia per impulso: 2kHz 125J, 200Hz 125J e 20kHz 8J. 
Dall’insieme dei dati ottenuti per queste 3 condizioni è emersa la necessità di 
studiare in modo approfondito l’effetto biologico che l’interazione tra luce UV e cellule 
viventi determina, in particolare considerando l’ induzione del danno al DNA (sia 
come formazione di dimeri di timidine, sia come double strand breaks), attivazione di 
pathways di rilevamento di danno e di induzione di morte, nonché l’attivazione di 
programmi pro-apoptotici (come l’induzione delle Caspasi e dei ROS). L’idea sottesa 
alla scelta di effettuare queste analisi addizionali è la possibilità che informazioni 
sulla presenza di fenomeni quali la morte cellulare e il danneggiamento (sia delle 
proteine che del DNA), possono fornire indicazioni per quanto riguarda la scelta di 
nuove combinazioni dei parametri operativi del Laser (nonché parametri strettamente 
biologici e tecnici) in grado di massimizzare la resa di crosslink. 
Da queste analisi è emerso che la quantità di fotoni rilasciata verso il sistema 
cellulare in vivo, benché in grado di indurre un crosslink tra istoni e regioni promotrici 
di diversi geni, eccede la dose richiesta in quanto il sistema cellulare stesso risulta 
danneggiato a seguito dell’irraggiamento. 
Per questo motivo sono state analizzate altre combinazioni di frequenze di ripetizione 
e energia per impulso, andando progressivamente a scalare la quantità di energia 
totale fornita alle cellule. 
Questo processo ha determinato la diminuzione sia delle percentuale di morte (e 
quindi di tutti i fenomeni cellulari e sub-cellulari che di essa sono la causa) sia una 
massimizzazione della quantità di crosslink ottenuta. 
Il miglioramento sostanziale è stato ottenuto cambiando le caratteristiche della 
radiazione UV incidente, passando da un valore di 260nm a 300nm. 
A 300nm i nucleotidi che compongono il DNA sono ancora in grado di assorbire 
energia, ma le timine non hanno il loro picco di assorbimento. 
Questo determina una riduzione in formazione di dimeri di pirimidina e anche di 
danni strutturali alla fibra di DNA; il DNA integro assicura la migliore riuscita di un 
esperimento di ChIP, in quanto, molti dei passaggi della tecnica di 
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immunoprecipitazione della cromatina, sono affetti proprio dalla stabilità e qualità del 
DNA. 
L’insieme dei dati mostrati e discussi in tesi suggeriscono che, come per ogni tecnica 
biologica condotta in vivo, per la definizione delle migliori condizioni in cui indurre un 
crosslink tra proteine e DNA molti parametri fisici e biologici devono essere tenuti in 
considerazione. 
Prima di tutto, un ruolo chiave assumono le caratteristiche della radiazione UV laser 
incidente, per le quali è importante andare a definire il miglior equilibrio tra repetition 
rate, energia/impulso ed energia totale. 
Anche alcuni accorgimenti strutturali possono influire sulla riuscita dell’esperimento di 
induzione del legame stabile e la ChIP a valle, tra cui la geometria dell’apparato 
Laser utilizzato, la velocità di agitazione del campione in cuvetta, il materiale di cui è 
composto la cuvetta stessa e la composizione delle soluzioni utilizzate in ChIP (in 
particolare prestando attenzione alla quantità di detergenti). 
L’aspetto più importante da considerare resta comunque il modo in cui il sistema 
biologico risponde all’interazione con la luce UV, mediante l’attivazione di 
meccanismi di rilevamento e riparo del danno, nonché mediante l’induzione dei 
fenomeni di morte cellulare. 
Al fine di creare legami stabili tra DNA e proteine, al sistema cellulare deve essere 
quindi fornita una quantità di energia sufficiente per promuovere l’attivazione 
elettronica delle basi del DNA e dei residui laterali della proteine, ma l’energia totale 
rilasciata non deve eccedere determinati valori per i quali i fenomeni distruttivi 
prevalgono su quelli culminanti con la creazione di legami covalenti. 
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SUMMARY: 
Establishing a stable covalent bond between proteins and nucleic acids, usually 
referred to as crosslinking is a powerful tool of molecular biology, which affords 
access to study otherwise transient interactions between bio-molecules. Crosslinking 
with fs- UV lasers has been presented in the literature as a revolutionary technique to 
increase the otherwise low process yield of conventional methods based on chemical 
catalysts, conventional UV sources, or longer UV pulses. It is known that crosslinking 
induced in cells by ultrashort laser pulses has a twofold advantage over conventional 
methods. (i) It binds only species that are in proximity (“zero length” covalent bond) of 
the absorbed photons rather than favoring unspecific bonds amongst many possible 
species in the cell. (ii) It should only operate until the radiation is incident on the 
sample, thus paving the way for time-resolved studies of transient interactions. 
Moreover, when combined with biochemical techniques such as Chromatin 
Immunoprecipitation (ChIP)  to analyze the produced bonds, the UV laser method will 
make feasible the characterization of the dynamics of the transcription factors 
bindings on chromatin in living cells, thus overcoming the technical limitations of the 
current technologies. The aim of this research project was to find the best operating 
condition for the induction of crosslink between DNA and proteins in living human 
cells mediated by an UV laser source, by the exploration of ultra short laser 
characteristics. Particular attention was focalized on the role of laser repetition rate 
and on the total energy parameter. To screen in a easy and rapid way the possible 
combinations of both parameters a cellular model was construct, in which the 
crosslink yield is analyzed as readout of  fluorescence signals. On the bases of so 
obtained informations, ChIP experiments were carried out against a specific 
epigenetic mark (Ch3K4H3) on different genetic promoter regions, coding for 
apoptosis involved protein (TRAIL), structural protein (H2B) and cellular trafficking 
involved one (SCAMP5). The response of human cells to UV laser radiation was also 
kept in consideration, looking at cellular mortality, cell phases distribution and DNA 
damages induction, in order to clarify the principles underpinning the crosslink 
induction processes. It was found that in some laser operating conditions, although 
the crosslink induction was still present, the DNA damages (and the consequent cell 
death) were too high to allow the ChIP experiment itself. Instead the conditions in 
which the cell viability was maximized, and so the apoptotic and pro-death cellular 
pathways minimized, fitted with effectively crosslinked experimental points (in terms 
of protein stability and DNA amplificability).   
The set of data displayed and discussed in the thesis, suggests that as each in vivo
technique, for the establishment of UV Laser mediated crosslink many physical and 
biological parameters need to be consider. 
First of all, the UV Laser light characteristics assume key role in the setting of ChIP 
experiments by the definition of the better balance between total energy and 
repetition rate. Also some structural features are important: among them the 
apparatus’s geometry used for the irradiation, the material of the cuvette, the size of 
Laser beam, the speed of stirring. The most important thing to consider, however, is 
still the cellular behavior in response to the UV incident radiation and the way by 
which the crosslink could be formed. 
To be sure that the creation of stable bonds between DNA and proteins is obtained, 
the cells must be hit with sufficient energy and the energy reaching the biological 
model  does not disrupt the proteins or DNA itself.
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THE EPIGENETIC 
Early advances in genetics led to the paradigm: phenotype (an organism 
characteristics/behaviour) is determined by genotype (its genetic make-up). This was 
later amended  by the well-known formula P = G + E, encompassing the notion that 
the visible characteristics of a living organism (the phenotype, P) is a combination of 
hereditary genetic factors (the genotype, G) and environmental factors (E). 
In the wake of early work by Waddington, more recent results have emphasized that 
the expression of the genotype can be altered without any change in the DNA 
sequence. This phenomenon has been tagged as “epigenetics”. 
Epigenetics has been defined as “the study of stable alterations in gene expression 
potentials that arises during development and cell proliferation” {Jaenisch, 2003 #1} , 
or as “alterations in DNA function without alterations in DNA sequence” {Jones, 2001 
#2}. The central idea behind the concept of epigenetics is that although the DNA 
sequence of almost all the nucleated somatic cells in the body of an adult mammal is 
identical (except some very specialized cells whose development requires DNA 
rearrangements), the phenotypes of those cells can be quite different because 
alternate subsets of genes are expressed at different times in development and 
during cellular differentiation. In other words, each cell type in an organism has its 
own epigenetic profile or signature {Morgan, 2005 #3}. 
So, in contrast to many of the other ‘omics’ — proteomics, transcriptomics, 
metabolomics and so forth — epigenomics does not simply enhance genome 
sciences, but instead challenges the concept of the linearity between genome and 
phenotype: while information within the genetic material is not changed, instructions 
for its assembly and interpretation may be.  
Modelling this new paradigm the equation is modified to P = G + E + EpiG. 
Therefore the development of tissues and organisms depends upon the acquisition of 
distinct programs for gene expression among individual cell types. These programs 
are maintained in a heritable state by epigenetic mechanisms that impart cellular 
memory. At the core of such gene regulation are mechanistic pathways that affect the 
packaging of DNA into chromatin, thereby regulating the degree of DNA accessibility 
to transcriptional complexes. Clearly, the regulation of the chromatin structure is a 
complex and dynamic process. It is modulated at several levels by distinct 
mechanisms such as DNA methylation, nucleosome remodeling, histone post-
translational modifications, incorporation of histone variants,  and non-coding RNA. 
Aberrations in such epigenetic mechanisms are likely to impact gene expression as 
well as other physiologically critical processes such as chromosome condensation, 
segregation, and apoptosis. 
Several lines of evidence indicate that tumorigenesis in humans is a multistep 
process in which a succession of genetic changes leads to the progressive 
conversion of normal cells. While genetic alterations can account for some of these 
changes, many of the alterations in gene expression observed in cancer are caused 
by epigenetic modifications. These observations highlight the relevance of epigenetic 
mechanisms toward the establishment of proper cellular function. 
Alteration of these mechanisms cooperates with genetic mutations and contributes to 
the establishment and progression of neoplastic diseases. 
Thereby epigenetics “provide a new paradigm for disease etiology and basic 
mechanisms in toxicology and evolution not previously appreciated. 
The classical theory of recessive oncogenesis predicted a mutational mechanism for 
the inactivation of tumor suppressor (TS) genes. This prediction has been amply 

confirmed, but an alternative, non-mutational, pathway for loss of TS gene activity 
has also come into focus. For some TS genes, this epigenetic pathway is more 
frequent than the mutational one” {Tycko, 2000 #4}.
Functionally, epigenetic marks act to regulate gene expression, silence the activity of 
transposable elements and stabilize adjustments of gene dosage, as seen in X 
inactivation and genomic imprinting . 
In addition, epigenetic features may play a role in short-term adaptation of species by 
allowing for reversible phenotype variability. The modification of epigenetic features 
associated with a region of DNA allows organisms, on a multigenerational time scale, 
to switch between phenotypes that express and repress that particular gene. 
Whereas the DNA sequence of the region is not mutated, this change is reversible. It 
has also been speculated that organisms may take advantage of differential mutation 
rates associated with epigenetic features to control the mutation rates of particular 
genes.  
From this argument seems evident that  “epigenetic approach, which in some ways is 
a Lamarckian approach can be more informative than a purely genetic approach”
{Jablonka, 1998 #5}. But comprehensively studying all the epigenetic and 
epigenomic factors related to a multitude of diseases and health conditions will take 
much more work.  
A comprehensive Human Epigenome Project is a lot more complicated than a 
Human Genome Project. There is only one genome, but an epigenome varies in 
each and every tissue. The rapidly growing acceptance of epigenetics, a century after 
it first surfaced, is a huge step forward, in Jirtle’s opinion. “We’ve done virtually 
nothing so far,” he says. “I’m biased, but the tip of the iceberg is genomics and 
single-nucleotide polymorphisms. The bottom of the iceberg is epigenetics.” {Yoo, 
2006 #6} 
EPIGENETIC REGULATION OF CHROMATIN STRUCTURE AND FUNCTION 
Chromatin is composed of  both DNA and histone proteins, HI, H2A, H2B, H3, and 
H4. The repeating unit of chromatin is the nucleosome, defined as two of each of the 
core histones, H2A, H2B, H3, and H4 wrapped almost twice by approximately 146 
base pairs of DNA (see figure 1 below). 
The nucleosome establishes the first level of chromatin organization. 
Nucleosomes themselves can be stacked and coiled to form higher order structures; 
one example of which is the 30 nm chromatin fiber. 
Necessarily, wrapping of DNA as nucleosomes and compaction into higher order 
structures (see Figure 1 below), inhibits DNA-dependent nuclear processes. 
Accessing DNA, which is structured as chromatin, is a major challenge for 
transcription, replication and repair in all cells. Several mechanisms have evolved to 
allow access including chromatin remodeling by ATP-dependent protein complexes 
and enzymes that modify histone N-terminal tails.  
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Fig 1: The repeating unit of the chromatin is the nucleosome, defined as two of each of the core  histones H2A, 
H2B, H3 and H4 wrapped almost twice b approximately 146 base pairs of DNA
The histone proteins are highly conserved, essential proteins found in every 
eukaryotic organism.  
The properties of these proteins are fundamental for the structure and function of 
chromatin overall. The core histones, H2A, H2B, H3, and H4 are low molecular 
weight (10-14 kDa) proteins {Johns, 1967 #7}. 
Histone H1, the linker histone, is slightly larger than the core histones (21 kDa) and is 
found at half the molar concentration of H2A, H2B, H3, and H4 {Hayashi, 1978 #8}.  
Extending from the central histone fold core domain of histones are the N-terminal 
tails . The crystal structure of the nucleosome lacks definition of the N-terminal tails 
outside of the nucleosome, leading to the conclusion that the tails are highly 
dynamic, exist in a random configuration and extend from the nucleosomal core 
{Luger, 1997 #10}. 
These tail domains contain a number of conserved amino acid residues including 
lysine, arginine, and serine. Histone tails, which sustain a basic charge, can interact 
with the poly-anionic backbone of the core DNA, marginally contributing to 
nucleosome stability. Therefore, regulation of chromatin structure and transcription is 
often mediated through post-translational modifications that alter specific residues 
along these tails. 
This post-translational protein modifications are acetylation, phosphorylation, 
ubiquitylation, methylation, and others, which  can affect the accessibility of nuclear 
factors to DNA or induce the recruitment of such factors involved in transcription or 
chromatin assembly pathways. 
Combinatorial patterns of these modifications are correlated with specific regulatory 
states and, as an informational mechanism for gene regulation, are called the 
"histone code" {Fischle, 2003 #11} {McGhee, 1980 #12}. 
DNA-histone octamer interactions occur through the neutralization of negatively 
charged backbone phosphate groups by direct interactions and water-mediated 
hydrogen bonds with lysines and arginines. Additionally, hydrophobic interactions 
occur between residues such as threonine, proline, valine, and isoleucine and the 
deoxyribose groups of DNA {Luger, 1997 #10}. The lack of specific interactions with 
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the nitrogenous base pairs corresponds with the lack of nucleotide-sequence 
specificity of histone-DNA interactions. 
This kind of interaction is extremely dynamic: DNA wrapped around a histone 
octamer can be blocked from interactions with proteins essential for transcription, 
replication and other nuclear processes. 
Exposure of regulatory elements within DNA can occur either by sliding of 
nucleosomes, to position these sequences within linker DNA, or by transitionally 
lifting the DNA molecule off the nucleosome. The first process is actively regulated by 
chromatin remodeling complexes, while the second process occurs passively in 
solution {Kassabov, 2003 #13}. 
Arguably, the most important function of chromatin may be repression and silencing 
of gene expression. 
While repressed genes may share some of the characteristics of continuously 
silenced chromatin, defined as heterochromatin, they retain the potential for active 
transcription and are placed in the subdivision of chromatin known as euchromatin. 
The term "silenced" is used here with regards to a maintained absence of 
transcriptional activity, and "repression" for short-term or active down-regulation of 
transcription.  
Silenced chromatin (versus repressed chromatin) can be further subdivided into 
constitutive, primarily at centromeric and telomeric regions, and facultative 
heterochromatin, such as the inactivated X-chromosome {Maison, 2002 #14} 
{Richards, 2002 #15}.  
Briefly, both types of heterochromatin are present within highly condensed and 
pericentric regions of chromosomes, often consisting of long stretches of repeated 
elements. They also share the properties of widespread histone hypoacetylation, and 
DNA methylation. Additionally, recent results support the participation of unique,  
noncoding siRNAs and dedicated enzymatic complexes in the silencing of both 
constitutive and facultative heterochromatin {Grewal, 2002 #16}. 
HISTONE ACETYLATION AND CHROMATIN REMODELLING 
The organization of eukaryotic chromatin has a major impact on all nuclear 
processes involving DNA substrates. Gene expression is affected by the positioning 
of individual nucleosomes relative to regulatory sequence elements, by the folding of 
the nucleosomal fiber into higher-order structures and by the compartmentalization of 
functional domains within the nucleus.  
Because site-specific acetylation of nucleosomal histones influences all three aspects 
of chromatin organization, it is central to the switch between permissive and 
repressive chromatin structure.  
Acetylation is a dynamic phenomenon with the steady state mediated by the 
opposing activities of two classes of enzymes: histone acetyltransferases (HATs) and 
deacetylases (HDACs) {Jenuwein, 2001 #17} {Richards, 2002 #18} {Rabinowicz, 
2003 #19 (see Figure 2). 
These activities involve large regulatory complexes that are capable of responding to 
specific DNA sequences and can contain transcription factors, regulatory ligands, 
and signal transduction and cell cycle proteins.  
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Fig 2: Acetylation is a dynamic phenomenon with the steady state mediated by the opposing activity of two 
classes of enzymes: histone acetyltransferase (HATs) and deacetylases (HDACs) 
Histone acetylation occurs at the -amino groups of evolutionally conserved lysine 
residues located at the NH2 termini of histones (see Figure 3). 
All core histones are acetylated in vivo, but acetylations of H3 and H4 have been 
more extensively characterized than those of H2A and H2B. 
HATs transfer acetyl moiety from acetyl CoA to the lysine residues; in the 
deacetylation reaction, HDACs catalyze the removal of acetyl groups from histones. 
Individual HATs and HDACs display distinct specificities in terms of the individual 
lysine residues and the particular histones they affect. 
Whatever it is widely accepted that histone acetylation is essential to establish a 
transcriptionally competent state of chromatin {Kadonaga, 1998 #20} {Strahl, 2000 
#21} {Tse, 1998 #22}.  
However, the relation between chromatin conformation and histone acetylation is 
complex and three different effects could be important {Hansen, 1998 #24} {Hansen, 
2002 #23}. 
First of all, acetylation might modulate interactions between histone tails and the 
DNA.  
Fig 3: Histone targets of acetylation  
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Non-acetylated histone tails carry a large number of positively charged lysine and 
arginine residues (<100 per nucleosome) that interact with the negatively charged 
phosphate groups of the DNA backbone {Allan, 1982 #25} {Fletcher, 1995 #26} 
{Hansen, 1998 #24} {Hansen, 2002 #23}. These electrostatic interactions are highly 
dependent on ion concentration {Usachenko, 1994 #28}.   
Moreover the histone tails could affect inter-nuclesomal association {Luger, 1998 
#29}. An interaction between the positive N-terminal H4 tail and a highly negative 
region on the exposed H2A-H2B surface has been identified in the crystal structure of 
the nucleosome {Luger, 1997 #10}. Again, acetylation of the corresponding lysine 
residues is likely to weaken this interaction. 
In  the end the effect of acetylation per se on nucleosome structure appears rather 
modest {Wang, 2000 #30}. However, specific acetylation patterns displayed by the 
histone tails may also function to recruit further modulators of chromatin structure. 
The dramatic changes in promoter structure that accompany transcriptional activation 
are, therefore, presumably not the direct result of acetylation, but due to the 
synergistic actions of several factors. These include other covalent modifications 
such as phosphorylation, as well as the rearrangement of histones/nucleosomes 
relative to the DNA by nucleosome remodeling factors (as the proteins of the 
SWI2/SNF2 family). No matter how the acetylation of core histone  allows the 
chromatin structure to transform from the resting closed conformation to an activated 
open form (see Figure 4, below). Thus, this allows binding of TATA box-binding 
protein (TBP), TBP-associated factors and, finally, RNA polymerase II, which initiates 
gene transcription. This molecular mechanism is probably common to all genes, 
including those involved in differentiation, proliferation and activation of cells {Lee, 
1998 #27} {Vettese-Dadey, 1996 #31}. 
Fig 4: The acetylation of core histone allows the cromathin structure to transform from the resting closed 
conformation to an activated open form 
From all exposed tell now it’s evident, anyway, the importance that acetylation keeps 
in the maintenance  of cellular homeostasis. Several lines of evidence indicate that 
tumorigenesis in humans is a multistep process in which a succession of genetic 
changes leads to the progressive conversion of normal cells. While genetic 
alterations can account for some of these changes, many of the alterations in gene 
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expression observed with cancer are caused by epigenetic modifications and, in 
particular, by un aberrant pathway of acetylation/deacetylation. Imbalance of histone 
acetylation/deacetylation in promoter regions contributes to the deregulation of gene 
expression and has been associated with carcinogenesis and cancer progression. 
HATs and HDACs  
Acetylation of histones is a reversible and dynamically regulated process controlled 
by a large family of enzymes termed histone acetyltransferases (HATs) and histone 
deacetylases (HDACs). 
Currently, there are four groups of proteins with intrinsic HAT activity. They are as 
follows: GCN5 and P/CAF, which are related to the yeast HAT; the cyclic adenosine 
monophosphate response element-binding protein (CBP) and p300, which act as co-
activators for a number of transcription factor complexes {Bannister, 1996 #32}; 
TAF250, a part of the basic transcription complex TFIID that binds with the TATA 
box; and finally SRC-1 and ACTR, which are coactivators for the ligand-activated 
nuclear receptors {Ogryzko, 1996 #33} {Mizzen, 1996 #34}.  
With mounting excitement, researchers soon showed that several other known 
transcriptional coactivators  possess HAT activity. These identifications directly linked 
the regulation of histone acetylation to the transcription machinery and provided a 
unifying model of transcriptional co-activators as histone-modifying enzymes. 
So the acetylation allows greater access to the DNA by the general transcription 
machinery, helping it to initiate transcription (see Figure 5 below). Interestingly, many 
of the HATs also contain bromodomains, which have acetyllysine binding activity 
{Dhalluin, 1999 #35}. Bromodomains bind acetylated lysines on the histones, thus 
allowing the HATs to further acetylate their targets, creating a positive feedback 
system to efficiently activate transcription {Yang, 2002 #52}. 
By its nature, reversible acetylation of a target implies that the acetyl group can also 
be removed. For every acetyltransferase that acetylates a substrate, there must be a 
deacetylase that does the reverse. Although prominent exceptions do exist, generally 
speaking, HDACs are anti-HATs: they are associated with transcription repression 
complexes and repressive chromatin states. 
Fig 5: Transcriptional repression vs transcriptional activation 
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There are two protein families with HDAC activity (see Figure 6 below): the recently 
discovered SIR2 family of NAD+-dependent HDACs (this family will not be subject of 
discussion in this thesis), and the classical HDAC family. Members of the classical 
HDAC family fall into two different phylogenetic classes, namely class I and class II. 
          
Fig 6: Schematic depiction of the different isoforms of HDAC. Bars depict the length of the protein. The catalytic 
domain is shown in blue. 
Class I HDACs are significantly smaller than class II HDACs and are predominantly 
nuclear proteins (see figure 7 below), although a recent report has indicated that 
HDACS may be cytosolic in smooth muscle cells {Waltregny, 2004 #78} {Waltregny, 
2004 #79}. Like some HATs, the class I HDACs generally function as part of protein 
complexes. The complexes include Sin3, NuRD, and CoREST {Heinzel, 1997 #36} 
{Humphrey, 2001 #37}. 
Class II HDACs are further divided into subclasses IIa and IIb. 
The class IIa HDACs consist of HDAC4, 5, 7, and 9 {Verdin, 2003 #38}. This 
subfamily of HDACs shares several unique properties. First, they all contain the N-
terminal non-catalytic MITR (MEF2-interacting transcription repressor) homology 
domain. This domain serves critical functions as both a protein-protein interaction 
domain and a regulatory domain subject to phosphorylation {Miska, 1999 #39} 
{Grozinger, 2000 #40}. Second, they are all critical regulators of MEF2, a family of 
transcription factors important in muscle differentiation and neuronal apoptosis. Third 
and most importantly, they are all regulated by phosphorylation dependent 
subcellular trafficking {McKinsey, 2000 #41}. All of the class IIa HDACs are subject to 
nuclear export via a nuclear export signal at the C-terminus  {Wang, 2001 #59} 
{McKinsey, 2001 #80}. The sub-cellular localization of these HDAC members is cell 
type-dependent and tightly regulated by specific signaling events. 
Class lIb deacetylases include HDAC6 and HDAC10. They are characterized by a 
tandem repeat of complete (HDAC6) or partial (HDAC10) catalytic domains 
{Grozinger, 1999 #43} {Guardiola, 2002 #42}. HDAC6 and HDAC10 are also unique 
in their resistance to select deacetylase inhibitors, such as trapoxin B, which can 
potently inhibit the deacetylase activity of both class I and IIa. 
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Fig 7: Schematic classification of HDACs
Despite the presence of some class-specific sequence motifs and the generally low 
homology between classes, HDACs crystal structures confirm a highly conserved 
active site and substrate-binding pocket.  
The conservation extends across classes I, II, and IV. 
The catalytic domain of HDAC is formed by a stretch of C390 amino acids consisting 
of a set of conserved amino acids. The active site consists of a gently curved tubular 
pocket with a wider bottom. Removal of an acetyl group occurs via a charge-relay 
system consisting of two adjacent histidine residues, two aspartic residues (located 
approx. 30 amino acids from the histidines and separated by approx. 6 amino acids), 
and one tyrosine residue (located approx. 123 amino acids downstream from the 
aspartic residues). An essential component of the charge-relay system is the 
presence of a Zn2+ ion. This atom is bound to the zinc binding site on the bottom of 
the pocket. 
So in the HDAC active site, a central motif of completely conserved residues 
coordinates a Zn ion and is complemented by a second group of highly conserved 
residues involved in the enzymatic reaction and substrate binding (see Figure 8). 
One of these residues, a Y, had been postulated to act as a transition-state stabilizer 
because of its position in various enzyme-inhibitor complexes.  
Although generally highly conserved, this residue is substituted by H in all vertebrate 
class IIa HDACs. Examination of the available structures showed that H, a 
conservative substitution of Y, should not be able to act as a transition-state 
stabilizer, thus compromising enzymatic activity according to the observation that 
class IIa HDAC presents a low catalytic efficiency in comparison to class I HDAC. 
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Fig 8: Sequence motif conservation (A) and active-site geometry (B)
To exert their function, HDACs need to be in the nucleus, where their predominant 
substrate is found. The nuclear localization of HDACs occurs via a nuclear 
localization signal (NLS) or via co-localization together with other proteins. Most 
HDACs contain a NLS, but some can be cytosolic as well (see Figure 7); this 
depends on other regulatory domains. Class I HDACs are found almost exclusively in 
the nucleus; 
class II HDACs are able to shuttle in and out of the nucleus in response to certain 
cellular signals. 
Extensive studies have shown that the change of the acetylation state of histone is 
correlated with dramatic biological consequences in the cell (see Figure 9 below). 
Disruption of HAT and HDAC function is 
associated with the development of cancer, 
and malignant cells target chromatin-
remodeling pathways as a means of disrupting 
transcriptional regulation {Mahlknecht, 2000 
#45}.  
Of the various hypotheses describing 
deregulation mechanisms, three have been put 
forth frequently:  
1) disordered hyperacetylation could activate 
promoters that are normally repressed, leading 
to inappropriate expression of proteins 
 2) abnormally decreased acetylation levels of 
promoter regions could repress the expression 
of genes necessary for a certain phenotype 
 3) mistargeted or aberrant recruitment of 
HAT/HDAC activity could act as a pathological 
trigger.  
Even though no direct alterations in HDAC 
genes have been demonstrated in cancer, the 
association of HDACs with various oncogenes 
and tumor suppressor genes is now well 
established, as is the potential for HDAC 
involvement in tumorigenesis {Kristeleit, 2004 
#46}. 
In acute promyelocytic leukaemia (APL), for 
Fig 9: Unbalance between HDAC  and HAT 
activity causes cancer disease (R.N SAHA et 
all., Cell death and differentiation 2006 Nature 
group editor) 
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example, the oncoprotein produced by the fusion of the PML (promyelocytic 
leukaemia) gene and the retinoic acid receptor α (RARα)  a gene appears to 
suppress the transcription of specific genes through the recruitment of HDACs. Thus 
the cancer cell is unable to undergo differentiation, leading to excessive proliferation. 
Similar phenomena have been described for RARα-PLZF (promyelocytic leukaemia 
zinc finger protein) fusion, AML1 (acute myelocytic leukaemia protein 1)-ETO fusion, 
and also in the Myc-Mad-Max signaling pathway involved in solid malignancies. 
It is clear that HDAC enzymes seldom operate alone. Many proteins, with various 
functions such as recruitment, co-repression or chromatin remodelling, are involved 
in forming a complex that results in the repressor complex. The most important signal 
involved in the initiation process of repression is situated in the DNA. Methyl groups 
bound to the cytosine residues situated 5’ to guanosines in DNA, in socalled CpG 
islands, are directly responsible for the recruitment of the HDAC complex via proteins 
such as methylated-CpG binding proteins and methyl-CpG-binding-domain-
containing proteins, or via the enzymes that methylate the CpG islands, the DNA 
methyltransferases. 
Given these insights into the function of HDAC enzymes, it is not surprising that 
HDAC inhibitors are emerging as promising clinical therapeutics for cancer.  
Indeed, HDAC inhibitors have been shown to result in the accumulation of 
hyperacetylated histones and to induce numerous anti-cancer effects including 
apoptosis, cytostasis, differentiation and inhibition of tumor angiogenesis in 
numerous cultured cell lines and in vivo. 
HISTONE METHYLATION 
Histone methylation is lagging behind acetylation in its characterisation, but is rapidly 
catching up {McBride, 2001 #47} {Zhang, 2001 #48}. In the past months, a number of 
methyltransferases have been discovered, proteins that read the methyl-lysine code 
have been identified, and a cross talk between methylation and phosphorylation has 
been recognised. The targeting of methyltransferases to specific promoters has been 
established as a crucial mode in their action and enzymes that either activate or 
repress transcription have been uncovered.
Histone methylation, perhaps more than any other form of modification, has 
demonstrated the power of modifications over DNA-based functions, regulating 
fundamental processes such as gene transcription and DNA repair. Furthermore, 
since the discovery of the first histone methyltransferase {Rea, 2000 #49}, the 
potential for the methylation ‘mark’ to control epigenetic events has caught the 
imagination of workers in this field. However, the recent discovery that methylation 
can be reversed {O'Carroll, 2000 #50}  has shaken the dogma that a ‘permanent’ 
methylation mark is necessary for epigenetic control.
Histones may be methylated on either lysine (K) or arginine (R) residues. It is 
possible that methylation induces alterations in chromatin architecture, either 
condensing or relaxing its structure. However, a methyl group is relatively small and 
its addition to lysine or arginine residues does not neutralize their charge, so it is 
unlikely that methylation alone will significantly affect chromatin structure. It is more 
likely that it creates binding sites for regulatory proteins that contain specialized 
binding domains. Lysine side chains may be mono-, di- or tri-methylated, whereas 
the arginine side chain may be mono-methylated or (symmetrically or asymmetrically) 
di-methylated. At present, there are 24 known sites of methylation on histones (17 
are lysine residues and 7 are arginine residues). If we take into consideration all 
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three possible methylation states of lysine and arginine, there are potentially 3* 
10^11 distinct methylation states of histone proteins. Although all of this 
combinatorial specificity may not be used, this calculation highlights the vast potential 
for the regulation of function, and the enormity of the task of understanding how 
methylation works. 
Lysine methyltransferase 
Methylation of lysines residues is known 
to occur on histone H3 (K4, K9 and K27) 
and H4 (K20). The SUV39 protein was 
the first histone methyltransferase to be 
discovered. The methyltransferase 
activity of SUV39 is directed against 
lysine 9 of histone H3 and its catalytic 
domain resides within a highly conserved 
structure, the SET domain. The 
sequences within the SET domain are 
not however sufficient for enzymatic 
activity. Methylation is only seen when 
two flanking cystein-rich sequences 
(PRE-SET and POST-SET) are fused    
to the SET domain. 
Fig 10: dendogram of SET domain containing proteins 
Figure 10 shows a dendogram of previously characterised human proteins that 
possess a SET domain, showing that they can be grouped into four classes. The 
classification is based on, first, the similarity between the human SET domains and, 
second, their relationship to SET domains in yeast (S. cerevisiae). Two groupings 
show similarity to either yeast SET1 or SET2, thus defining two of the classes (see 
Figure 10 above). Another class has SUV39 as its defining member and a fourth 
family represents homologues of the RIZ SET domain.
Arginine methyltransferase 
Methylation at arginines occurs within the tails of histone H3 (R2, R17, R26) and H4 
(R3). Arginines can be either mono-methylated or dimethylated on the guanidino 
nitrogen. Dimethylation can either be symmetric or asymmetric and enzymes are 
classified according to their ability to carry out one or the other reaction. There are 
five known arginine methyltransferases (Figure 11) that have a highly conserved 
catalytic domain. PRMT1, PRMT3 and PRMT4/CARM1 are classified as Class I 
enzymes as they can catalyse the formation of asymmetric dimethylated arginine 
whereas PRMT5/JBP1 is classified as a class II enzyme as it catalyses symmetric 
dimethylation. Remarkably there are very few recognisable domains outside the 
catalytic domains of these enzymes, unlike the case of lysine methyltransferases. 
The only features are a zinc finger structure in PRMT3 required to recognise RNA-
associated substrates and an SH3 domain in PRMT2 that suggests a signalling role 
for this enzyme. Presumably the regions outside the catalytic domain are likely to 
dictate substrate specificity. To date, PRMT1 has been shown to modify histone H4 
at Arg3 in vivo {Strahl, 2001 #58} {Wang, 2001 #59} whereas PRMT4/CARM1 has 
the potential to modify histone H3 at Arg2, Arg17, Arg26 and several unidentified 
carboxy-terminal residues in vitro {Chen, 1999 #60}. PRMT5 has a preference for 
H2A and H4 in vitro but the sites of methylation are as yet unknown. 
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Fig 11: Arginine methyltransferases 
Demethylation of lysines 
Until recently, the methylation of histones was thought to be an irreversible process. 
The dogma surrounding this irreversibility of methylated lysines within histones came 
about from several lines of research. First, reports from over 30 years ago concluded 
that methylated lysines have the same half-life as histones. Second, themore recent 
discovery that methylation at H3K9 is responsible for forming and maintaining 
heterochromatin (a very stable and heritable chromatin state) bolstered the argument 
that methylation of histones is a permanent ‘epigenetic’mark. Third, themere fact that 
a demethylating enzyme had not been discovered, althoughmanyworkers had 
searched for it, reinforced the view that methylation was a static process. This view 
had a chink in its armour from the very beginning: an enzyme with demethylase 
activity had been reported by Paik and Kim in 1973 {Paik, 1973 #61}, although this 
activity was never attributed to a particular protein. Indeed, the reversibility of 
methylation became apparent a few years ago when antibodies against methylated 
arginine or methylated lysine residues were used in chromatin immunoprecipitations. 
These experiments revealed that the methylation of histone residues appeared to be 
reduced under certain conditions. This prompted the idea that demethylation was a 
likely possibility, and a proposal was put forward which suggested that such an 
enzymatic activity would function through an amine oxidase reaction {Bannister, 2002 
#62}. Recently, the enzyme LSD1 (lysine-specific demethylase 1; also referred to as 
BHC110 or p110b) was identified, which is able to demethylate a specific lysine (K4) 
within histone H3 using an amine oxidase reaction. This enzyme had previously been 
identified in a number of repressor complexes {Hakimi, 2002 #63}, a fact that fits well 
with its ability to demethylate the activating methylation site at H3K4. However, 
demethylation by LSD1 is limited to mono- or di-methylated H3K4: it cannot 
demethylate tri-methylated H3K4. This is precisely as predicted for an amine oxidase 
reaction, yet it is the tri-methylated state that is most associated with active genes. 
Because the transcription of many genes is dynamic, enzymes capable of removing 
the tri-methylated state should exist. In addition, enzymes that mediate tri-
methylation, such as enhancer of zeste homolog 2 (EZH2), are implicated in cancer, 
so it is probable that the cell has enzymes to reverse this methylation and 
counterbalance this potentially dangerous methylation state. Demethylation of tri-
methylated lysine would require a distinct set of enzymes to the amine oxidases. 
Such enzymes will most probably function through a pathway involving a 
hydroxyradical attack. 
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Removal of arginine methylation 
The search for arginine demethylases over the last few years has been fruitless. 
However, the fact that lysine demethylases such as LSD1 exist, makes it much more 
likely that there is an arginine demethylase. The amino oxidase reaction, through 
which LSD1 works, is predicted to be compatible with the demethylation of 
methylarginines as well as methyl-lysines. However, an alternative pathway for the 
reversal of arginine methylation has been proposed and recently shown to be 
operational on histones in mammalian cells. This pathway involves the removal of a 
methyl group from an arginine by the conversion of the methyl-arginine residue into 
citrulline. This process is termed deimination, since the methyl group is removed 
along with the imine group of arginine. The enzyme that mediates this reaction, 
peptidyl arginine deiminase 4 (PADI4), converts unmodified arginine and mono-
methylated (but not di-methylated) arginine to citrulline at specific sites on the tail of 
H3 and H4. This activity of PADI4 is linked to the repression of an oestrogen-
controlled gene, pS2 {Bannister, 2005 #64}. 
THE APOPTOSIS PROGRAMM 
Cell death can be classified into two forms based on morphologic and biochemical 
criteria: necrosis and apoptosis. 
Necrosis is the non-physiologic or passive type of cell death that is usually caused by 
extreme trauma or injury to the cell; it generally affects cells in groups rather than 
single cells and evokes inflammation when it develops in vivo.  
Necrotic cells cannot maintain proper plasma membrane function so they can no 
longer regulate osmotic pressure. The cells swell and rupture, spilling their cellular 
contents into the surrounding tissue, resulting in the nonspecific cellular destruction 
that leads to an inflammatory response necessary to remove the debris and begin 
tissue repair.  
The other morphologic pattern of cell death is apoptosis which is a physiological 
process of cellular suicide required for the maintenance of cell homeostasis, 
embryonic development and for the differentiation and function of hematopoietic and 
lymphoid cells. 
Morphologically, apoptosis is characterized by margination and condensation of 
nuclear chromatin (pyknosis), cytoplasmic shrinkage, nuclear fragmentation, and 
blebbing of the plasma membrane. The cell subsequently breaks up into membrane 
enclosed fragments, termed apoptotic bodies, which are rapidly recognized and 
engulfed by neighboring cells or macrophages. Considerable biochemical changes 
occur within the apoptotic cell to facilitate neat packaging and removal of apoptotic 
bodies by phagocytosis. Modifications of the cytoskeleton and the cytoplasmic 
membranes are required for cell shrinkage to occur.
From a biochemical, intracellular, point of view several major signaling pathways may 
lead to apoptosis in mammalian cells {Orrenius, 2003 #66} {Orrenius,  #65} (see 
Figure 12 below). In the extrinsic, receptor-mediated pathway the ligation of surface 
receptors (e.g., CD95, TNFR1) is followed by the formation of the death-inducible 
signaling complex (DISC), resulting in the activation of procaspase-8. In type I cells, 
caspase-8 activates procaspase-3, which cleaves target proteins, leading to 
apoptosis. In type II cells, caspase-8 cleaves Bid, which, in turn, induces the 
translocation, oligomerization, and insertion of Bax and/or Bak into the mitochondrial 
outer membrane {Orrenius, 2003 #66}. This is followed by the release of several 
proteins from the mitochondrial intermembrane space, including cytochrome c, which 
forms a cytosolic apoptosome complex with Apaf-1 (apoptosis activating factor-1) 
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and procaspase-9 in the presence of dATP. This results in the activation of 
procaspase-9, which triggers the caspase cascade by activation of procaspase-3. In 
the intrinsic pathway, death signals act directly or indirectly on the mitochondria to 
cause the release of proapoptotic proteins from their intermembrane space. This cell 
death pathway is controlled by Bcl-2 family proteins (regulation of cytochrome c 
release), inhibitor of apoptosis proteins (IAPs) (inhibition of caspases), second 
mitochondrial activator of caspases (Smac), and Omi (negative regulation of IAPs). 
The intrinsic pathway may also operate via caspase-independent mechanisms, which 
involve the release from mitochondria and translocation to the nucleus of at least two 
proteins, apoptosis inducing factor (AIF) and endonuclease G (EndoG).  
Nuclear effects of AIF include chromatin condensation and formation of high–
molecularweight DNA fragments. The role of EndoG in cell death is still unclear. 
When DNA damage is the trigger of the apoptotic response, the initially activated 
caspase is procaspase-2. Its activation also leads to the release of cytochrome c and 
apoptosome formation, although the precise mechanisms for this are unclear. 
Fig 12: Major signaling pathways leading to apoptosis
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IONIZING RADIATION, DNA DAMAGE AND CELLULAR DEATH 
The genetic information required for the identity and function of eukaryotic cells 
resides within their DNA. During the lifetime of a cell, DNA can be continuously 
damaged from a variety of factors. As un-repaired or mis-repaired DNA damage can 
result in genetic or genomic instability, changes in cellular identity and function, cell 
death, and, in multi-cellular organisms, neoplastic transformation; eukaryotic cells 
have evolved efficient mechanisms to detect and repair DNA lesions induced within 
each phase of the cell cycle {Emanuel, 2007 #68}. 
Ionizing radiation produces a wide spectrum of DNA lesions, such as: base damage 
(pyrimidine dimmers formation), sugar damage, single strand breaks (SSB), double 
strand breaks (DSB), DNA-DNA and DNA-protein crosslinks. Both the spectrum of 
the induced lesions and their spatial distribution are affected by radiation quality. It is 
expected that densely ionizing radiation produces clustered ionizations with relative 
high efficiency. In addition to lesions correlated at very local scale (complex lesions), 
radiations quality may affect also the production of lesions correlated at larger 
distances. This is determinate by the interplay between the chromatin structure and 
the radiation track structure. 
Exposure of DNA to UV radiation has a mutagenic effect on cellular systems. 
Cyclobutane pyrimidine dimers (CPDs)1 and pyrimidine (6-4) pyrimidone 
photoproducts [(6-4)PDs] are the two major stable photoproducts in UV-irradiated 
DNA (Figure 13). Their yield is dependent on the sequence {Haseltine, 1980 #70} 
{Sage, 1993 #71} , the methylation status of cytosines {Brash, 1982 #72} {Pfeifer, 
1991 #73}, the DNA structure {Lyamichev, 1991 #74} {Tang, 1991 #75}, and the 
binding of sequence-specific proteins to DNA {Becker, 1984 #76} {Tornaletti, 1995 
#77}. In order for dimerization to occur, adjacent pyrimidine bases must rotate 
substantially from their average B-form DNA conformation. 
Fig 13: Photoproducts in UV-irradiated DNA 
In order to  understand how DNA lesions are repaired in eukaryotic cells, it is 
important to know how lesions are formed in chromatin and whether and how they 
affect chromatin structure. Some general principles are applicable:  
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(i)       Distortions of DNA structure introduced by folding into chromatin may 
affect damage formation.  
(ii)       DNA structure may be fixed by protein-DNA interactions and, hence, 
prevent the conformational changes that are required for damage 
formation.  
(iii)       Accessibility of DNA and, hence, DNA lesions is restricted on the 
chromatin surface by steric exclusion and, consequently, affects DNA-
damage formation by bulky reagents or damage recognition by proteins.  
(iv)       Dynamic properties of chromatin, such as dissociation/reassociation, 
nucleosome mobility, folding, and unfolding will affect DNA distortions and 
accessibility {Schieferstein, 1996 #69}. 
Keeping in mind that a strong relationship between dimers formation, chromatin 
structure and protein-DNA interaction  exists, two are the mainly cellular pathways to 
repair UV light induced dimers: the photoreactivation and nucleotide or base-excision 
repair pathways. 
In the photoreactivation process, the Pyr-Pyr dimers are restored back into individual 
pyrimidine bases in a reaction catalyzed by the enzyme DNA photolyase. The 
commonly accepted model for the photorepair mechanism proposes that the dimer 
splitting is a consequence of a single electron transfer from the enzyme to the dimer; 
a mechanism recently verified by quantum chemical calculations. 
Nucleotide excision pathway (NER) is the essential repair process for pyrimidine 
dimers adducts. 
There are two NER sub-pathways: global genomic NER repair (ggNER) and 
transcription-coupled repair (TCR), which differ mainly in the step of recognition of 
the DNA lesions. TCR preferentially repairs the transcribed strand or transcribed 
genes compared to the untranscribed strand or silenced genes. In other words, the 
transcribed strand or genes that are undergoing transcription exhibit a faster rate of 
repairing DNA damage than the untranscribed strand and the overall genome. RNA 
polymerase II plays a critical role in the recognition of DNA damage in the TCR 
pathway. 
The current TCR model proposes that RNA polymerase, stalled at a lesion point, 
directs the recruitment of repair enzymes to the transcribed strand of an active gene. 
This model assumes that RNA polymerase II must be removed from the lesion site of 
the transcribed strand to provide access for the repair complex, which initiates the 
repair process through unwinding the double helix at the damaged site, removal of 
the DNA terminus, and finally filling the gap and joining the DNA strands {An,  #67}. 
DNA damage triggers biochemical signals that activate, in addition to DNA repair, 
checkpoints responsible for delay in cell cycle progression that allows more time for 
DNA repair. If DNA damage cannot be repaired, checkpoints aim to induce 
permanent cell cycle arrest or cell death in the attempt to eliminate such severely 
damaged cells. Checkpoints at G1/S and S-phase prevent replication of damaged 
DNA and those at G2/M phase prevent segregation of damaged chromosomes. 
Component of this complex signaling pattern have been classified as sensors of DNA 
damage, signal transducers and effectors (Figure 14). 
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Fig 14: Components of signaling pathway involving in DNA damage recognition 
This pathway is based on protein phosphorilation cascade. 
Sensors scan chromatin for damage and translate it into biochemical signal that 
modulate the function of other proteins. Sensors include Rad1/Rad9/Hus1 complex, 
Rad27. Also ATM is close to the start of signaling pathway. 
Downstream of sensors, signal transmission is accomplished by transducers, such as 
Chk2,  p53, Brca1, Nbs1.  
P53 induces genes such as p21 which is an inhibitor of Cdk-containing complexes, 
essential for entry in S-phase, 
therefore inducing G1 arrest. Such 
a pause in cell cycling is welcome 
because it allows the cells enough 
time to repair the DNA damage 
inflicted by the mutagenic agent. 
This p53 also helps in the repair 
process directly by inducing the 
transcription of GADD45 (growth 
arrest and DNA damage), which 
encodes a protein involved in DNA 
repair. If during the pause in cell 
division the DNA damage cannot 
be successfully repaired, normal 
p53, induces apoptosis (Figure 15). 
Fig 15: p53 and UV mediated DNA damage 
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CHIP PROCEDURE
Elucidating mechanisms controlling nuclear processes requires an understanding of 
the nucleoprotein structure of genes at endogenous chromosomal loci. Traditional 
approaches to measuring protein-DNA interactions in vitro have often failed to 
provide insights into physiological mechanisms.  
Given that most transcription factors interact with simple DNA sequence motifs, 
which are abundantly distributed throughout a genome, it is essential to pinpoint the 
small subset of sites bound by factors in vivo.  
Signaling mechanisms induce the assembly and modulation of complex patterns of 
histone acetylation, methylation, phosphorylation, and ubiquitination, which are 
crucial determinants of chromatin accessibility and in general, the assembly of these 
patterns acts as prelude for transcriptional activations.  
These seemingly complex issues can be directly investigated by a powerful 
methodology termed the chromatin immunoprecipitation (ChIP) assay. 
ChIP assay is a method used for experiments in molecular biology. The purpose of 
this assay is to determine whether proteins including (but not limited to) transcription 
factors bind to a particular region on the endogenous chromatin of living cells or 
tissues and, in reverse ,to determine the genomic regions interact to specific proteins. 
The in vivo nature of this method is in contrast to other approaches traditionally 
employed to answer the same questions. 
The target proteins of ChIP are histones (in a modify or native state) and transcription 
factors because these are responsible of the normal cellular functionality, including 
many processes as DNA synthesis, repair and assembly of transcriptional machinery. 
The chromatin immunoprecipitation (see figure 16 below) is able to provide a spatial 
and related temporal image of the chromatin state in a cell and, in addiction, is able 
to determine in which way and in which position the transcriptional factors interact 
(directly or indirectly)  with DNA. 
The principle underpinning this assay is that DNA-bound proteins (including 
transcription factors) in living cells can be cross-linked to the chromatin where they 
are situated.  
This is usually accomplished by a gentle formaldehyde fixation or through the 
exposure of living cell to UV light lamps. The next paragraph will be dedicated  to the 
methods for the crosslink's induction. 
Following the crosslink’s induction, the cells are lysed and the DNA is broken into 
pieces 0.2-1 kb in length by sonication.  
Once the proteins are immobilized on the chromatin and the chromatin is fragmented, 
whole protein-DNA complexes can be immunoprecipitated using an antibody specific 
for the protein in question.  
The DNA from the isolated protein/DNA fraction can then be purified. The identity of 
the DNA fragments isolated in complex with the protein of interest can then be 
determined by PCR using primers specific for the DNA regions that the protein in 
question is hypothesized to bind. 
From the short explanation is clear the complexity of this method so it’s important 
evaluate step by step the ChIP protocol. 
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Fig 16: ChIP procedure 
After the crosslink’ s induction between amino acid residues of protein and nucleotide 
bases of DNA, the citoplasmatic membrane of the cells must be destroyed and the 
nuclei sonicated. 
Sonication is a rapid and straightforward way to shear the chromatin fragments and 
generate the smaller sized fragments desired. By controlling the sonication time and 
strength one can generate relatively uniform size populations and increase the 
resolution of the technique. 
The treatment of nuclei in suspension with inaudible ultrasound (greater than about 
18 kHz) results in  them disruption.  
Ultrasonication utilizes the rapid sinusoidal movement of a probe within the liquid. It is 
characterized by high frequency (18 kHz - 1 MHz), small displacements (less than 
about 50 m), moderate velocities (a few m s-1), steep transverse velocity gradients 
(up to 4,000 s-1) and very high acceleration (up to about 80,000 g). Ultrasonication 
produces cavitation phenomena when acoustic power inputs are sufficiently high to 
allow the multiple production of microbubbles at nucleation sites in the fluid. The 
bubbles grow during the rarefying phase of the sound wave, then are collapsed 
during the compression phase. On collapse, a violent shock wave passes through the 
medium. The whole process of gas bubble nucleation, growth and collapse due to 
the action of intense sound waves is called cavitation. The collapse of the bubbles 
converts sonic energy into mechanical energy in the form of shock waves equivalent 
to several thousand atmospheres (300 MPa) pressure. This energy imparts motions 
to nuclei which disintegrate when their kinetic energy content exceeds the membrane 
strength. 
Much of the energy absorbed by nuclei suspensions is converted to heat so effective 
cooling is essential during sonication procedure. 
In addiction it’s important keep in mind that the presence of detergent (SDS) in the 
sonication buffer improves sonication efficiency considerably, but can induce foaming 
during sonication.  
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Foam makes the chromatin sample unsuitable for ChIP, probably as a result of the 
surface tension imposed by the foam, which can disrupt protein conformation. 
Foaming can be prevented by decreasing the sonication power. 
Sonication is now used to disrupt the nuclear membranes and to fragment the cross-
linked chromatin fibers. It is crucial to generate the appropriate length of chromatin 
fragments as it can greatly affect the read-out one obtains at the end of the 
procedure. Just think, excessive sonication could render a useful chromatin lysate 
completely useless. A length of ~500bp-1000bp is generally accepted as optimal. 
Unfortunately, it is very difficult to standardize the number of sonications required 
from laboratory to laboratory. Therefore, the procedure must be optimized in the 
individual laboratories and should be carefully performed for each lysate. When the 
chromatin is extract from cells and fragmented, it is incubated with an antiboby 
against specific transcriptional factors or histones. 
Antibodies (Ab) are the most important factor for a successful ChIP experiment. In 
fact is possible detect only these proteins against which are commercially available 
Ab with high affinity and specificity and, in addiction, different antibody preparations 
have distinct properties, which can affect the ChIP results. The affinity for epitopes 
differs between antibodies, affecting the resulting signal levels. For example, 
antibodies can differ in their sensitivity towards crosslinks or adjacent modifications 
and the crosslink’s induction may cover up the epitope that the antibody is able to 
recognize on the protein linked to DNA resulting in a decrease in binding efficiency of 
the antibody when increasing the amount of crosslinked species. 
At the last DNA isolated from the precipitated chromatin has to be analyzed to 
determine which DNA fragments are present in the precipitate. For the detection of 
specific DNA fragments, various methods are available, and the chosen method 
determines to what extent the data can be analyzed quantitatively. Commonly used 
analysis methods are conventional PCR and quantitative PCR. Alternative methods 
are microarray analysis and slot blotting. 
Analyzing ChIP precipitates by quantitative real-time PCR (QPCR) has several 
advantages over conventional PCR. The QPCR technique does not quantify the 
amount of PCR product at the end of the PCR reaction, as with conventional PCR 
band densitometry. Instead, the initial amount of template DNA is calculated from the 
kinetics of the PCR reaction. During a QPCR run, the accumulation of PCR product is 
measured every cycle. The number of cycles needed to reach a certain amount of 
PCR product – 'Cycle threshold' or Ct value, and a calibration line, are used to 
calculate the initial amount of DNA template. 
Quantitative PCR analysis for ChIP can be performed using DNA-dye based or 
probe-based PCR product detection chemistries. The most widely used DNA-dye 
based QPCR chemistry employs the fluorescent dye SYBRgreen for detection of the 
amplicon. SYBRgreen is only fluorescent when bound to double-stranded DNA 
(dsDNA), and the amount of fluorescence is proportional to the amount of dsDNA. 
SYBRgreen detects a PCR product independent of its DNA sequence, so this 
chemistry can be used for all primer sets. 
In order to obtain high quality QPCR data, the primer sets used need to meet specific 
criteria. If primer sets are not optimized, this may result in amplification artifacts 
and/or an inaccurate quantification. 
The amplification efficiency can be improved considerably by designing the length of 
the amplified fragment between 80 and 500 bp. 
The ChIP and QPCR procedure consists of many steps that can influence the final 
results. Before the obtained data can be interpreted, the variation caused by all these 
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steps must be taken into account. The QPCR data have to be normalized for 
differences in the amount of input chromatin, precipitation efficiency and variation in 
the recovery of DNA after the ChIP.  
Importantly, normalization only serves to correct for this technical variation, it should 
not affect biological variation. 
These procedures to obtain the data’s normalization involve the constitution of 
internal control during the development of the ChIP experiment. 
The two internal controls are the so called INPUT and the so called NO ANTIBODY. 
With the term input we refer  to a part of sample which at the starting point is keep 
away from the rest and amplified with the same primers using in the ChIP. 
The input sample will be indicative for the presence and amount of chromatin used in 
the ChIP reaction so this DNA sample should yield a PCR product with all primer sets 
used (the input is so a positive control). 
The NoAb control is a chromatin sample to which nonspecific control serum is added 
instead of a specific antibody. The NoAb sample is treated the same way as the ChIP 
samples. The QPCR signals resulting from the NoAb samples indicate the amount of 
background signal generated by the chromatin preparations and ChIP procedure. 
Ideally, the washing steps remove non-specifically bound chromatin, resulting in an 
absence of QPCR signals for the NoAb samples. In reality however, it is not 
uncommon to find a PCR product for the NoAb control sample. 
The NoAb is useful for the background subtraction. 
With this method the background signals, as measured with the NoAb control, are 
subtracted from the signals obtained from the ChIP samples. It is assumed that by 
subtraction of the background signals only the true enrichment is shown. The major 
shortcoming of this method is the fact that the levels of background signal in the 
NoAb control samples may be different from those in the ChIP samples. 
Finally the chromatin immunoprecipitation  assay is important for understanding the 
molecular interactions’ s role, but like other in vivo techniques it presents benefits and 
disadvantages. 
Benefits:
• Good specificity 
• It’s a tool for the study of the mechanisms at the base of  neoplastic processes 
in vivo 
• Results with high scientific value 
Disadvantages:
• The antibody is the technique’s limiting condition
• The protocol is complex and hard-working 
• It’s more expensive 
THE CROSSLINK INDUCTION  
Protein–DNA interactions play a major role in molecular biology. They are involved 
not only in structural organization of the DNA within the cell nucleus, but also in DNA 
replication, DNA recombination and repair, as well as in gene regulation and 
transcription. Chemical and enzymatic methods have been developed to study 
protein–DNA interactions in vitro and, more recently, also in vivo by genomic 
footprinting . However, many protein–DNA interactions are not strong enough to be 
detectable with available techniques of genomic footprinting. Therefore, several 
methods have been used to stabilize these interactions, including chemical  and UV 
light  crosslinking.
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The UV light is able to excite the electronic state of  proteins and DNA which relax by 
means of the formation of a covalent bond. 
However, this reaction is relatively inefficient and the formation of a photo-induced 
product is strongly dependent on structural parameters such as the proximity of 
reactive amino acids and base. 
Not all amino acids and bases are equivalent with respect to this photo-induced 
reaction. So the amino acids more responsive to UV crosslink’s induction posses an 
aromatic ring  in its structure or, in general, many free electrons. 
Irradiation with UV creates covalent bindings between the reactive groups of DNA 
and amino acids such as thymine and cysteine, serine, methionine, lysine, arginine, 
histidine, tryptophan, phenylalanine or tyrosine. 
Usually the UV crosslink is obtained with UV lamps which can induce a stable bond 
between DNA and proteins in vitro but also in living cells. Irradiation of lining cells 
with UV light lamps of wavelength near 260 nm produce covalent bonds at contact 
points of nucleic acids and protein (mainly transcriptional factors and histones which 
are already tightly associated with DNA in the nucleus). The proximity in fact affects 
mainly the method’ s efficiency because UV light is a zero length crosslinker so 
theoretically, is able to induce the bond’s formation only between proteins and DNA’s 
bases which are jet close together. So the occurrence of a crosslink must depend on 
a combination of factors, including the inherent photoreactivity of the nucleotides that 
are joined, the correct distance and geometrical arrangement of the nucleotides and 
the molecular dynamics at the site of the crosslink. 
In addiction photo-crosslinking with low power UV lamps requires long exposures to 
obtain even low levels of crosslinking and could cause enough photo-damage to the 
DNA to cause redistribution of proteins. The most common change on DNA is 
represent by the  production of  pyrimidine dimers. The formation of pyrimidine 
dimers is associated with the excitation of the triplet state of the DNA base. 
For these reasons often the UV method is replaced to the chemical crosslink’s 
procedure that employs like bifunctional reagent the formaldehyde. 
Formaldehyde is the cross-linking agent of choice for the experiments on the 
chromatin’s structure. The reaction of formaldehyde with proteins has been 
extensively investigated, although the general picture is not yet clear since the nature 
of the reaction is dependent on the conditions employed. 
It is easy to handle, water-soluble, and active over a wide concentration range. Most 
importantly, it readily traverses biological membranes, allowing cross-linking to be 
performed on intact cells.  Formaldehyde crosslinks primary amino groups such as 
those on lysines and the bases adenine, guanine and cytosine forming methylene 
bridges. For its chemical quality the formaldehyde is able to induce the crosslink as 
between DNA and proteins, as between proteins and proteins. 
 Protein-protein and protein-DNA crosslinks are formed between groups within 
distances of approximately 2 Å.  These modifications are reversible: extended 
incubation at 65°C breaks the protein-DNA bonds whi le the protein-protein cross-
links can be reversed by boiling. 
The crosslink’s reaction is a duble-steps process the formation which involves the 
creation of a Schiff base because of the interaction of the immino and amino groups 
on the proteins whit the formaldehyde (figure 17 below). 
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Fig 17: The crosslink’s reaction with formaldehyde is a double-step process
In the second step, this activated compound is able to connect another amino group 
forming a stable bridge. Interestingly because formaldehyde efficiently produces 
protein-nucleic acid as well as protein-protein crosslinks,  this method can, in 
principle, be utilized to detect proteins that bind DNA directly as well as those that 
bind DNA through other factors. This feature is at the same time , the great 
advantage and disadvantage of formaldehyde crosslink’s induction. 
In fact in ChIP experiments it’ s important that are able to link the DNA much 
transcriptional factors as possible, but at the same time it’s fundamental that positive 
falses are minus as possible. Inducing protein-protein bonds formaldehyde is able to 
connect large transcriptional multicomplex to related DNA regions but in this complex 
it might include phisiological extrain proteins. 
However, because chemical crosslinking usually changes protein charge, creates 
protein–protein crosslinks and is a multi-step process that produces chemical bridges 
of significant length, perturbations in structure can result. 
In conclusion the chemical methods, however, disturb the equilibrium within the cell 
due to the general reactivity of the chemical agents and UV light generates heat, 
which can also perturb the interactions under study. Furthermore, both methods are 
slow, requiring times in the range of minutes. Therefore, they are not suitable for the 
study of rapid binding kinetics. In fact the proteins-DNA interactions are dynamic in 
vivo and their study needs to the rapid freezing of the interaction at a particular step 
during the assembly of the complex. To meet this requirement it’s under investigation 
the development of a new tool that induces UV light crossilink mediated by UV laser 
pulsed system. 
UV LASER CROSSLINK 
Biomolecules never function in isolation. In living systems, proteins, nucleic acids, 
carbohydrates, lipids, and metabolites crowd together. Specific interactions occurring 
within this melange are the basis of biological function and regulation. 
Ideally, the scientist could peer inside the cell and observe interactions in their native 
setting. Since nonperturbing nanoscopic vision does not (yet) exist, alternative 
approaches are needed. Historically, biochemists often employed a reductionist 
strategy: remove a molecule from the cellular milieu and study its behavior in a test 
tube environment of defined composition. More recently, methods have been 
	

	
developed to probe the cellular environment surrounding a specific biological 
molecule. In particular, for the study of the transcription factors-DNA complexes 
many methods are now available. 
These techniques such as immunoprecipitation of native nucleoprotein complexes 
attempt to ‘capture’ the native proteins bound to specific sequences. These methods 
have the potential to give artificial results, because the proteins are non-covalently 
bound to DNA and are subject to redistribution during chemical treatment, isolation or 
immunoprecipitation of the DNA–protein complex. 
So, these types of experiments generally disrupt the highly organized cellular context. 
Such a deconstructionist approach can lead to false positive results, where 
molecules appear to interact with partners they would not normally encounter, and to 
false negative results, when low-affinity interactions fail to survive disruptive washing 
steps. This kind of problem can be overcome by chemical or UV-light induced 
crosslinking to ‘freeze’ DNA–protein interactions. Chemical crosslinking with 
formaldehyde has been extensively used to prepare samples for electron 
microscopy, and study the distributions of histones and other proteins along DNA. 
However, because chemical crosslinking usually changes protein charge, creates 
protein–protein crosslinks and is a multi-step process that produces chemical bridges 
of significant length, perturbations in structure can result. Also, because chemical 
crosslinking is slow it cannot be used for kinetic studies and might trap unlikely 
interactions. 
However photochemical crosslinking of proteins to the nucleic acids has been applied 
to study a variety of nucleic acid binding proteins. Irradiation with UV light of 
wavelength near 260 nm produces a ‘zero length’ covalent bond between contact 
points of nucleic acid and protein and it occurs in the time scale of  seconds. 
Therefore, it is believed to produce less perturbation to structure than chemical 
crosslinking. In addition, 266 nm laser light could reduce the production of  protein–
protein crosslinks. Photo-crosslinking with low power UV lamps requires long 
exposures to obtain even low levels of crosslinking and could cause enough-photo 
damage to the DNA to cause redistribution of proteins. 
Some of these problems can be avoided using high powered UV lasers (for the Laser 
theory principles, look at the next paragraph), which achieve high efficiency of 
crosslinking, sometimes in a single pulse. 
So crosslinking by short pulsed UV lasers is a potentially powerful tool to investigate 
such DNA–protein interactions, especially transient interactions and binding kinetics, 
because the number of photons required for covalent complex formation can be 
delivered very rapidly, in nano-, pico- or even femtosecond intervals, and the high 
energy of the pulses should result in efficient crosslinking. 
The mechanism leading to UV laser crosslinking induces the excitement of the 
electronic state of the biomolecules which culminates with the creation of a stable 
bound between them. 
This mechanism can be understood as a two photon process. In particular, regard to 
the DNA-proteins interaction we can observe the excitement, indifferently, of the DNA 
bases or of the aminoacid side chains. This occurs because both posses a delocalize 
electronic system which can be excited with  a radiation of suitable wavelength. 
Cleary the aminoacid side chains which preferentially undergo to the photo-laser 
induction are the aromatic ones (mainly tyrosine, phenylalanine and tryptophane). 
If we are watching to DNA (but the same is valid for a protein system) there are two 
possibilities for a two photon transition which leads to crosslinking (see Figure 18 
below). 
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Fig 18: Crosslink induction mediated by UV laser: energy diagram 
In both cases the first photon excites the S0–S1 transition. From the S1 state a 
second photon can directly promote the excited DNA base to the high singlet level 
SN, which causes crosslinking. As there is a certain probability for intersystem 
crossing (typical intersystem crossing rates are k isc = 10^9/s), a fraction of the 
excited molecules will relax to the first excited triplet state T1. From T1 a second 
photon can lead to excitation of high triplet states TN, which can also cause 
crosslinking. The ratio m(S1/T1)  between excitation via the singlet or triplet path 
depends on the pulse length of the exciting laser, the effective lifetime of the excited 
singlet state S1 and the intersystem crossing rate.
In practice only very few crosslink events are due to the excitation via two photons at 
the singlet state. In fact, the critical parameter in UV laser crosslinking of proteins to 
DNA is not the total amount of energy but a combination of intensity and pulse 
length. Pulse length determines which path is used to initiate crosslinking. Although 
the singlet path is more efficient, it is difficult to achieve singlet excitation because of 
the very short effective lifetime in the singlet state S1.  
Pulses with a pulse length well below the effective lifetime of S1 should lead to pure 
singlet-mediated DNA–protein crosslinking. 
The triplet state T1 is more stable of the S1 state and its longest lifetime increases 
the possibility that a second photon is able to excite the transition to Tn state. 
The Tn state (like also Sn state) possess enough energy for the crosslink’ s 
induction. So, if we know the lifetime of the two transition state S1 and T1 which is 
fixed because is dependent to the chemical species in exam, the crosslink’s yield 
depends on the intensity and length of the applied UV laser pulses. 
By changing the pulse length the path leading to crosslinking can be chosen. For a 
pulse length shorter than the intersystem crossing rate constant, singlet-mediated 
crosslinking dominates, whereas pulses which are long compared with the 
intersystem crossing rate constant lead to crosslinking via the triplet channel. 
One problem with UV laser crosslinking is the difficulty of comparing results obtained 
with different proteins and different DNA sequences. This is due to differences in the 
nature and strength of the interaction and to the involvement of different amino acid 
side chains and DNA bases. In some cases water molecules mediate the contacts 
between amino acids and DNA bases. 
In addiction the great capability of UV laser crosslink is the possibility, that it offers, to 
study the molecular interactions in vivo. 
So at the UV laser pulsed systems are submit living cells or nuclei. 
However, there could be fundamental differences between the results of crosslinking 
in cells or nuclei compared to crosslinking isolated nucleoproteins, as done in most 
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studies. First, suspensions of cells or nuclei scatter significant amounts of the 
incident light, reducing the intensity of the light within the samples. Second, the local 
concentration of DNA in nuclei is very high, leading to an internal filtering effect that 
could also decrease the effective intensity of the light. Third, the high local 
concentration of DNA in nuclei might trap free radicals that could increase 
photochemical degradation of the DNA and proteins. 
LASER THEORY 
A laser is an electronic-optical device that emits temporally and spatially coherent, 
nearly monochromatic light radiation. The term "laser" is an acronym for Light 
Amplification by Stimulated Emission of Radiation. 
From its name it’s clear that the stimulated emission’s rule is fundamental for its 
functionality. Before coming to the stimulated emission phenomenon it’s worth 
recalling a few basic principles of quantum physics. The atomic populations of any 
system at equilibrium in nature, without an external source of energy, stabilize to 
values predicted by the Boltzmann’s distribution. This distribution predicts an 
exponential drop in atomic population with increasing energy. Let’s recall a central 
concept of quantum mechanics: atomic energies are confined to certain allowed, 
discrete values. By applying the Boltzmann’s law, we may predict the population of 
atoms for each discrete energy state.  So, if the temperature of the entire system was 
raised, the atomic distribution would shift towards higher energies. However, the 
population of a lower energy level will always exceed that of a higher level. 
The energy difference between the upper and lower energy states of any radiative 
transition is manifested as the photon energy and, hence, the wavelength of the 
emitted (decay to the lower level) or the absorbed (jump to the higher level) light. 
Normally, emission of light is mainly the result of a spontaneous decay from excited 
to low-lying energy states until the ground state of the system is reached. During 
such a decay process the exceeding energy of the system is emitted as light in the 
so-called SPONTANEOUS EMISSION (see Figure 19).  
Fig 19: Spontaneous emission
Another mechanism, known as STIMULATED EMISSION also takes place; this is not 
dominant over the spontaneous emission until the atomic population of the ground 
state excides the population of any excited state. Stimulated emission occurs when 
an external radiation source, having a wavelength resonating with that of photon 
associated to an atomic transition, finds an atom in the excited state. Then, there is a 
finite probability for the external radiation field to induce a transition to the atomic 
ground state while a photon is emitted, identical to the incident radiation photons in 
energy and direction, for energy and momentum conservation. The fact that these 
two photons are identical makes the radiation emitted by stimulated emission 
coherent and monochromatic, two key properties of laser light. Additionally, the fact 
		
that the two photons are emitted in the same direction will play a role—along with a 
well-aligned cavity—in making the light collimated, another key property of laser light. 
In essence, the original photon is amplified by this process; this is the reason for 
which it is called stimulated emission (see Figure 20). 
Fig 20: Stimulated emission 
Let us now consider a situation where energy is injected into a system at thermal 
equilibrium to cause a population of atoms at a higher energy level to be larger than 
that of a lower level (PUMPING). Such a non-equilibrium condition is, indeed, 
required for lasing action in almost all lasers. Energy may be injected selectively to 
pump an upper energy level from which transitions occur to a lower level. 
Pumping may be realized in several ways, including electrical, thermal, optical, 
chemical, or nuclear. Lasers often utilize electrical or optical pumping. In the latter 
case, when the medium where lasing action takes place (ACTIVE MEDIUM) is a solid 
material, light from a flash-lamp or an arc-lamp is focused onto a rod containing the 
lasing atoms.  
Commonly used solid state laser active media include ruby (chromium ions in an 
aluminum oxide host glass) and YAG (neodymium ions in an yttrium–aluminum–
garnet host glass). 
The lasing atoms absorb photons of incident pump light and become excited to upper 
energy levels. 
Regardless of the method, the end goal of pumping is to excite high-energy states 
within the lasing medium so that the population of atoms at a high-energy state is 
greater than the population of atoms at a low-energy state for the lasing transition. 
This population inversion is a pre-requisite for the laser action to occur: if it is not 
maintained, atoms will absorb rather than emit photons and the light intensity will 
decrease rather than being amplified while traveling through a medium.  
THREE AND FOUR LEVELS LASER 
Lasers are classed by the number of energy levels involved in the actual lasing 
process as three- or four-level lasers. In a three-level system (see Figure 21 below), 
energy injected into the gain medium excites atoms to a pump level above the upper 
lasing level.  
From there atoms very quickly decay to the upper lasing level, with no radiation 
emission (non-radiative transition). This upper level has a lifetime sufficiently long so 
as to ensure population inversion. The lasing transition now occurs between the 
upper level and the ground state, which plays the role of lower level in the lasing 
transition, with consequent laser light emission in the process.  
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Fig 21: Three levels laser system
An improvement of this scheme is obtained with a four-level structure, where the 
laser transition takes place between the third and second excited states on the 
energy axis (see Figure 22). Decay of the lower laser level must be much more rapid 
than the lasing transition to ensure a good population inversion and, consequently, 
an efficient lasing  action. 
In fact, in a four-level system, laser gain is realized as soon as pumping is applied to 
the system. Pump energy is injected into the pump level, which decays, in most 
cases, almost instantaneously to the upper lasing level. The active medium is such 
that the upper level has a longer lifetime than the lower one, therefore a population 
inversion occurs almost immediately after pump energy is injected. For the above 
reason four-level systems are more efficient than three level ones, and by far the 
most commonly used. 
LASER COMPONENTS 
A laser source is an optical cavity, constituted by an active medium between two 
mirrors, pumped by an external energy source (see the Figure 23 below).  
This pump source can be a flash-lamp or an electrical power supply, or chemical 
reaction or another laser, depending on the specific system in use. 
The pumping energy is directed into the gain medium, namely the material which 
gives different lasers their individual characteristics. There are many different 
materials used as active/gain media including crystalline solids usually doped with 
transition metal or rare earth ions, gases such as CO2 or He and Ne, semiconductors 
such as gallium arsenide and liquids dyes. 
Fig 22:  Four levels laser system 
	
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                         Fig 23: Laser components

When energy is pumped into the gain medium it causes population inversion and the 
release of a great number of photons via stimulated emission. A pair of mirrors are 
placed at the front and back of the gain medium, respectively, to constitute a closed 
optical cavity.  
                                                                 Fig 24: Light amplification in laser active medium 
One of the two mirrors is fully reflective (HR), whereas the other one is only partially 
reflective (output coupler). Photons emitted due to stimulated emission  pass through 
the medium many times getting more and more (light amplification) until they pass 
through the output coupler and escape from the laser cavity to form the output laser 
beam (see Figure 24). 
                                                    Aim of the thesis
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AIM OF THE THESIS 
The study of molecular biology involves the dissection of biological systems to 
identify and isolate individual molecules, determine their characteristics by which to 
understand what is their role and function inside the cells. Once defined  the function 
of a single molecule, it is joined by networks of interaction-structure-function, in order 
to describe the interconnections that characterize a biological system. 
But it is known that biological systems are complex and their function depends, 
mostly, from the multiple interactions that determine the individual components 
together in a given time and in a given context. Therefore, this approach, called 
reductionist, turns out to be very useful in fields of biology whose ultimate goals are 
to understand the spatial and temporal evolution of molecular interactors.  
From this observation emerges the need to look at the "cellular world" with a new 
approach that aims to study living organisms as systems that evolve over time, ie 
dynamic interaction of parts in its composition. In this need is called to answer a new 
branch of biology, called Systems Biology.   
Systems biology begins with the knowledge of genes and proteins present in the time 
thing in an organism, and uses techniques of transcriptomics, metabolomics and 
proteomics to assess the dynamic changes resulting from a perturbation of the 
system itself. This discipline makes extensive use of the approaches of systems 
theory, bioinformatics and mathematics-statistics with the aim of creating a more 
complete model of the functioning of biological systems. Instead of molecular biology, 
which focuses on biological macromolecules, with particular attention to the nucleic 
acids and proteins, systems biology is not concerned with the individual but the 
molecular mechanism of the dynamic interactions between different molecules to 
form a system over time . The dynamic aspect, namely the strong dependence on 
the time of the training programs of biological structures and processes, is the aspect 
that strongly characterizes the systems biology science than the rest of the "omics".  
The innovation that has enabled the birth and development of systems biology is the 
introduction of high-throughput technologies that allow us to study simultaneously a 
wide variety of molecules (mRNA, proteins, lipids, metabolites) involved in biological 
processes and integrate data from different experiments in a unified vision. The 
features that must have high-throughput technologies that can be integrated into a 
systems biology project are: speed of execution, simultaneous experiments, large 
amount of data resulting from the experiment itself. These characteristics are 
inherent in ChIP-laser technology currently under investigation in the research line 
"development of an ultra-short laser source for the study of epigenetic modifications 
on chromatin. The main objective of the research line "development of an ultra-short 
laser source for the study of epigenetic modifications on chromatin" consists in the 
development and subsequent creation of an experimental platform that, through the 
use of a laser source, both in able to induce cross-link reactions between DNA and 
proteins within living cells to study the evolution in time and space of both the 
transcriptional machinery, much of the epigenetic code.  
The need for such equipment and technology arises from the fact that the rapid 
development of applied research in the field of "Systems Biology" has now reached a 
critical level in terms of technology, as conventional chemical methods for the 
induction of covalent bonds between DNA and transcriptional factors as steps 
preliminary experiments of chromatin immunoprecipitation have a number of inherent 
technical limitations with regard to selectivity, sensitivity, precision, efficiency, 
dynamic interactions, masking and modification of certain epitopes.  
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This laser technology, therefore, is a valid alternative to these traditional methods as 
it is able to induce links between DNA and proteins in very short intervals of time and 
with  high efficiency of reaction. The idea that drives this project is the observation, is 
confirmed by experimental data that evidence in the literature, that an ultrashort UV 
laser can excite the electronic states of nitrogenous bases composing the DNA and 
amino acid side residues of proteins that bind DNA itself.  
Once absorbed energy, the system DNA-protein relaxes to the ground state via the 
formation of a covalent bond. The creation of this link, obtained by a method "foto-
physic", opens up a range of possibilities for study of interaction in "real time" and 
rapid decoding of "cross talk" between transcription factors, enhancers, epigenetic 
modulators and DNA.   
The reducing time scale of crosslink induction increases the number of proteins-DNA 
interaction that can be analyzed by “omic” science, and in general helps to clarified 
the temporal sequence of the events constituting the biological phenomenon (for 
example the epigenetic code variation).  
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MATERIALS AND METHODS 
Cell lines.
MDA-MB231 and MCF7 were cultured using standard procedures. Both cell lines 
were cultured in Dulbecco's modified Eagle's medium (DMEM-Euroclone) 
supplemented with 10% FCS (Sigma), 50g/ml penicillin-streptomycin (Gibco) and 
2mM glutamine (Gibco).  Cell lines were maintained at 37°C in a humidified 
atmosphere of 95% air, 5% CO2 as previously reported. 
Trypan Blue staining 
Cells treated and un-treated were seeded at an initial concentration of 1*10^6 
cells/ml cells in 6-well tissue culture plates. 
After 24 h, cells were collected by trypsinization and counted in duplicate; Trypan 
blue (Euroclone) dye exclusion was used to determine a cell growth curve. The 
number of cells was reported in comparison to a control-non treated samples. 

Optical microscope observation and cell images capture 
Treated and un-treated cells were analysed with phase-contrast optic microscope 
(EVOS) and cellular images were capture with camera integrated inside the 
microscope. 
Each experimental point was carried out in triplicate. 

Western blotting analysis and antibodies. 
For immunoblotting, MDA-ERalpha-GFP cells were lysed (50mM Tris–HCl pH 8.0, 
150mM NaCl, 1% NP-40, 10µM NaF, 0.1mM Na3VO4), 40µg/ml PMSF and protease 
inhibitors (SIGMA). Insoluble material was removed by centrifugation, and protein 
concentration was determined by Bio-Rad assay (Biorad). Lysates (30µg protein) 
were loaded onto SDS-PAGE gels and proteins were transferred to nitrocellulose 
membranes (Schleicher and Schuell, Dassel, Germany) and recognized by specific 
antibodies. The antibody against total p53 (1:1000) was purchased from BD 
Transduction Laboratory (BD) {Bontempo, 2009 #85}. 
The antibodies against phS1981 ATM (1:1000) and phS139 H2AX (1:1000) were 
acquired from Abcam. 
The antibody against Ack373-382 p53 (1:500) is made from Upstate; NBS1 (1:1000) 
is an antibody product by R&D Systems, while ERKs (1:1000) is a Santa Cruz one. 
Primary antibodies were detected using horseradish peroxidase-linked anti-mouse or 
anti-rabbit (Amersham Biosciences), conjugates as appropriate and visualized using 
the ECL detection system (Amersham Biosciences). 

Histone detection  
MDA-ERalpha-GFP cells were harvested and washed twice with ice-cold PBS 1x 
(Euroclone). Then cells were lysed in Triton Extraction Buffer (TEB: PBS containing 
0.5% Triton X 100 (v/v), 2mM phenylmethylsulfonyl fluoride (PMSF), 0.02% (w/v) 
NaN3) at a cellular density of 107 cells per ml for 10 minutes on ice, with gentle 
stirring. After a brief centrifugation at 2000 rpm at 4°C, the supernatant was removed 
and the pellet was washed in half the volume of TEB and centrifuged at before. The 
pellet was resuspended in 0.2M HCl at a cell density of 4x107cells per ml and acid 
extraction was proceeded over night at 4°C on rolli ng table. The day after the 
samples were centrifuged at 2000 rpm for 10 minutes at 4°C, the supernatant was 
removed and protein concentration was determined using the Bradford assay. About 
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10 g of acid-extracted protein were loaded on 15% SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to nitrocellulose. The nitrocellulose was 
incubated with anti phS139H2AX  (Abcam) and the analyses were performed 
according to the supplier's suggestions. Ponceau red staining was used to normalize 
for equal loading {Garcia,  #82}. 

Cell cycle analysis 
The cells were harvested and resuspended in staining solution containing RNAse A, 
propidium iodide (50 g/ml), sodium citrate (0.1%), NP40 (0.1%) in PBS 1X for 30 
min in the darkness. Cell cycle distribution was assessed with a FACScalibur flow 
cytometer using the Cell Quest software (Becton Dickinson, Milan, Italy) and 
analyzed by standard procedures using the same software and the ModFit LT 
version 3 Software (Verity, Topsham, ME, USA){Milite,  #81}. 

Cell death analysis 
For cytofluorimetric analysis, cells were cultured and irradiated in specific LASER 
operating condition. Than cells were collected in 0.1% sodium citrate and 50 g/ml 
propidium iodide (PI). After 30’ incubation, the percentage of cells with sub-G1 DNA 
was evaluated for flow cytometry with a FACS analyzer (FACScalibur; BD 
Biosciences, San Jose, CA) {Souto,  #83}. 
ROS production Analysis 
To measure intracellular ROS levels, cells grown at 70% confluence were collected 
and suspended in PBS. After the crosslink induction performed with LASER device in 
the selected conditions, the oxidation sensitive fluorescent probe dihydroethidium 
(DHE, Invitrogen, Carlsbad, CA, USA) was added at 5 M. After 30 min of incubation 
under protection from light, the cell suspension was subjected to flow cytometry 
analysis.  

DNA extraction and purification 
DNA extraction and purification was obtained by using Qiagen kit, following the 
directions provided. 
Caspases3/7 activation assay 
Cellular damages and so apoptosis was detected by examining caspase 3/7 activity 
following the manufacturer’s instructions (B-Bridge). The methodology is based on a 
fluorochrome inhibitor of caspases (FLICAs). The detection of caspases 3/7 activity is 
based on  an inhibitor peptide sequence (DEVD) targeted by both caspase 3 and 
caspase 7. The red probe is sulforhodamine B (SR). 
The probes also contain a fluoromethyl ketone group (FMK), which forms a covalent 
bond with the active caspase enzyme; because of the non-polar nature and relatively 
small molecular weight of these FLICA probes, they are cell-permeant. Because the 
SR-DEVD-FMK FLICA reagent becomes covalently coupled to the enzyme, it is 
retained within the cell while any unbound SR-DEVD-FMK FLICA reagent diffuses 
out of the cell and is washed away.  
After 1 h of incubation of a sample of 1 * 10 ^6 cells with the caspases 3/7 SR-DEVD-
FMK substrate and two washings in PBS, all samples were analyzed by FACS using 
a FACSCalibur (Becton Dickinson, NJ) and the Cell Quest Technology (Becton 
Dickinson, NJ). 
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Immunoprecipitation assay (IP). 
Cell extract was prepared from pellets of MDA-ERalpha-GFP cells to 80% confluence 
in 150-mm tissue culture plates. Proteins were extracted in buffer containing NP-40 
(0.5%), Tris–HCl pH 8.0 (20mM), NaCl, (150mM), PMSF (1mM), Glycerol 10%, 
EDTA (1mM) and 1X Complete protease inhibitor mixture (SIGMA) for 20 minutes on 
ice. Cell debris was removed by centrifugation for 10 minutes 12,000 ×g and the 
soluble material was incubated with the antibodies against ERalpha (Santa Cruz) and 
GFP (Abcam) at the recommended concentrations overnight a 4°C. The immune-
complexes were precipitated with Sepharose-protein A/G Plus (Santa Cruz 
Biotechnology) for an additional 2 hours at 4°C. Af ter four washes in lysis buffer and 
two in PBS, the proteins bound to beads were eluted and  resuspended in SDS-
PAGE sample buffer and analyzed by Western blot to verify specific IP. 
Transfection of  pERalpha-EGFP-C1 in MDA-MB231 cells 
pERalpha-EGFP-C1 vector (kindly provided by Ken-Ichi Matsuda, Department of 
Anatomy and Neurobiology, Kyoto Prefectural University of Medicine) {Matsuda, 
2002 #84} was transfected into MDA-MB231 cells thanks to Lipofectamine™ 2000 
Transfection Reagent (Invitrogen). First of all 2 x 105 cells were plated in each well of 
a 12-well plate. After the cells have been adhered we proceed to prepare the 
lipofectamine reaction mixture, composed of 1 ml of Opti-MEM (Invitrogen) plus 4 µl 
of Lipofectamine Reagent and we left it at RT for 5 minutes, shaking every 30 
seconds. Then the DNA mix was set: 1 µg of  plasmid up to 30 µl with sterile TE 1X. 
At this point the Lipofectamine mixture was combined with DNA solution and was 
incubated for 20 minutes at RT, shaking every 2 minutes. In the end the cells were 
washed with sterile PBS twice and the final mixture was added them gently; after 6 
hours complete D-MEM medium (Euroclone) was supplied to MDA-MB231 cells
Transfection efficiency evaluation 
The efficiency of transfection was calculated thought FACS (FACScalibur; BD 
Biosciences, San Jose, CA) analysis looking at GFP presence inside MDA-MB231 
transfected cells. The percentage of GFP-positive cells was analyzed  as shift along 
FL1 channel, in comparison with un-transfected cells 
Cell sorting
The cytofluorimeter used to sort MDA-ERalpha-GFP cells is FACS ARIAII (Becton  
Dickinson). Data were analysed with Diva 6.1 software.  
After the construction of G1 gate on the base of physical parameters (FSC and SSC) 
to isolate an omogeneous cell population, the dot-plot of GFP-positive cells was 
obtained. The FACS calibration was carried out through Accudrop beads, all the 
needles  and connection were sterilizied with 70% ehanol and washed with 1x sterile 
PBS. 
The threshold of GFP positive cells was set on G2 gate and the cells were collected. 
Pyrimidine dimers formation assay 
The pyrimidine dimers formation, after the exposure of living cells at UV LASER 
radiation, was evaluated and misured following the manufacturer’s instructions 
(Abnova). 
The Abnova cellular UV-Damage Detection kit based on the formation of CPDs on 
the genomic DNA that was detected by anti-CPDs antibody. 



To enable antibody binding to CPDs on the genomic DNA, cell must be fixed, 
permeabilized and DNA denatured. Detector anti-CPDs antibody is pipetted into the 
wells and allowed for 1 hour, during which time it binds to any CPDs. Unbound 
antibody is washed away and horseradish peroxidase-conjugated secondary 
antibody is added, which binds to the detector antibody. The horseradish peroxidase  
catalyzed the conversion of the chromogenic substrate tetra-methybenzidine (TMB) 
from a colorless solution to a blue solution (or yellow after the addition of stop 
reagent). The colour is quantified by spectrophotometry (Abs 450nm) and reflects the 
relative amount of CPDs in the cells. 
Comet Assay 
Trevigen’s CometAssay, or single cell gel electrophoresis assay, provides a simple 
and effective method for evaluating DNA damage in cells. Alkaline Comet assay is 
used to detect small amount of damage including single and double stranded DNA 
breaks. 
First of all 1*10^5 cells (treated and untreated with LASER device) are immobilized 
on a bed of low melting point agarose and then gently lysed (Lysis Solution  cat: 
4250-050-01). 
The assay is performed in alkaline conditions  (0,4g NaOH, 200mM EDTA) to unwind 
and denature the DNA and to hydrolyze sites of damages. 
The remaining nucleoids are subjected to electrophoresis in an Alkaline 
Electrophoresis Solution pH> 13 (8g NaOH, 500mM EDTA pH8) and subsequent 
staining with a fluorescent DNA intercalating dye (SYBR Green staining solution). 
The Comet visualization is performed with epifluorescence microscope (Zeiss). 
In Fluoresecence Experiments 
Cells transfected and irradiated were gently lysed to preserve the integrity of nuclear 
membranes. 
Then they are sonicated and the DNA was recovered with Qiagen DNA extraction kit, 
following manufacture’s instructionsthe The protein ERalpha-GFP l.inked to DNA (on 
ERE sequences) was purified and the quantity of GFP signal (related to the amount 
of crosslink induction) was measured with fluorescence scan plate reading (TECAN 
INFINITE 2000). 
  
ChIP experiements 
The antibody used in ChIP experiments was :3CH3K4H3 (Abcam). The analysed 
genomic regions were: 
H2B Prom   F           TGTACTTGGTGACGGCCTTA 
H2B Prom   R           CATTACAACAAGCGCTCGAC 
TRAIL Prom   F           AGTTTCCCTCCTTTCCAACG 
TRAIL Prom  R           CACTGAAGCCCTTCCTTCTCT 
Myog F                      AAGTTTGACAAGTTCAAGCACCTG 
Myog R                    TGGCACCATGCTTCTTTAAGTC  
SCAMP5 F                      GAACTAGCACCTCGGACAGC 
SCAMP5 RAGGAGGAGCAGCCTTAGGAG 
The MDA-ERalpha-GFP cells were crossliked with formaldehyde (positive control) 
and with Laser device at different combinations of repetition rate, energy for pulse, 
time duration and UV light output.
Then the cells were lysed (Buffer B: 20 mM HEPES pH 7.6, 10 mM EDTA, 0.5 mM 
EGTA, 0.25% triton-x100; Buffer C: 50 mM HEPES pH 7.6, 150mM NaCl, 1mM 
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EDTA, 0.5mM EGTA) and sonicated in a specific Buffer D (20mM HEPES pH 7.6, 
1mM EDTA, 0.5mM EGTA)+ 0.05% SDS + protease inhibitors. 
The sonicator employed was Bioblock Vibra Cell 72434. 
The chromatin immuprecipitation  was carried out over night at 4°C in ChIP mix (PIC, 
MQ water, Incubation Buffer, chromatin, antibody, blocked beads). The Incubation 
Buffer contains: 10 mM Tris pH 8.0, 150 mM NaCl, 1mM EDTA,0.5 mM EGTA, 
0.15% SDS, 1% triton-x100 and protease inhibitors 
The beads were washed, the crosslink reversed and the purified DNA was analyzed 
by RealTime-PCR, looking at specific regions of DNA. 
Immunofluorescence experiment 
MDA-ERalpha GFP cells were treated as suggested to manufacture antibodies 
suppliers. 
In particular the antibody was against ER-alpha (Santa Cruz) and reveled with Texas  
Red conjugated anti-rabbit. 
Nuclei were stained with Hoechst for 10 minutes; images were analyzed with 
fluorescence microscope (ZEISS). 
Laser apparatus 
PHAROS is a custom, versatile femtosecond laser as a source of UV/visible 
ultrashort pulses. It is based on the new active medium Yterbium tungstate 
(Yb:KGW) that shows several distinctive features which make it an attractive 
alternative to Ti:sapphire based system. Yb: KGW, having broad enough emission 
spectrum to support <200 fs pulse generation, can be directly pumped by diode 
lasers at 980 nm making the system less complex and more reliable. Due to high 
pump absorption cross section and low heat emission/power consumption rate 
Yb:KGW systems offers high output power and near- diffraction limited beam quality.  
The PHAROS Laser is able to deliver high-energy UV- fs-pulses in the energy range 
10-150 microjoule per pulse at a repetition rate variable within almost six orders of 
magnitude, between 1 Hz and 200 kHz. The carrier wavelength of such pulses is 263 
nm, in order to match the first UV absorption band window of DNA bases which 
covers the 250-280 nm range. 
This laser utilizes the chirped pulse amplification technique (CPA) to deliver ultra-
short, ultra-intense pulses with no damage to the employed optics. Hence, it is made 
of four parts: 
• Laser Oscillator 
• Pulse Stretcher  
• Regenerative amplifier 
• Pulse Compressor 
The oscillator includes two active medium rods and it’s optically pumped by Xe flash-
lamps. After the pumping,  the modes are locked (Kerr lens mode-locking) so that a 
train of equally spaced pulses– with energy of ≈1 nJ and duration of ≈100 fs - is 
produced, the time distance between two pulses being approximately 15 ns.  The 
pulse energy is low enough to prevent the occurrence of self-induced phenomena in 
the active medium and damaging of all the crossed optics in  the oscillator. To keep 
the intensity low the Chirped Pulse Amplification technique is adopted (see the figure 
I below concerning the scheme of principle of the CPA technique).  
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Fig I: CPA technique 
The pulse is stretched by a pair grating to  extend the  pulse duration thereby  
reducing the peak power. It acts by inducing spatial dispersion in the pulse so that 
different spectral components travel different paths and are lined up at the stretcher 
exit. 
Peaks with low power are then  amplified in the regenerative amplifier with no risk of 
damages for the active medium and the optics of the regenerative amplifier. achieved 
The pulse leaving the stretcher lasts  ≈300 ps and enters  the regenerative amplifier.  
The regenerative amplifier is a laser cavity itself. The pulse coming from the stretcher 
acts as a seed for the lasing action into the amplifier cavity and gets strongly 
amplified by passing back and forth into the amplifier laser rod, thus taking all the 
gain acquired in the pumped amplifier active medium. The pulse oscillates within the 
amplifier cavity until it becomes amplified by a factor of about 106. It is, then, 
extracted from the regenerative amplifier cavity by means of an electro-optic ultra-fast 
switch. The compressor is made by a second pair grating and works in the opposite 
way with respect to the stretcher, so it compensates for the dispersion introduced by 
the stretcher through two diffraction gratings. In the compressor  the colours which 
traveled a longer distance into the stretcher and were, , delayed take a shorter path 
and are re-phased in time with colours that arrive first.  
The compressor is made of all-reflection optics so it can generate a pulse with a peak 
great power with no risk of damages. 
The recompressed pulse has a duration of 130 fs an energy of about 4 mJ at a 
repetition rate of 2 kHz. The repetition rate can be as high as 200 kHz at the 
expenses of the pulse energy. 
Such laser source is followed by a series of harmonic generator contained in a case ( 
“HIRO”, Light Conversion). 
The FHG (see the Figure II ) is able to generate a UV femtosecond pulses starting 
with a near-infrared laser source. 
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           Fig II: Harmonic generation principles 
The second harmonic generation is achieved by  non-linear crystals which have a 
small group velocity difference between the fundamental and the harmonic wave, a 
large non linearity and exhibit no absorption at both the fundamental and harmonic 
wavelength. These crystals need to be  also transparent at twice the harmonic 
frequency to avoid two photons absorptions.  
For the above reasons the typical choice, in this case, is KDP. 
“HIRO” is the harmonics generator for “PHAROS” laser providing conversion to 515 
nm, 343 nm and 258 nm wavelengths.  
With its small foot print – 155x325mm – and a wide variety of fixing methods “HIRO” 
fulfills the need of all – OEM, industrial and scientific users. Depending on the model 
of “HIRO” it can provide the second and the fourth or the second, the third and the 
fourth harmonic. The active harmonic is selected by manual rotation of the knob – 
changing the harmonics will never take longer than a few seconds. 
“HIRO” shows a lot of features: 
 High conversion rate to the second/third/fourth harmonic 
 Easy switching between active harmonic 
 Small footprint 
 Integrated separation of the harmonics 
 Flexible in fixing and easily customized to include additional options such as 
splitting the harmonics, continuum generators, beam expanders/down-
collimators    
The principal of operation of “HIRO” is based on collinear generation of the higher 
harmonic of laser radiation in angle-phase-matched nonlinear crystals. The optical 
layout of “HIRO” also includes the beam size reduction and collimation optics to 
ensure highest conversion efficiency into the harmonics. One active harmonic can be 
selected from the “HIRO” at a time. However the residual lower harmonics can be 
also accessed through the output ports. All the harmonics exit the housing already 
separated from the lower ones by a couple of dichroic mirrors. 
Alternatively the output of “PHAROS” laser device could be sent to “ORPHEUS” 
device to convert the infrared pulses in visible light. 
“ORPHEUS” is a collinear optical parametric amplifier of white-light continuum 
pumped by “PHAROS” laser. It shows high output stability throughout the entire 
tuning range, high output pulse and beam quality, full computer control via USB port 
as well as lots of optional frequency mixers to extend the tuning range from UV up to 
mid-IR ranges.  
It can also operate at wide range of repetition rates from 1 kHz up to 1 MHz. 
Parametric amplification is performed with the second harmonic of pump laser. 515 
nm pump beam is generated inside of OPA unit with computer controlled angle 
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adjustment. Fresh/residual fundamental and second harmonic radiation (1030 nm 
and 515 nm respectively) are accessible from dedicated output ports.  
ORPHEUS provides tunable OPA output (630-2600 nm) with residual second 
harmonic and fundamental radiation beams at the same time. Collinear optical 
parametric amplification (OPA) has been used for more than a decade to generate 
ultra-broadband pulses in the visible frequency range (~300-750 nm). 
The basic idea behind the concept of OPA is illustrated in Figure III below.  
Briefly, when the signal and pump are collinear so that it is only possible to amplify a 
relatively narrow range of frequencies at once.  
However, at certain non-collinear angle  between pump and signal beams, the 
phase matching curve becomes essentially flat in a broad frequency range over 
which simultaneous amplification of signal frequencies is possible.  



Fig III: OPA 
In the schematic Laser configuration below (Figure IV), the possibility to switch from 
“PHAROS”-“HIRO” to “PHAROS”-“ORPHEUS” is explained.
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1. Full PHAROS output to HIRO
2. Full PHAROS output to ORPHEUS
3. 50% to HIRO

Fig IV: Schematic Laser configuration 
In the configuration 2 (Full PHAROS output to ORPHEUS) only some combination of 
repetition rate and energy for pulse are allowed, as shown in the figure V immediately 
below.  
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Fig V: ORPHEUS tuning curve 
It is interesting to note that a third configuration also exists, by which the output of 
PHAROS could be spitted 50% to HIRO and 50% to ORPHEUS. This configuration 
will be an useful tool to perform “double colors”  crosslink experiments. The rationale 
of two colors experiments is reported in the Supplementary table 2, in attach at the 
end of the thesis.  
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RESULTS 
Establishing a stable covalent bond between proteins and nucleic acids, usually 
referred to as crosslinking {Solomon, 1985 #86} is a powerful tool of molecular 
biology, which affords access to study otherwise transient interactions between bio-
molecules. Crosslinking with fs- UV lasers has been presented in the literature as a 
revolutionary technique to increase the otherwise low process yield of conventional 
methods based on chemical catalysts, {Solomon, 1988 #87} conventional UV 
sources,{Zhang, 2004 #88} or longer UV pulses{C. Russmann, 1997 #89}.  
It is known that crosslinking induced in cells by ultrashort laser pulses has a twofold 
advantage over conventional methods. (i) It binds only species that are in proximity 
(“zero length” covalent bond) of the absorbed photons rather than favoring unspecific 
bonds amongst many possible species in the cell. (ii) It should only operate until the 
radiation is incident on the sample, thus paving the way for time-resolved studies of 
transient interactions. Moreover, when combined with biochemical techniques such 
as Chromatin Immunoprecipitation (ChIP) to analyze the produced bonds, the UV 
laser method will make feasible the characterization of the dynamics of the 
transcription factors bindings on chromatin in living cells, thus overcoming the 
technical limitations of the current technologies{Lis, 1985 #90}. 
The first step in the project has consisted in testing a femto-second laser system 
(PHAROS) with the aim to optimise UV-laser photo-induced cross-linking with high 
efficiency. The PHAROS in use is able to deliver high-energy UV- fs-pulses (in the 
energy range 10-150 microjoule per pulse) at a repetition rate variable within almost 
six orders of magnitude, between 1 Hz and 200 kHz. The carrier wavelength of such 
pulses is 263 nm, in order to match the first UV absorption band window of DNA 
bases which covers the 250-280 nm range. These characteristics offer the advantage 
of making such laser source particularly suitable for the project purpose as it has (i) 
high energy/pulse and (ii) high and variable repetition rate, thus looking promising for 
fast, highly-efficient, damage controlled laser induced DNA-protein cross-link.  
In order to evaluate the capability of this UV laser source to induce the cross-link 
between DNA and proteins and for understanding the optimum conditions in which 
this cross-link can be obtained, a vast range of biological experiments have been 
made next to General Pathology Department of S.U.N. University. 
First of all a fast and highly powerful method has been creating to test a variety of 
macroscopic parameters characterizing the DNA-proteins interaction in vivo mediated 
by laser light (see Supplementary Table 2 to the summarize of the method). These 
test responses are not referred to a single cell typology or a unique DNA-
transcriptional factor interaction, but they provide a great number of technical and 
biological data suitable for Laser-ChIP (L-ChIP) technique development. The key 
point in the experimental data-set has been the creation of a stable cell line 
expressing a transcriptional factor linked to the GFP protein; to ensure a 
homogeneous starting fluorescent clone population the cells have been selected with 
a cell sorter (FACSAriaII). For this purpose MDA-231 cells (that are Estrogen 
Receptor negative Breast Cancer cells) have been transfected with a vector coding 
for Estrogen Receptor α, linked to Green Florescent protein (ER-GFP). The 
Estrogen Receptor α is a ligand-activated receptor that is a member of the 
steroid/nuclear receptor (NR) superfamily and acts like a transcriptional factor when 
binding particular DNA regions (ERE: Estrogen Responsive Elements). The NR ER
is recruited on the minimal consensus ERE sequence that is a 13 bp palindromic 
inverted repeat sequence (IR): 5'-GGTCAnnnTGACC-3' and though an highly 
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conserved C domain (comprised of two functionally distinct zinc fingers) it interacts 
directly with the DNA helix. Even though MDA-231 are ER-negative cells in their DNA 
are present the ERE sequences; so in the obtained ER-GFP clones is possible to 
observe a green fluorescent signal (with an emission wavelength at 510 nm) directly 
on the chromatin.
So first of all, the MDA-MB 231 cells were transfected with  pERalpha-EGFP-
C1vector and the efficiency of transfection was measured at FACS looking at the 
percentage of GFP fluorescent signal present inside the cells. 



Fig 25:FACS Transfected GFP positive cells. The data are referred to the parental MDA-MB231 cell line 
In the figure 25 above is posssible to observe the shift of cellular popolation along the 
FL1-H (the green channel of FACScalibur station). 
Another experiment to confirm the transfection and the production of fusion protein 
Erα-GFP was the immunoprecipitation one. 

Fig 26: Immunoprecipitation analysis bringing out with Erα antibody and GFP antibody. The protein in the cellular 
extract was precipitated with a resin coupled with ERα antibody and the bound fraction was loaded on a 
poliacrylamide gel after bolotted against ERα and GFP
In the figure 26 is reported the immuprecipitation experiment, using two different 
antibodies aganist  the protein ERα and against GFP. 
As it is possible to note, the signals of both antibodies perfectly merge, as 
demonstration of fusion protein expression inside the cellular model. 
Confirmed the expression of fusion protein, the transfected cell line was sorted in 
order to obtain an homogeneous clone. As reported in figure 27, the sort experiment 
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was carried out using control (non fluorescent) parental MDA-MB231 cell and setting 
the threshold value for GFP presence at very high intensity. 
After the sorting session, from a percentage of GFP-positive cells equal to 29,1%, the 
transfected cell line presented then a GFP positive percentage of about 90%. 


Fig 27: Cell sorting images obtained with FACSAria and analyzed with Diva 6.1 softwear. The data are referred to 
the parental cell line 
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The localization of the fusion protein was also determinated by experiments of 
immunofluoresence, staining the transfected cells with an antibody specific for the 
Estrogen Receptor α and looking at the GFP signal.  
As it is possible to note form figure 28 both colors (red caused by Texas Red 
conjugated secondary antibody and green related to GFP presence) co-localize in 
the nuclear and peri-nuclear cellular region.  

Fig 28:immunofluorescence images obtained by staining the transfected cells with ERα (red color) and looking at 
the GFP signal (green color) 
Verified the ER-GFP production and the suitability of the method, MDA  ER-GFP 
cells constitute the starting biological material for optimising the laser source 
parameters and then utilizing the established settings for experiments of ChIPs.  
1x106 cells/point in a volume of 20 µL of saline solution have been irradiated with the 
PHAROS pulses in a 96 MW support. A specific protocol for chromatin extraction and 
purification has been set up thereby allowing the measurement of GFP as readout of 
cross-link (see Supplementary Table 2 to the scheme of “in fluorescence” protocol).  
Chemically induced crosslinkink called “positive control” in the following, in which the 
covalent bind between DNA and proteins is obtained by using formaldehyde as in 
vivo chemical bi-functional reagent, has been compared to photo-induced crosslink 
obtained with several different sets of the laser source parameter value.  
The “negative control” in the following, instead, represents the case when the same 
amount of cells is analysed without being treated for the cross-link induction (neither 
trough the chemical way, nor with the laser methodology), therefore acting as a 
background  remover. 
As the critical parameter in optimising UV laser cross-linking of proteins to DNA is 
probably not only the total amount of light energy absorbed by the target, but a 
combination of light intensity [energy/(duration x unit area)], pulse length, irradiation 
time, and repetition rate a great number of irradiation conditions have been evaluated 
and are currently under evaluation.  
It is worth stressing that the above interplay amongst several parameters of the laser 
source setting is not known neither on empirical basis, nor from the microscopical 
point of view. 
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Fig 29: Fluorescent scan methodology at three different Laser operative conditions. The data are reported by 
comparing with a negative and a positive ctr. The vale are average of 4 tests 
Figure 29 above shows the results obtained in three distinct laser source conditions, 
namely, when keeping constant the laser pulse energy and the irradiation time, equal 
to 110 µJ, for 1 minute, but varying repetition rate. Experiments are averages over 
four points. 
As it possible to note, by increasing the repetition rate, at the same value of 
energy/pulse, the florescence increases. As the fluorescence value is related to 
stable bonds induction,  the yield of crosslink improves by increasing the repetition 
rate. 
The same experimental protocol has been applied for the set of data shown in fugure 
30. 
In this figure it is possible to observe that, with cells irradiated with the maximal pulse 
energy currently available, corresponding to 140 µJ, a correlation exists between 
irradiation times and repetition rates; the fluorescence recovery is larger when the 
laser induction is shorter in time (probably due to the small value of irradiated cell 
disk). 
It is intresting to note that when the energy/pulse value is equal to 140uJ (no more 
110uJ), the differences among repetition rates are are negligible (the value of 
florescence recovery is always simillar despite the variation of Hz). 
In addition, many different laser conditions have been able to yield a fluorescent 
recovery higher than the positive control (chemical cross-link).  
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Fig 30: In fluorescence experiments carried out maintaining constant the energy/pulse parameters and varying 
the time of exposure to the UV Laser light 
These laser conditions differ mainly for the repetition rates, that is the number of 
pulses per second that hits the biological samples.
In the figure 31, results relative to a comparison between irradiation performed with 
laser beams having two different sizes were reported: crosslink obtained with the 
ordinary output beam, which has a diameter of about 2.5 mm and does not match the 
well size of the target has been compared with crosslink obtained, in the same 
conditions, but using an enlarged beam size (a diamter of approximately  6 mm) 
which exactly mathces the well size. 
This test has the aim to optimise the irradiated volume of the sample. Indeed, the 
ordinary laser beam dimension is not large enough to couple the entire well used as 
experimental support; so, when the laser bam is in its “normal state” only about 1/3 of 
the cells are actually irradiated. 
When the laser beam is enlarged, by simply using an optical lens, up to the well 
dimension, it shines the entire air-solution contact surface. It is worth mentioning that 
the irradiated volumes are very small, amounting to about 20 µl, which implies a very 
thin disk to irradiate, having a height of about 1 mm.  
This reduced thickness to travel throgh minimises light absorption and scattering 
which might cause a lower light fluence to be available for the irradiation of the the 
deeper solution layers. 

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Fig 31: Comparison between two different Laser output sizes to merge the sample in an effective way 
However, beam enlargement is obtained only by paying the price of a reduction of 
the pulse intensity. In fact, the same nominal amount of power is spread out over a 
wider surface. 
Moreover, in practice, enlarging the beam implies also a reduction of the overall 
pulse energy  due to reflection losses from the lens.  
Due to this, an about 25% energy loss is measured in the enlarged compared to the 
ordinary beam. 
The above two reasons could explain why the fluorescent recovery, in the enlarged 
case, is generally lower than in the normal one (see in figure 31 the grey bars 
compared with black bars). 
However, also in this last experiment it is possible to note the complex interplay that 
occurs among the severeal physical paramenters of the laser source which affects 
the response of the biological sample. 
It is also important to keep in mind that no use of any device has been done so far to 
mix up the solution while irradiating. This choice is motivated by two reasons:  
(i) some irradiation times are so short that no mix can be successfully performed  
(ii)  the solution volume used so far is very small and thin, making hard to employ 
      any such mixing tools. 
To overcome these limitation, another procedure to irradiate the cells was set, in 
which living cells were resuspended in 1ml of buffered saline (PBS) and  solution was 
stirred (Figure 32 below).  
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Fig 32: Geometry of Laser apparatus device coupled with for cell irradiating support. 
When compared to the initial procedure performed into a volume of 20µL , in a 96Mw 
support, this procedure showed a clear advantage most likely due to the different 
concentration of the cells as well as to the possibility to irradiate the target in a very 
uniform way, what was a problem, instead, with the previous configuration that used 
20µL droplets.  
In fact, when using droplet targets, a peripheral, non-negligible region of the target 
volume contained in the well is not properly irradiated. This causes a systematic error 
in under-estimating the photo-induced cross-link. 
As expected, the ‘GFP-method’ allows to screen a lot of conditions simultaneously. In 
figure 33 are reported the data obtained in different experiments in which laser 
repetition rate and its energy/pulse have been changed. 
Also for this new setting in a large volume and at low cellular concentration, the 
contribution of repetition rate, energy /pulse and time of irradiation were estimated. 
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Fig 33: “In fluorescent” experiments done with 1ml cuvette geometry 
The repetition rates spare from 100Hz to 20Khz to cover the total range of laser 
PHAROS operative conditions.  
The values of energy/pulse parameter were instead chosen in accordance with the 
characteristics of Laser device in use. 
In every case the yield of crosslink induction, expressed as fluorescence readout, is 
comparable to the chemical experimental point and very reproducible as 
demonstrated by the low standard deviation (SD have been calculated on 
sestuplicates). 
To better understand the role of repetition rate and the energy, attention was focused 
on two ‘extreme’ conditions: 200Hz with 125micro joule and 20KHz with 8 micro 
joule.  
To date is still unclear what is the key mechanism by which the amount of obtained 
crosslink induction is similar in the two under-study operative modes, although the 
employing Laser parameters are so different one from each other. 
On the base of these preliminary observations was under investigation the rule of 
cellular concentration and time of irradiation as key factors for the crosslink induction.  
As the cellular concentration is concerned it was (data not shown) evident that, when 
number of cells is too high, the laser beam is not able to penetrate deep inside the 
solution, causing a decrease in the crosslink yield. Hence the necessary of the 
stirring, jet explained above 
To check different irradiation times, in the same operating laser conditions and with 
the same amount of cell, equal to 1 million, two different times of irradiation were 
been tested. 
Figure 34 shows that also with 1 minute of irradiation the crosslink induction is good 
enough to be comparable to the chemical experimental point. 
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Fig 34: Role of time of irradiation in “in fluorescence experiments” 
The encouraging results, obtained with the ‘GFP-method’, suggested the set up of 
others experimental conditions. 
In particular at the total amount of the energy for pulse/repetition rate combinations 
the Laser setting 2Khz 125J was added because, in term of repetition rate, it is the 
“natural output” of the PHAROS Laser device. 
One of the drawbacks arising  from the interaction between a  cellular model and an 
UV radiation was the estimation of damages inside the cells, looking at DNA integrity, 
proteins stability and cellular viability. 
For this reason a lot of experiments were done; all of these experiments may help to 
elucidate the molecular bases of the crosslink reaction inside living cells.  
In particular, the presence of cellular death (that is an expression of to cellular 
damage) could be important parameter to choice the best conditions to achieve the 
crosslink induction.  
As it is shown in the figure 35 below, in the three selected laser conditions (2Khz 
125uJ, 200hz 125uJ, 20Khz 8uJ) a study on cellular viability was performed using the 
ability of Propidium iodide (PI) to selectively enter inside death cells. 
On the same experimental points, also analysis of cell cycle progression and 
fluorescence recovery (obtained with “GFP-Method” ) were done. 
All these data are shown on the panel 35, in the next page. 
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Fig 35: In fluorescence experiment (A), PI incorporation (B), cell cycle analysis (C) and image capture (D) in three 
different Laser conditions 
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As  additional proof of cellular death, the viability of irradiated cells was also 
estimated by microscope observation (Fig 35, panel D). 
Also in this case, the data suggest that the Laser irradiation of living cells cause 
some dramatic changes inside the cells bring them to dead. 
At the same time also a study on cell cycle distribution of the irradiated cells, 
compared with control ones, was carried out to analyze if the UV Laser Light lead to 
the accumulation of cells in one of the cell cycle checkpoints. 
As it possible to note from figure 35 no accumulation in a particular cell cycle phase 
is induced. So, probably the observed death  is a very rapid phenomenon not closely 
related to cell phase checkpoints. 
To verify the DNA damage that might be produced by the irradiations the activation of 
pathways known to respond to DNA damage and apoptosis cascade activation have 
been tested. Following the UV exposure, the cell reacts by the activation of some 
pro-apoptotic pathways in which the induction of p53 and p53-regulated proteins is 
observed. The p53 tumor suppressor protein, a key regulator of cellular responses to 
stress, is stabilized and activated after DNA damage. The rapid activation of p53 by 
ionizing radiation is largely dependent on the ATM kinase. p53 is phosphorylated by 
ATM shortly after DNA damage, resulting in enhanced stability and activity of p53. 
The cross-talk between p53 and ATM is, for this reason, the starting point to check 
the presence of UV  inducted DNA damage. Also the presence of histone H2AX 
phosphorylated on S139 is a marker of DNA damage and has been evaluated. 

Fig 36: Western Blot panel for proteins involved in DNA damage recognition. 
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MDA231-Erα-GFP cells have been irradiated with an UV laser source in the two 
different ‘extreme’-operating conditions. For each laser condition, additional points 
have been carried out in which the cells have been kept at room temperature for a 
time of 30 minutes after irradiation (cells with waiting time). Indeed, during the 30 
minutes the DNA repair mechanisms and DNA damage signalling pathways, in a cell, 
are normally activated. Western blot analysis shown in Figure 36, reveals that the UV 
damage-response pathways are only partially activated in the cellular model used, 
after the exposure of cells at an UV source for the irradiation time of 1 minute. In 
particular, H2AX phosphorylation is few altered, whereas p53 and ATM 
phosphorylations seem to be induced but no real difference has been detected 
between the irradiated samples with waiting time. This last observation confirms the 
idea that the observed cellular death is an early event. 
Despite the time in which the cellular death occurs, from the figure 37 below it is clear 
that happens through the activation of caspases 3/7 and the production of reactive 
oxygen species (ROS). 
Fig 37: ROS and Caspases 3/7 activation assay in the three selected conditions. 
Caspases are aspartate-specific cysteine (interleukin-1beta converting enzyme/CED-
3) proteases present in cells as inactive or low activity proenzymes (zymogens) that 
are sequentially activated to promote apoptosis.  
The caspases most often associated with apoptosis are caspases 2, 3, 6, 7, 8, 9 and 
10. Caspase cascades are composed of upstream (initiator) caspases (caspase 2, 
caspase 8, caspase 10), which are activated by death receptor signalosomes (DISC); 
caspase 9, which is activated by the mitochondrial cytochrome C/Apaf-1 derived 
apoptosome; and downstream (effector) caspases (caspase 3, caspase 6, caspase 
7) that cleave proteins involved in programmed cell death events. Caspase 2, 
caspase 8 and caspase 10 are activated by death receptor signalosomes (death-
inducing signaling complex (DISC)). 
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In addition to activating caspase-3, caspase-6 or caspase-7 directly, caspases 8 or 
10 activates pro-apoptotic factors such as BID that induce the release of cytochrome 
C from the mitochondria. Caspase 9 is activated by the mitochondrial release of 
cytochrome C. Cytosolic cytochrome c binds and induces oligomerization of 
apoptotic protease activating factor 1 (APAF-1) followed by recruitment of 
procaspase-9 to form an apoptosome. Apoptosome-associated procaspase-9 self-
activates and then activates downstream caspase 3 and/or caspase 7. 
The downstream executioner caspases (3,6,7) cleave: proteins involved with DNA 
processing such as DNA fragmentation factor (DFF-45); the DNA repair enzymes 
poly(ADP-ribose) polymerase (PARP); and DNA fragmentation factor 45 kDa subunit 
(ICAD); signaling molecules such as the Rho-GTPase GDP dissociation inhibitor (D4-
GDI); enzymes protein kinase Cd (PKCd), cytosolic phospholipase A2 (cPLA2); 
sterol-regulatory element-binding proteins (SREBP); p21-activated kinase 2 (PAK2); 
and DNA-dependent protein kinase catalytic subunit (DNA-PKcs); and structural 
proteins such as a-fodrin, actin, and lamin. 
As reported in literature, the reactive oxygen species are produced instead, after the 
exposure to UV radiations. High levels of ROS cause oxidative stress inside the cells 
bringing them to death.  
So both data shown in figure 37 are consistent one with another. 
With some of the operating Laser conditions an experiment of chromatin 
immunoprecipitation (ChIP) was also done, to confirm that the selected combinations 
of repetition rate and energy for pulse were also able to induce the crosslink between 
DNA and proteins in the cellular model (see  figure 38). 
Among the three combinations of energy and rep/rate discussed at now, only two of 
these (2Khz 125uJ and 200Hz 125uJ) were  employed in  the ChIP experiment as 
the minimum and the maximum value of live/death cells. 
In this ChIP experiment an antibody against 3CH3K4H3 histone was employed to 
pull down the TRAIL promoter region in MDA-ERα-GFP cells. In the figure 38 is 
reported the genome browser data related to the occurrence of this histone mark on 
the specific selected region in different cell lines. 
The second amplificated gene, called in figure 38 below Myo, represents the 
negative control of the data set because is not specific per the histone mark selected, 
and so the value of recovery remains unchanged among the different experimental 
points. 
Although the signal of recovery obtained with chemical experimental point is greater 
than the physics, it is also possible to note that, particularly for the point 2khz 125uJ 
the recovery of 3CH3K4H3 is good enough and it is due with a time of exposition 1 
order of magnitude minor than chemical.  
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Fig 38: ChIP experiment employed 3CH3K4H3 antibody, The amplificated genetic region is TRAIL promoter one. 
In the Panel above is reported the genome browser analysis to confirm the presence of the epigenetic mark on 
TRAIL pReg. 
As more than once, reference was made to cellular damages induced by incident UV 
radiation, the recovery values after ChIP experiment on TRAIL promoter region 
lowest than chemical could be caused by photoproducts presence or DNA structural 
damages. 
So, looking at all the results, another question kept in consideration was if the DNA 
itself, after the laser crosslink induction, could be damaged and if this damage could 
cause problems for the ChIP experiment and subsequent DNA amplification. 
So the presence of pyrimidine dimers was evaluated, at the first, for the three 
employed conditions (Figure 39). 
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Fig 39: Pyrimidime dimers formation assay carried out on two different tumoral cell lines 
This experiment was done in two different cell lines, to exclude that the previous 
manipulation of MDA-ERα-GFP (e.i. transfection) could interfere with the DNA 
stability. 
As it is possible to note from figure 39, both cell lines react in the same way at the 
Laser treatment, with value of pyrimidine dimers formation more or less equal.  
The preliminary data regarding the photo-products formations in irradiated living cells 
were the input to keep lower the energy. 
In fact if an high dose of very energetic photons is able to induce the crosslink 
formation between DNA and proteins, too much energy could damage the interacting 
system up to be a limitation for ChIP study itself and ChIP-seq downstream analysis. 
So other combinations  of laser operating modes were explored, with the idea of the 
minimization of DNA damage but at the same time, an optimization of the crosslink 
yield. 
As shown in figure 40 below, additional experimental points were carried out in which 
the amount of total energy results to be different to the three ones tested until now. 
In particular, 2khz 125uJ condition was maintained and other experimental points 
differing for total energy were added. 
These experimental points were obtained keeping constant the repetition rate but 
varying the energy/pulse value (starting from 90uJ up to 30uJ) 
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Fig 40: ChIP experiment on scaling energy experimental points, Also in this case the anyibody was 3CH3K4H3 
and  
the amplificated regions were: TRAIL promoter, H2B promoter, Scamp5 promoter. 
In this ChIP experiment additional genomic regions were analyzed by Real Time-
PCR after immunoprecipitation of chromatin. Indeed, the data were compared to a 
negative and a positive (chemically induced crosslink) experimental points. 
As it is possible to observe each gene reacts in a different manner at the same 
irradiation session, indicating that a preferential behavior exists in relation to Laser 
crosslink induction. 
As the crosslink induced by UV Laser is a “zero length” reaction independent of 
reactivity and length of bi-functional reagents, some changes to the protocol for ChIP 
experiments were done, for promoting the permanence of only stable links between 
DNA and proteins. 
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Increasing the percentage of detergents (e.g. SDS) the recovery related to 
3CH3K4H3 is improved for the TRAIL genetic region comparing to the one shown in 
figure 38. 
Regarding the region of H2B, it seem to be negative for the crosslink induced in the 
presented Laser conditions, instead for the region of SCAMP5 is always present a 
detectable recovery. 
Also in this case, the genome browser of selected genic regions were shown (see fig 
41). 
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    Fig 41: Genome browsers panel for H2B SCAMP5 promoter regions in relation to the specific epigenetic mark. 
With high energies of Laser device a preferential crosslink is thus induced but it  is 
plausible that the quantity and quality of crosslink could be improved by varying the 
Laser energy and the way by which this energy is supplied to the biological system. 
Also for these experimental points an analysis of mortality and cell cycle distribution, 
after the irradiating session, was been made. 
As sown in figure 42 by scaling the total energy, a
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Fig 42: cell cycle progression and PI incorporation experiments 
The figure 42 shows that the cells die because their cell membrane is permeable to 
staining with PI, but the activation of apoptosis (detected with FACS analysis) is only 
quite present after few hours from the irradiating session. 
Consistent with this idea the expression of pro-apoptotic proteins and the related 
percentage of cellular death was analyzed, scaling the quantity of total energy for 
each experimental point. 
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           Fig 43: Western blot panel of pro-apoptotic proteins 
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From the data presented in figure 43, some key proteins in the pathway leading to 
apoptosis (but in general also in other forms of cellular death) are inducing and this 
induction is caused by the total amount of energy in the time unit, but also by the way 
in which this energy is supplied to the cells. 
In fact many of the case shown in the figure posses the same quantity of energy 
released to the cellular model in the time of 1 minute, but by varying the combination 
of energy for pulse and repetition rate; the biological effect  is not the same for all and 
it is greater in the “not extremely stressed” conditions (see table 1 below). 
Table 1: Characteristics of employed laser conditions 
In the same conditions the caspases3/7 activation and the ROS production were also 
tested (see figure 44 below). 
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Fig 44: Caspases 3/7 activation (A) and ROS production (B) assays 
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It is interesting to note that both assays show the same trend, demonstrating the 
enormous biological effect induced by UV laser device. Looking at the data, the 
observed cellular death is due to a complex system of activation involving ROS 
production and caspases cascade, but the final step in this complex process 
culminates to cellular death. 
The cellular death was quantified by FACs analysis, and as shown in figure 45, it is 
clear that a correlation between energy released and death exists. 
Analyzing all the data concerning the wbs, caspases and ROS production, it is 
easy to note that extreme conditions of repetition rate and energy/pulse  activate  the 
same way the pathways of cell damage. By focusing on the group of experimental 
points that has  total energy equal  to 3600 mJ you can see the different 
behavior with regard to protein expression. In addiction these 3 experimental points 
induce, in the same manner, the caspases 3/7 but  differently the ROS production. 
This trend could suggest an non linear response of cellular system to UV laser 
treatment. The experimental point in which is low enough  the activation of caspases 
and ROS is 200hz 125uJ (total energy= 1500). For this condition however, the 
stronger induction of protein-induced by damage is observed.The total energy of this 
point is similar to the energy of the condition 2khz 15uJ (1500 vs 1800) but the 
biological effects are very different between them, with a percentage of ROS and 
caspases activation bigger than twice.  
Fig 45: PI incorporation analysis 
It is interesting to note that, in the two different conditions mainly analyses at now 
(2khz 125uJ and 20Khz 8uJ), the percentage of cellular death is quite similar though 
the quantity of energy scales among them. It could suggests that a threshold value 
exists exceeded it the biological effect is the same. 
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Confirming this hypothesis there is also the data regarding the points 2khz 30uJ and 
200hz 125uJ. For these the total energy is, respectively, 3600 and 1500 but the 
percentage of cellular death remains unchanged.  
The cellular death was also confirmed by microscope observation and images 
capture. The figure 46 shows that after the UV laser crosslink induction the cells lose 
the ability to  link them selves at the plate and at 24h from laser treatment they are 
mostly dead. The images are referred only to few experimental points (other laser 
conditions are data not shown). 
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                                                 Fig 46: Images captures of cells after irraditaion 
Probably the cellular death is also due to DNA fragmentation, induced by the UV 
exposure and thought the activation of pro-apoptotic pathway (keep in mind the 
caspases 3/7 activation) as show in figure 47. 
In the panel below some images of comet assay are presented in the laser condition 
in which caspases and ROS activation was detect. Also in this case, the data are 
compared with a negative control (without tail); each laser condition induces DNA 
fragmentation and the length of tails is related to the percentage of damage itself. As 
yet explained below the damage is function of quantity of energy released to the 
cells. 
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In the panel of comet assay images only few laser conditions are reported with the 
aim of showing the rationale of the experiments. the other laser setting are included 
in the Table Supplementary 3, in attach at the end of thesis. 
Fig 47: Comet assays 
In the same conditions, an evaluation of the quantity of pyrimidine dimers formation 
was carried out and the obtaining results were shown in the figure 48 below. 
In each tested condition is present the positive signal to the pyrimidine formation with 
no significant differences among each experimental point. 
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Fig 48: Dimers production assay carried out in two different cell lines 
Since the presence of DNA damage, as already explained above, may be a limitation 
for the downstream analysis, also other laser settings were tested to reduce the 
cellular death (that could be directly related to DNA damages). 
In the next figure (Figure 49, below), the data related to cellular death were reported, 
in which the cells were irradiated with very few total energy. 
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Fig 49: PI incorporation at low energy values (A) and “In Fluorescence” experiments (B) 

Table 2: Characteristics of employed laser conditions 
So, in the first panel some additional points were shown and it is immediately evident 
that low energies (listed in the Table 2, above) correspond to low level of death. 
Some of these points were also analyzed for the ROS production, and also in this 
case the percentage of ROS inside the cells decreases in a proportional way to the 
decrement of energy (see fig 50) 
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Fig 50: ROS production assay 
Though in the employed conditions the rate of cellular death and the production of 
ROS decreases, the energy released to the cellular system is enough to promote the 
crosslink reaction between proteins and DNA (ERα-GFP protein and ERE 
sequences) as shown in the figure 49, panel B. 
Continuing on this idea, the final UV laser wavelength was changed, from the 260nm 
to 300nm, to reduce the absorption of energy to the thymines that constitute the 
candidates to the pyrimidine dimers formation and usually are present in the regions 
of DNA breaks (figure 51, below). 
Fig 51: Spectral absorption of DNA bases 
To verify the reduction of DNA damages and to analyze the global effect on living 
cells, first of all an experiment of PI incorporation was done. 
In figure 52 is reported the comparison between the two different wavelengths. 
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Fig 52: PI incorporation at different UV Laser outputs (260nm and 300 nm) 
As previous shown, at the low energies with wavelengths equal to 260nm no cellular 
death is immediately appreciable. The same is true also with the wavelength output 
of 300nm. But looking at the percentage of dimers formation the question is quite 
different (se figure 53). 
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Fig 53: Dimers formation  assay at 260nm and 300nm 
Especially for the 2khz 7J experimental point is present a strong reduction in dimers 
formations (which is still evident also in the 7khz 7J condition). 
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The decrease of dimers formation and the absence of cellular death after few 
minutes from the irradiating session doesn’t exclude the cellular death after 24h from 
the laser treatment, as shown in figure 54. 
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Fig 54: Cell count with Trypan blue staining and images capture after irradiation 
In both these selected conditions the ChIP experiment was done. As shown in figure 
55 the recovery of DNA is good enough in both conditions. Also in this experiments 
different genic regions were analyzed and they show a different behavior if compared 
with the same genetic regions analyzed after high energetic UV exposure. 
		


Fig 55: ChIP experiment 
For the 7Khz 7J point a good recovery was obtained in 260nm condition but also 
with UV output near the 300nm. 
An interesting improvement in this ChIP experiments is the recovery value for the 
H2B promoter region for which, in the previous experiments (compare figure 40 with 
figure 55) at high intensity of energy, no signal was obtained. 
One of the possible explanations for this trend could be the sequence of the analyzed 
promoter regions. In fact by using low energetic laser conditions  the DNA damage is 
minimized and an UV output of 300nm is only quite absorbed by thymines, so DNA 
sequences with a reduced content of paired T residues can react at the crosslink 
induction better than others. 
H2Bp 121bp 
TGTACTTGGTGACGGCCTTAGTACCCTCGGACACGGCGTGCTTGGCCAACTCCCCAGGCAGCAG
CAGGCGCACGGCCGTCTGGATCTCCCTGGAGGTGATGGTCGAGCGCTTGTTGTAATG
TRAILp184bp 
CACTGAAGCCCTTCCTTCTCTATTCTTTTATAGTCAGTGAGGAAATGAAAGCGAATGAGTTGTTTT
TCTGGGTTCTGTGGCCTTGGCCCCACCCACATCTATTGAACCTGCAACTGTCCCTCCCCTTTCCT
ACTGCCCAGGGACAGCTCTTGTCTCAAAGTAGTCGTTGGAAAGGAGGGAAACT
Tabel 3: Characteristics of amplificated regions after ChIP experime
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DISCUSSION 
The availability of the DNA sequence of many eukaryotic genomes and the 
generation of high density tiling arrays covering such entire genomes has made it 
possible to decipher the regulatory principles that are based on the interplay of trans-
regulatory TFs and their cognate cis-regulatory DNA recognition sequences at 
genome-wide level. At the chromatin level a mutual interplay between TFs and 
epigenetic modifiers (DNA and histone modifying machineries) sets up determinants 
of regional gene (in)activity.  
The ensemble of histone modifications at a given gene locus has been proposed to 
establish an “epigenetic code” of great complexity. Irrespectively of whether such a 
code does exist or whether chromatin modifications rather constitute a step in signal 
transduction, it has become increasingly clear that chromatin modifications constitute 
docking sites for regulatory factors. Thus, decryption of the information encoded by 
genomes requires a deconvolution of the genetic and epigenetic programs and the 
interplay between these two regulatory levels. In addition to their enormous potential 
and power for the study of gene regulation mechanisms such analyses will also 
provide important tools for diagnosis, prognosis, and therapy of diseases. 
The chromatin immune precipitation (ChIP) technique is the tool of choice  for 
analysis in which is important to isolate the DNA-transcription factors complexes. 
To face limitations of conventional ChIP, a ChIP in which the binding between DNA 
and transcriptional factors is obtained by the use of a laser system (photo-induction) 
has been set-up. 
The overall objective of the work has been to establish a novel  ChIP technology that 
is based on highly efficient, precise, robust and reproducible laser-assisted DNA-
protein photo-crosslinking (termed “LChIP”).  
LChIP may overcome the limitations of the formaldehyde-based crosslinking and 
allows deciphering genomic information into TF and epigenetic mediator-modulated 
networks with unprecedented accuracy, sensitivity and precision at a dynamic range 
of magnitudes larger than possible with XChIP. In the future LChIP will be 
established for genome-wide studies.  
UV laser crosslink DNA and proteins is generally regarded as a two-step process, 
even though recent studies suggest that one UV-photon process can be the 
dominant mechanism for cross-linking nucleic acid bases with proteins in vitro. 
Nevertheless, due to their complexity, interactions in living cells follow reaction paths 
not easily reproducible in vitro, and results obtained in vivo clearly show the non-
linear response of the living cells to a high-intensity laser.  
Within the two photon excitation scheme a first UV photon excites the DNA base from 
the singlet S
0 
ground state to the first excited S
1 
manifold. From the second S
1 
level 
the molecule can absorb a second photon, which promotes the DNA base to high 
lying singlet S
N 
levels above the ionization limit (I.L.).   
The generated cation radical and the electron may recombine and possibly initiates 
crosslinking with hydrogen-bonded amino acids. There is, however, a finite 
probability for an intersystem crossing (I.C.) to the triplet T
1 
manifold, which has a 
long lifetime compared to the singlet S
1 
level. Absorption of a second photon then 
leads to a transition to high lying T
N 
levels above the ionisation limit. The ions 
produced via the triplet channel can also initiate crosslink to the contacting proteins. 
Processes leading to DNA damage can be initiated at any of the four excited states 


S
1
, S
N
, T
1
, and T
N
, but only S
N 
and T
N 
lead to crosslinking. Thus, to reduce DNA 
damage the population times in the non-productive states S
1 
and T
1 
should be 
minimized. From this point of view singlet channel to crosslink (via S-states) is to be 
favored to triplet channel (via T-states) as it is much faster thus reducing residence 
time in the intermediate, excited state which leads to cell damage without directly 
contributing to crosslink.  
In this process the crosslinking yield  strongly depends on pulse intensity and pulse 
length. 
By changing the pulse length the path leading to crosslinking can be chosen. For a 
pulse length shorter than the intersystem crossing rate constant, singlet-mediated 
crosslinking dominates, whereas pulses which are long compared with the 
intersystem crossing rate constant lead to crosslinking via the triplet channel. 
The  induction of UV laser crosslink between DNA and proteins presents, respect to 
the conventional chemical crosslink formation, the following advantages: 
 Shorter times of exposure 
 Reduced protein-protein bonds formation 
 Good yield 
 Possibility to analyze the kinetic of TFs and DNA binding in real time 
So crosslinking by short pulsed UV lasers is a potentially powerful tool to investigate 
such DNA–protein interactions, especially transient interactions and binding kinetics, 
because the number of photons required for covalent complex formation can be 
delivered very rapidly, in nano-, pico- or even femtosecond intervals, and the high 
energy of the pulses should result in efficient crosslinking with  no formation of a-
specific products. 
So, even though the conventional ChIP is a excellent technique to study the binding 
events to DNA, the Laser-ChIP is able to surpass the technical limitations of the 
original bottom-up process.  
These intrinsic limitations comprise: 
Selectivity: Formaldehyde introduces covalent bonds between protein-DNA and 
protein-protein complexes. Transcription factors (TFs) are generally embedded within 
complexes/machineries that display multiple interaction surfaces (with DNA or 
between subunits). This has two consequences: (i) factors that bind DNA directly or 
indirectly via protein-protein interactions with chromatin components will be 
crosslinked with vastly different efficiencies depending on the stability of the 
interaction and (ii) a single protein/complex can be crosslinked to more than one site 
in the genome e.g. in the case of enhancer-promoter looping. Native-ChIP can only 
be employed efficiently for very stable interactions, predominantly histone 
(nucleosome)-DNA interactions. The novel Laser-ChIP technology will identify direct 
protein-DNA contacts preferentially if not exclusively under certain conditions 
(wavelength, repetition rate, energy/pulse).  
Accuracy and efficiency: The overall performance of conventional ChIP depends 
critically on the efficiency of the first step, the crosslink of factors to DNA by 
formaldehyde exposure of intact cells. However, chemical crosslinking is diffusion-
controlled and varies considerably with cell type, manipulation, storage and purity of 
the chemical. Due to the progressively increasing non-specific crosslink by chemical 
crosslinkers, formaldehyde crosslinking has to be stopped long before a maximal 
crosslinking of DNA to protein has been reached. This implies low efficiency of the 
subsequent immunoprecipitation. L-ChIP involves ultra-fast physical crosslinking by 
femtosecond UV lasers specifically designed for highly efficient DNA-protein 
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crosslinking. Once calibrated it operates fully reproducible and highly accurate, and is 
cell and operator independent.  
Dynamics and half-lifes of DNA interactions: TFs bind with highly different 
kinetics/half-lives to DNA/chromatin. Current technologies do not allow studying very 
short-lived interactions. Due to its ultra-fast crosslinking, LChIP will allow fundamental 
studies on the mechanisms of DNA/chromatin recognition by DNA-binding regulatory 
factors.  
Sensitivity: Conventional XChIP requires large amounts of cells (about 10
6 
to 10
8 
cells) as starting material. Given its high efficiency documented in proof-of-principle 
experiments , LChIP in its current state of development already provides the 
sensitivity for regular TF analyses thus facilitating the analysis of very small numbers 
of cells (e.g. from patients samples) and subpopulations (e.g. hematopoietic cells).  
Single cell, tissue crosslinking and sorting: Current ChIP technologies do not 
permit crosslink of selected individual cells or frozen tissue slides and subsequent 
analyses of defined population. LChIP linked to with microscopic and cell-sorting 
platforms using microfluidic systems will permit to photo crosslink subsets of cells 
‘on-the-fly’, crosslink cells in particular phases of the cell cycle, or leukemia blasts for 
genome-wide analyses.  
Epitope masking and modification: Formaldehyde crosslinking alters lysine 
residues, which can be part of antibody epitopes in targeted DNA binding proteins, 
particularly in modified histones. This has several serious drawbacks: (i) it reduces 
substantially the IP efficacy in epigenetic studies and yields <<1% are commonly 
observed, (ii) due to the covalent stabilization of entire complexes, antibody epitopes 
may reside inside a complex, which would become accessible due to dissociation if 
only DNA crosslinks would occur, (iii) epitope-tagging is limited to peptides that are 
not modified by formaldehyde. LChIP will not affect protein epitopes and hence have 
a dramatically higher IP efficacy allowing the use of epitope-tagging approaches with 
highly efficient antibodies independent of the presence of lysines. 
The rationale at the bases of the entire experimental data set was: 
 the creation of a powerful tool (ERα-GFP methodology) to analyze in a short 
time the best conditions for the UV Laser crosslink induction 
 the validation of the method by performing ChIP analysis 
 the evaluation of cellular behavior in response to Laser treatment 
 the correction of the starting hypothesis on the bases of obtaining results 
Regarding to the first point the establishment of a rapid methodology to start the 
screening of Laser conditions was necessary to have an idea of the direction in which 
to move the first passes. As jet explained below, the setting of Laser device is 
composed by a lot of parameters to manage. Among them the energy/pulse, the 
repetition rate of photons, the time of irradiation, the total released energy, the 
number of hits and the wavelength of UV output Laser light. 
The combination of all these parameters increases strongly the number of biological 
proofs that are important to realize the setting.  
For this reason the availability of a screening test that links in a direct way the 
crosslink yield to the fluorescence signal was suitable for the purpose. 
With this test, whose principles were already been explained in the chapter Results, a 
lot of experimental conditions were tested simultaneously by varying the proper Laser 
parameters but also several technical and biological terms, as cellular concentration 
and typology of saline buffer. 
At the end of this preliminary session of data, as expected, some operative conditions 
were discovered in which the protein ERα-GFP was crosslinked to DNA fiber. 
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This conditions correspond to: 2Khz 125uJ, 200hz 125uJ and 20Khz 8uJ; the 
irradiation time was fixed to 60”, though in some conditions, and with the 20ul 
configuration, after a second of irradiation the recovery of crosslink was quite similar 
to 60” ones. 
It is important to keep in mind that, for the characteristic of this assay, the obtaining 
data constituted only a preliminary idea on the “final” L-ChIP establishment. 
In fact with this methodology was not considered the amplificability of DNA and the 
stability of crosslinked proteins but it only confirmed the capability to interfere with 
cellular processes (e.s the transcription and the epigenetic code) by the creation of 
stable bonds between DNA and proteins (transcriptional factors in particular). This 
factor explains also the motivation to choice time of irradiation that are lower than the 
chemical one but not very short for a ChIP experiments. 
In addition, because its technical simplicity, the ERα-GFP test is not affected by 
variability and it is quantitative if reported to a negative and positive control. 
In some of selected conditions founded through ERα-GFP method, the ChIP analysis 
was done. The conditions were: 2Khz 125uJ and 200hz 125uJ, chosen on the bases 
of value of cellular mortality (in particular, among the three different conditions 
previous listed, the one with the highest value of % cellular death and the lower one). 
As shown in Results, the ChIP experiment was performed looking at the 
trimethylation of lysine 4 of histone H3 and the % of chromatin immunoprecipitation 
(related to the quantity and quality of crosslink induction) was expressed as % of 
recovery of TRAIL promoter region sequence of DNA. 
The choosing to amplify the TRAIL promoter region could be justify with different 
motivations: i) TRAIL is an important protein involved in cell death and tumor fighting, 
ii) the TRAIL promoter region is affected by many epigenetic modifications and iii) its 
promoter region was extensively studied by the work group in the Department of 
General Pathology of SUN, Naples. 
The recovery in this ChIP experiment did not reach the value of the chemical one, but 
it was, however, good enough to continue the study.
In particular, it is worth pointing  out that a result comparable with the chemical 
crosslinked point was achieved through a decreasing in time of 1 order of magnitude 
(15 minutes versus 1 minute). 
The decrease of the induction time to obtain the crosslink allows to study a wider 
range of biological phenomena involving the interaction between DNA and proteins 
and the methods could be useful for study the time scale of all the interactions that 
occur on a specific region of DNA. 
The crosslink obtained with Laser source is a “zero-length” reaction, so, compared 
with the chemical methodology, it is less susceptible to the downstream conditions of 
ChIP experiments. 
For this reason, by vary a bit the protocol for the immunoprecipitation reaction (e.i 
increasing the % of detergents) the recovery of 3CH3K4H3 far exceeded the value of 
the positive control. 
The idea was to promote the stay of direct bounds between DNA and proteins 
comparing with a chemical link mediated by the insertion of a bi-functional reagent 
interacting with protein and DNA respectively. 
The most interesting thing is however the selectivity and preferential behavior of 
different genetic region to the crosslink induction with UV Laser light. 
As shown in Results, each DNA region analyzed by ChIP experiments acts as 
unique, though all of them are immunoprecipitated with the same antibody and the 
particular epigenetic mark is present on their promoter regions. 
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It could be justified by the characteristics of the DNA sequence composing the 
amplificated regions (TRAIL, H2B and SCAM5 promoters) or by the way by which the 
protein 3CH3K4H3 interacts with them (e.i. the orientation of DNA on the histone 
core, if the DNA regions protrude outward the histone or the region of crosslink 
resides in an area not accessible or poorly accessible to the photons released to the 
Laser device). 
To clarify this aspect it is need to study the 3D structure of wrapped DNA containing 
these regions, in relation to the particular epigenetic mark. 
One problem with UV laser crosslinking is the difficulty of comparing results obtained 
with different proteins and different DNA sequences. This is due to differences in the 
nature and strength of the interaction and to the involvement of different amino acid 
side chains and DNA bases. In some cases water molecules mediate the contacts 
between amino acids and DNA bases. 
It’s important to keep in mind that the Laser-ChIP is an in vivo technique. 
However, there could be fundamental differences between the results of crosslinking 
in cells or nuclei compared to crosslinking isolated nucleoproteins, as done in most 
studies. First, suspensions of cells or nuclei scatter significant amounts of the 
incident light, reducing the intensity of the light within the samples.  
Second, the local concentration of DNA in nuclei is very high, leading to an internal 
filtering effect that could also decrease the effective intensity of the light. Third, the 
high local concentration of DNA in nuclei might trap free radicals that could increase 
photochemical degradation of the DNA and proteins. 
These considerations underline the necessity of a thorough study regard the 
quantistic principles that rule the photo-crosslink induction. 
The synergy between theoretical calculations and experiments on chemical models 
together with the structural characterization of the photo-crosslinked products will 
help to understand the chemical principles governing the reactivity of DNA and 
proteins.  
Thus, the factors effecting the excitation of the DNA and the protein, the formation of 
intermediate reactive species, and the creation of the new DNA-protein bonds will be 
studied and this detailed description of the photochemical behavior of DNA in a 
protein environment will provide the knowledge needed for rational design and 
optimization of the crosslink experimental conditions. The identification of the 
electronic states of the DNA bases and the corresponding intermediate species 
involved in the DNA-protein bond-making process will also open the possibility of 
fine-tuning the laser wavelength in the visible range to selectively link the desired 
fragments. 
The DNA’s stability is a crucial factor for the success of a ChIP experiment because 
the fragility of its structure could interfere with the sonication step (bringing to the 
production of too short in length DNA fragments) that is fundamental for the 
precipitation mediated by the antibody and so for the amplification by PCR or in Real 
Time-PCR.  
From sonication tests (data not shown) performed on irradiated cells by varying the 
time of exposure to UV Laser treatment and by varying the conditions of sonication 
(in time of minute, amplitude, volume and etc..) was immediately evident the 
irradiated cells behaved differently. 
This observation was the first proof to the understanding of the possible DNA 
structural damage presence in the cellular model. 
To better understand the cellular behavior in response to the Laser treatment a lot of 
experiments were done, looking at cellular viability/mortality, the activation of 
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pathways of DNA damage recognition and repair, the cell cycle progression and the 
integrity of DNA itself. 
The idea was to discover a Laser condition by which the energy released to the cells 
was strong enough to promote the crosslink induction but not too hard to disrupt the 
DNA and to kill all of cells. 
So the first passage was to study in particular one condition (2khz 125uJ) keeping 
constant the repetition rate (equal to 2khz) and varying the parameter of energy to 
obtain, in the time unit of 1 minute, a scalar decrement of total energy. 
At this experimental points were also added some additional conditions, choosing the 
combination of rep rate and energy/pulse to achieve the same total energy  (3600 
mJ) of the experimental point 2khz 30uJ. 
For each point was analyzed first of all the cellular mortality, measured as capability 
of PI to pass through the cellular membrane of dead cells. 
From the total amount of data, the presence of two concomitant types of cellular 
death was discovered after the crosslink induction with the Laser device. One of this 
is active in the first minutes after the irradiation session, and culminates with a strong 
reduction in cell number after few hours past treatment. 
In cells that remain alive after treatment, the apoptotic pathway was activate, as 
demonstrated by caspases 3/7 activation, ROS production and the expression of 
some characteristic proteins. 
It is interesting to note that the activation of apoptotic pathway is mostly linked to the 
total energy released to Laser and absorbed by the cells. So the induction of 
apoptosis scales with the decrease of the total energy. 
The concomitant subsistence of both ways bringing to cellular death ensures that the 
geometry of irradiation (1 million of cells in 1 ml of PBS in a 1mm diameter quartz 
cuvette, in stirring) allows to hit all the cells present in. 
This is an additional proof of the improvement achieved by passing to a volume of 
20ul (with the same cellular concentration) to a volume of 1ml. 
It is interesting to note that for the experimental point at same total energy (2khz 
30uJ, 400hz 150uJ, 480hz 125uJ and 600hz 100uJ) the percentage of cellular death 
is different, as so the percentage of caspases activation, ROS production and protein 
expression. 
In fact it seems that an higher number of hits, with low energy each, affects less the 
cellular vitality in comparison to experimental points in which the same energy is 
released with fewer high energetic hits. 
This trend is also observed with regard to the expression of marker of damage 
proteins. 
The evaluation of cellular damages was also carried out looking at the presence of 
DNA dimers formation and double/single strand breaks.  
Both DNA lesions are present on the chromatin fiber, as confirmed by Comet assay 
and evaluation of bases dimers. The Comet assay, done on each experimental 
points, shows the production of DNA tails as function of damage (double strand 
breaks, in particular) that is, in turn, function of energy absorbed by the samples. 
The same is true for the dimers formation experiment, although the percentage of 
dimers is quite similar in all samples, indicating that in all conditions, the energy 
supplied is too much. Clearly the formation of adducts between TT bases requires 
less energy than one required for to break DNA strands and this could justify the 
data. 
Once understand that, in the used conditions, the DNA inside the cells was damaged 
and this damage could interfere with the downstream analysis, the next step (in the 
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definition process bringing to ChIP’s best conditions definition) was to progressively 
lower the energy, both for total number of photons, both for repetition rate. 
As confirmed by data regarding PI incorporation and ROS production, keeping lower 
the energy, the cells remain alive after the irradiating session, and this aspect is 
related to the reducing of DNA damage. 
To confirm that a low energy the crosslink induction was optimized, the Laser setting 
utilized for the ChIP experiment were 7Khz 7uJ and 2khz 7uJ. 
Regarding the condition 7khz 7uJ, the energy was scaled of a factor of 5, comparing 
to the previous analyzed 2khz 125uJ. 
Moreover the repetition rate was increased (passing from 2khz to 7khz) because, 
high rep/rate value with low energy for pulse seems to be preferred by the cells (as 
explained jet above). 
It is also important to note that in the condition 7Khz 7uJ, the ROS and caspases 
activation was very low, as soon as the percentage of cellular death. 
So the choice of this condition was been made because it combines some 
requirements for a theoretical good yield of crosslink formations: low value of cellular 
mortality, low percentage of ROS and caspases 3/7 activation but, however a not too 
reduced energy. 
The recovery of ChIP experiment in this condition was bigger than the positive control 
for the region of TRAIL promoter, instead for the genomic region H2B promoter the 
signal is still too low, but anyway present if compared with negative control. 
The trend of ChIP experiment is different when the output of Laser device is setting 
on a wavelength of 300nm. 
With the UV wavelength of 300nm is reduced the absorption of T and C residues, so 
theoretically the formation of dimers could be reduced and structural damages could 
be avoided; as confirmed by data, the pyrimidine dimers are still present also in this 
conditions, but in less percentage, comparing with the same experimental point in 
which the output UV is set on 260nm (corresponding to the spectral region in which 
the absorption of T and C is greatest). 
H2B promoter region seems to be crosslinked to 3CH3K4H3 in a better way, when 
the UV output is 300nm (referred to negative and positive experimental point) and the 
value is approximately equal to the chemical one. 
Regarding the TRAIL promoter region, instead, it seems to be less susceptible to 
vary the UV wavelength, as emerged looking at the recovery values, that are similar 
in the condition 260 and 300nm. 
The set of data displayed and discussed at now, suggests that as each in vivo
technique, for the establishment of UV Laser mediated crosslink many physical and 
biological parameters need to be consider. 
First of all, the UV Laser light characteristics assume key role in the setting of ChIP 
experiments by the definition of the better balance between total energy and 
repetition rate. 
Also some structural features are important: among them the apparatus’s geometry 
used for the irradiation, the material of the cuvette, the size of Laser beam, the speed 
of stirring. 
The most important thing to consider, however, is still the cellular behavior in 
response to the UV incident radiation and the way by which the crosslink could be 
formed. 
To be sure that the creation of stable bonds between DNA and proteins is obtained, 
the cells must be hit with sufficient energy and the energy reaching the biological 
model  does not disrupt the proteins or DNA itself.

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Abstract: We investigate the interactions between proteins and
DNA in solutions of living cells, triggered by UV, 200-fs laser
pulses. DNA-protein crosslinking is obtained with two different
techniques: conventional chemical or laser-induced. Our results
evidence a nonlinear response of the cells to the laser irradiation
in the investigated intensity range. The laser induced crosslink
efficiency can reach a value approximately twice higher than
that obtained with ordinary chemical methods. The experimen-
tal results are very well reproduced by a simple phenomenolog-
ical model based on the interplay between two-photon absorp-
tion by DNA bases and cell damage induced by high intensity
laser pulse.
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Measured (experimental points)/calculated (lines) DNA-
protein crosslinking yield in human U937 acute myeloid
leukemia cells versus the laser pulse energy for 2′ (circle) and
5′ (squares) irradiation times
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1. Introduction
Femtosecond ultraintense laser pulses have been widely
used so far micro- and even precise nano-machining of bi-
ological materials [1–5] and imaging of tissues for diag-
nostics purposes [6,7]. In this letter we focus on a differ-
ent type of application of femtosecond laser pulses to bio-
materials. In fact, we exploit the possibility of these pulses
to efficiently trigger bio-molecule dynamics and, in a near-
future prospect, to monitor the system response with high
temporal resolution.
Establishing a stable covalent bond between proteins
and nucleic acids, usually referred to as crosslinking [8] in
molecular biology, affords access to study otherwise tran-
sient interactions between bio-molecules, what is a cru-
cial task for all bio-sciences. At the same time, it is possi-
ble this way investigating the interaction of complex sys-
tems with femtosecond, intense laser pulses, which repre-
∗ Corresponding author: e-mail: carlo.altucci@unina.it
c© 2011 by Astro Ltd.
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Figure 1 (online color at www.lphys.org) Schematic layout of the experiment. In (1) solutions containing living cells are irradiated by
fs-UV laser pulses. This causes the formation of a covalent bond between an excited DNA base and a protein nearby. The samples are,
then, processed by ChIP protocol [26,27] and qPCR [28] to measure the amount of a specific DNA region, the TRAIL promoter, bound
to a specific protein, the H3K4me3 Histone [29]. (2) – (6) Scheme of the Chromatin Immunoprecipitation (ChIP) protocol consisting in
five serial phases before accessing the final qPCR (7) for detection and quantification. In (2) cells are opened and DNA is sheared, in (3)
the antibody of interest, which selectively recognizes only H3K4me3, is added. The last three phases consist in an immunoprecipitation
(4) to isolate the protein of interest and, consequently, the crosslinked DNA fragments. A reverse crosslink takes place in (5) and (6)
to purify and isolate the DNA fragments from the protein complexes. In (7), by means of qPCR, the appropriate DNA fragments are
hugely amplified in number so as to quantify the amount of TRAIL promoter DNA region linked to the H3K4me3 protein
sents a fascinating challenge for femto-chemistry and non-
linear physics. Crosslinking with fs-UV lasers has been
presented in the literature as a revolutionary technique to
increase the otherwise low process yield of conventional
methods based on chemical catalysts [9], conventional UV
sources [10], or longer UV pulses [11,12].
It is known that crosslinking induced in cells by ultra-
short laser pulses has a twofold advantage over conven-
tional methods: (i) it binds only species that are in proxim-
ity (“zero length” covalent bond) of the absorbed photons
rather than favoring unspecific bonds amongst many pos-
sible species in the cell and (ii) it should only operate until
the radiation is incident on the sample, thus paving the way
for time-resolved studies of transient interactions. More-
over, when combined with biochemical techniques such as
chromatin immunoprecipitation (ChIP) to analyze the pro-
duced bonds, the UV laser method will make feasible the
characterization of the dynamics of the transcription fac-
tors bindings on chromatin in living cells, thus overcoming
the technical limitations of the current ChIP technology
[10,13,14].
One of the essential questions about the interaction of
the UV laser light with living cells is the role played by
the laser intensity. In fact, while the advantages gener-
c© 2011 by Astro Ltd.
Published exclusively by WILEY-VCH Verlag GmbH & Co. KGaA www.lphys.org
Laser Phys. Lett. (2011) 3
ally offered by pulsed lasers over conventional radiation
sources to photo-induce crosslink are widely recognized,
it is still unclear if the photon absorption by DNA bases
is a single or rather two photon process. Past experiments
carried out on cellular fractions or in vitro purified DNA-
fragment/protein reported linear [15–18] as well as non-
linear dependence of cross-link yield on the laser inten-
sity [11,12,18–22], suggesting that the discrepancies may
result from the possible role played by the particular sys-
tem under study. Thereby, this strongly limits the scope of
in vitro experiments and pushes for experiments on living
systems like cells.
Here we report on the femtosecond laser irradiation of
human cells demonstrating the occurrence of DNA-protein
crosslinking in their most native state. Our results match
well with the two-photon absorption, thus corroborating
the mechanism based on the radical formation proposed in
[23]. Since the cross-link is demonstrated in ex vivo system
(e.g. living cells), we expect that such a finding is of rather
general validity. To explain our results we have adopted
a simple, phenomenological model to describe the excita-
tion process finding a fair agreement with the experimental
results.
2. Experiment and modeling
The scheme of our experiment, from the initial excitation
induced by laser pulses to the final measurement of the
amount crosslinked material, is summarized in Fig. 1, in
its seven steps. A solution of U937 human acute myeloid
leukemia cells (see supplemental material [24] for details)
was irradiated with the fourth harmonic (220 fs, 263 nm)
of a Twinkle laser source operating at a repetition rate of
33 Hz [25]. Various irradiation times and pulse energies
have been tested. For all experiments the cell concentra-
tion in the sample was 3.75×108 cells/ml whereas irradi-
ations took place at room temperature (see supplemental
material [24]). Shining a fs-UV-laser pulse onto the target
can cause two-photon absorption by the DNA bases fol-
lowed by the formation of a covalent bond with a protein
lying in the proximity of the excited base (1). Successively,
as shown in the (2) – (7) step sequence of Fig. 1, samples
were treated by a ChIP protocol [26,27]. It was, then, pos-
sible to isolate and measure, by quantitative polymerase
chain reaction (qPCR) (see [28] for a review), the amount
of a specific DNA region, named TRAIL-gene-promoter,
linked to a specific nuclear protein, named H3K4me3 [29].
In step (2) living cells are broken and the DNA is sheared,
whereas in step (3) an antibody is added to selectively rec-
ognize only those DNA fragments cross-linked with the
protein of interest (H3K4me3), thus enabling to fish them
on. During an incubation time (Fig. 1, step (4)) the im-
munoprecipitation protocol is carried out, whereas in steps
(5) and (6) selected DNA fragments are inversely cross-
linked and washed by removing the protein-antibody com-
plexes. Finally, in step (7) the appropriate DNA fragments
are amplified and quantified by qPCR.
In order to analyze the obtained results we have devel-
oped a simple phenomenological model for the response of
our system to the pulsed UV-irradiation, based on the fol-
lowing assumptions. i) Only DNA-bases of the cell chro-
matin get excited upon irradiation, ii) the dominant exci-
tation is initiated by two-photon absorption as reported for
ps pulses in [23,11], and iii) damage to the cells caused by
irradiation with intense UV laser pulses occurs at relatively
high peak intensities, larger than 2 GW/cm2, in agreement
with a typical threshold-like behavior with the pulse en-
ergy [30].
As long as the first hypothesis is concerned, it is well
known that aromatic amino-acids, tryptophan, phenylala-
nine, and tyrosine, which are abundant also in nuclear pro-
teins, absorbs at 260 nm. Thus, in principle, UV light could
also trigger crosslinking by first exciting proteins rather
than DNA. Nevertheless, the static UV (≈ 260 nm) ab-
sorption spectra of bases and aromatic amino-acids show
much stronger absorption of bases compared to amino-
acids. The influence of solvent and intra-cellular water-like
liquid has also been discarded in view of the negligible wa-
ter non-linear absorption at 260 nm at the used intensities
[31], the linear absorption being very small as well in this
UV window. The bi-photonic excitation mechanism based
on radical cation formation has been invoked in [23,11]
and relies on the two-photon absorption by the same base.
The two photons can also be absorbed by two different
bases of the DNA double strand, separated by not more
than two-three bases [32]. In this case, the decay channel
of the system is governed by base-stacking conformation
and the path followed by stacked bases can strongly differ
from that of unstacked ones. Although our results are in
agreement with two photon absorption mechanism, we are
not able to discriminate the actual microscopic absorption
mechanism.
Finally, by relying on the above hypotheses, it is easy
to work out the expression of the crosslinking process
yield, Y , as a function of the two macroscopic knobs of
our experiment, i.e. the pulse energy, Epulse, and the num-
ber of laser shots, Nshot, per irradiation. For the sake of
simplicity we will refer in the following to Epulse although
the relevant physical quantity turns out to be the laser pulse
intensity.
If Π(Epulse) is the probability that a DNA base is led
to double excited state by two UV photon absorption, and
D(Epulse) is the probability that a crosslinked specie sur-
vives after the irradiation of a single pulse (damage func-
tion), the overall yield, Y , after Nshot is:
Y
(
Epulse, Nshot
)
∝ (1)
∝ ΠDNshot−1 + Π(1−Π)DNshot−2 + . . . ,
where the sum is over Nshot terms each of them contain-
ing a polynominal in Π whose coefficients form the Pascal
triangle. The sum in Eq. (1) can be easily carried out to
give:
Y
(
Epulse, Nshot
)
= (2)
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kΠ
(
Epulse
)
DNshot−1
(
Epulse
)1− ξ(Epulse)Nshot
1− ξ
(
Epulse
) ,
where
ξ
(
Epulse
)
=
1−Π
(
Epulse
)
D
(
Epulse
)
and k is an instrumental constant.
If σ1 and σ2 are the cross sections for the first and the
second photon absorption respectively, and p is the proba-
bility the excitation leads to a covalent DNA-protein bond,
Π(Epulse) can be written as:
Π
(
Epulse
)
= pσ1σ2
E2pulse
E2photonA
2
, (3)
Ephoton = 4.5 eV being the single photon energy and A the
laser spot size onto the sample, which in our experiment
has been measured to be 0.25 cm2.
The damage function D(Epulse) has been chosen so as
to reproduce the above mentioned threshold-like behavior
of the crosslinked cells damage with the pulse energy [21]:
D
(
Epulse
)
=
1
2
[
1− Erf
(
Epulse −Eth
∆E
)]
. (4)
In Eq. (4) Eth stands for the energy threshold and ∆E for
the slope of the damage when the energy increases. It is
worth stressing that we have not accounted for possible
damage to non-crosslinked cells. Such an assumption has
been corroborated by checking irradiated non-crosslinked
cells by means of the fluorescence activated cell sorting
methodology and finding out that cell-damage is negligible
in our conditions.
We have used Eq. (2) to best-fit our measurements
which report the crosslink yield versus Epulse for 2 and
5 minutes irradiations, as shown in Fig. 2. The best-fit pa-
rameter values turned out to be pσ1σ2 = 4.4×10
−34 cm4,
Eth = 185 µJ, and ∆E = 30 µJ. The estimation of the prod-
uct σ1σ2 depends on the particular macromolecule under
consideration. For instance, the absorption cross-section
of liquid aqueous solution of thymine at the wavelength
of 282 nm for the S0→S1 transition triggered by fs laser
pulses is σ1≈ 3 – 10×10
−17 cm2 [33], whereas the ab-
sorption cross-section of a uridine molecule from the first
excited singlet state S1→S2 at 266 nm is σ2≈ 10
−15 cm2
[23,34]. These values would provide p≈ 0.1 when the
two-photon absorption involves two different bases each
of them making the S0→S1 transition, and p≈ 0.01 for
the mechanism involving one single base making the
S0→S1→S2 transition.
Eth = 185 µJ, and ∆E = 30 µJ are realistic val-
ues in the damage dynamics of tissues due to irradi-
ation with intense UV laser pulses [30]. In particular,
Eth = 185 µJ leads to a threshold intensity of≈ 3 GW/cm
2
for crosslinked cell damage in good agreement with the
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Figure 2 (online color at www.lphys.org) Measured (experimen-
tal points)/calculated (lines) DNA-protein crosslinking yield in
human U937 acute myeloid leukemia cells versus the laser pulse
energy for 2′ (circle) and 5′ (squares) irradiation times. The blue
and black horizontal lines represent the yield values obtained
with ordinary chemical methods and measured in non-irradiated
cells, respectively
value reported for cell damage in Chinese hamster ovary
by fs-345-nm laser pulses [35].
The behavior of the crosslinking yield versus the laser
pulse energy in Fig. 2 clearly demonstrates the nonlin-
ear response of the system to laser pulse irradiation. The
yield increases quadratically up to a maximum value, after
which it quickly drops off due to cross-linked cell damage.
The longer irradiation time results in a smaller yield due to
damage accumulation.
The maximum value falls at about 110 µJ for 2′ irradi-
ation, whereas it shifts to lower pulse energies (50 µJ) for
5′ irradiation, again due to higher damage. The fair agree-
ment between simulations and measurement is noticeable
in view of the high intrinsic fluctuations of the extremely
complex system under investigation. The error bars result
from the root mean square of the values measured in five
experimental runs carried out at different times with dif-
ferent samples of the same cell line. Thus, we can assess
that our analysis is reliable even though only few exper-
imental points are above the no-cross level, the latter be-
ing the amount of crosslink yield found in non-irradiated
cells. This value is about half the yield usually obtained
with ordinary chemical methods, which amount to ≈ 1 –
3% [8]. It is remarkable that the maximum yield obtained
in our experiment by inducing crosslink with UV fs-pulses
is about twice as high as the value achieved with chemi-
cal methods. Thus, not only ultrashort UV pulses produces
crosslink in time interval much shorter than those required
by chemical methods, but even the yield can be definitely
c© 2011 by Astro Ltd.
Published exclusively by WILEY-VCH Verlag GmbH & Co. KGaA www.lphys.org
Laser Phys. Lett. (2011) 5
larger than that obtained with the conventional methods
currently used.
This is a striking finding which could be even im-
proved paving the way to detect and study new interactions
in molecular biology, which are too weak to be detected
with standard techniques.
It worth stressing, however, that our model is far from
being a detailed description of the crosslink mechanism
in living cells from a microscopic prospect. Although we
claim the fundamental role is played by the two photon
absorption, we cannot state whether the absorption is lo-
calized in a single DNA base, as suggested in [11,12,23],
or there is a contribution from a collective excitation in-
volving two bases, rather close to each other in the double
strand DNA, as suggested in [32] and theoretically pre-
dicted in [36]. Even the mechanism involving two singly-
excited bases lying in the triplet T1 state, next to each
other, like in the bi-molecular triplet-triplet annihilation
[37] is compatible with our results.
We point out that our model reaches three important
goals:
1. it reproduces very well the response of our complex
system to laser pulse irradiation in a number of cases,
2. it sheds light on the investigated crosslink mechanism,
providing some explanation for the nonlinear behavior,
still being of general validity,
3. it relates the measurable DNA-protein crosslink yield
of a complex system such as a human cell directly to
macroscopic degrees of freedom, such as Epulse and
Nshot, which are controlled in the experiment.
Hence, after testing the reliability of the model by fit-
ting the measurements, we have looked for the best possi-
ble irradiation conditions within the Epulse – Nshot plane.
The result is shown as a contour plot in Fig. 3.
We notice that the maximum crosslink efficiency is ex-
pected at Nshot≈ 1000 and Epulse≈ 120 µJ. This corre-
sponds to about half a minute irradiation time and would
lead to yield enhancement of a factor of 2.5 over the result
achieved via the chemical method. Of course, the shorter
the irradiation time the smaller the induced damage in the
crosslinked cells.
3. Conclusion
In summary, we have experimentally demonstrated that
living human cells non-linearly respond to irradiation with
intense fs-UV-laser pulses. Amongst the phenomena trig-
gered by such pulses a highly efficient DNA-protein oc-
curs, which reaches yields twice (or even more) higher
than those obtained with ordinary alternative methods.
This observation provides an answer to the fundamental
scientific question, debated over the past decade, whether
the response of complex bio-molecules such as DNA and
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Figure 3 (online color at www.lphys.org) Map of the calculated
ratio of photophysical/chemical yield for DNA-protein crosslink
in living cells, as a function of the pulse energy and the number
of laser shots. The white horizontal lines refer to the experienced
conditions of the experiment, corresponding to 2′ and 5′ irradia-
tions, respectively
proteins in living cells is linear or non-linear. Our ex-
perimental results are well reproduced by a simple phe-
nomenological model based on the interplay between non-
linear UV-absorption by DNA and cell damage induced
beyond a typical pulse energy threshold. Our findings have
a twofold importance: on the one hand they shed light on
the physical behavior of highly complicated and interest-
ing bio-systems, such as DNA and proteins, in a physical
context typical of ultrashort non-linear dynamics driven by
fs laser pulses; on the other hand they pave the way for a
new technique aimed to establish DNA-protein crosslink
in living cells, which promises to have a huge impact in
molecular biology and bio-sciences. Such an approach can
replace ordinary methods to study the interaction between
DNA and proteins, due to its very high efficiency and gen-
eral applicability. Not least, the short irradiation time can
allow one to study the so-called transient interactions oc-
curring on a short time scale and generally undetectable
with conventional techniques.
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Abstract 
Objectives: Curative properties of medicinal plants such as Psidium guajava L. (Myrtaceae) have 
been often claimed by epidemiological studies on populations in which these fruits are consumed 
daily. However, a complete characterization of the active principles responsible for this capability 
has never been performed. We have characterized Guajava anticancer potential and identified the 
parts of the fruit involved in this anticancer action.  
Material and methods: Cell cycle, apoptosis, differentiation analyses, morphological-stainings, 
western blots.  
Results: We report that the Guajava acetonic extract exerts anti-cancer activities on hematological 
and solid cancers. Guajava extract anti-proliferative action is tightly bound to induction of apoptosis 
and differentiation. The use of ex vivo myeloid leukemia blasts corroborates that the Guajava extract 
is able to induce cell death. Guajava extract does not show anticancer effects on all the tested cancer 
cells indicating a selective activity against certain types of cancer models. The analyses of Guajava 
three different components, flesh, peel and seeds, identifies the flesh fraction as the relevant part for 
the induction of cell cycle arrest and apoptosis, whereas the peel component is responsible for 
differentiation. Guajava and the flesh-derived extract induces apoptosis accompanied by caspase 
activation and p16, p21, FASL, BAD and DR5 overexpression.  
Conclusions: Our findings show that the Guajava extract is able to exert anti-cancer action in vitro 
and ex vivo supporting the hypothesis of pro-apoptotic regulation against cancer. 
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Introduction  
The medicinal use of natural products - compounds that are derived from natural sources such as 
plants, animals and micro-organisms - precedes recorded human history probably by thousands of 
years. Only in the last decades natural products have taken on a role in drug discovery and 
development given that emerging sciences such as molecular biology and combinatorial chemistry 
appear to be able to satisfy the requests of the pharmaceutical industry. In concrete terms, the 
rational design of chemical compounds to target specific molecules often draws on what in nature 
already exists. Therefore improving and understanding the biological effects of many natural 
compounds represents a significant option for drug discovery in the field of biomedical sciences. 
Natural compounds, particularly plant derivatives, are the subject of an increasing number of 
studies and growing interest is being directed to plants that are well known for their medicinal 
properties. Among these, Psidium guajava L. (Myrtaceae) has a long history of officinal and 
medical use in many tropical American and Southeast Asian populations (1). Psidium guajava, 
considered native in Mexico (2), is widespread throughout South America, Europe, Africa and Asia. 
Based on archaeological evidence it has been known and used widely in Peru since pre-Columbian 
times. It grows in all the tropical and subtropical areas of the world, adapts to different climatic 
conditions, although dry climates are preferred (3). The main traditional use known is as an anti-
diarrheal. Other reported uses include treatment of gastroenteritis, dysentery, stomach ailments, and 
intestinal disorders due to pathogenic germs of the intestine (4). Its medicinal usage has been 
reported in indigenous systems of medicine in America more than elsewhere. Psidium guajava is a 
small three which is 10 metres high with thin, smooth, patchy, peeling bark. Leaves are opposite, 
short-petiolate, the blade oval with prominent pinnate veins, 5–15 cm long. Flowers are somewhat 
showy, petals whitish up to 2 cm long, stamens numerous (3). Fruit are fleshy yellow globose to 
ovoid berry about 5 cm in diameter with an edible pink mesocarp containing numerous small, hard, 
white seeds. From a phyto-chemical point of view Guajava fruits contain many phenolic 
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compounds (such as gallic and ferulic acid), flavonoids (such as quercetin, kaempferol, guajaverin), 
carotenoids, triterpenes, tannins and quinones. The heterogeneity of Guajava fruit constituents could 
explain the immense potential of this plant in the treatment of conditions such as diarrhea (5), 
gastroenteritis and rotavirus enteritis (6), wounds, acne, dental plaque, malaria, allergies, coughs, 
diabetes, cardiovascular disorders, degenerative muscular diseases (7,8), inflammatory ailments 
including rheumatism and menstrual pain, liver diseases etc (9) . Not surprisingly, Guajava also 
exhibits antioxidant (10) and anti-inflammatory effects as oxidative injury underlies many of these 
diseases (11). Recently, anticancer activity has been reported for Guajava and some other Myrtaceae 
fruits (12,13) supported by epidemiological studies on populations in which these fruits are 
consumed daily. However a deep analysis and a complete characterization of the active principles 
responsible for this capability have never been performed. 
Here, we have characterized the anticancer potential of Guajava and identified the parts of the fruit 
involved in this anticancer action.  
 
Materials and methods 
Plant material 
 Psidium guajava L. (Myrtaceae) fruits were collected from Brazil. Identification was carried out by 
Prof. Adriana Basile — Section of Plant Biology, Department of Biological Sciences, Federico II 
University of Naples, IT.  
Method of extraction        
P. guajava fruits, fresh or after storage at −20° C, were treated with Triton X-100 0.8% water 
solution to remove epiphytic hosts normally found on the surface. After extensive washings in TAP 
buffer (Tris-HCl pH 7.0 50 mM, NaCl 180 mM, NP-40 0.15%, glycerol 10%, MgCl2 1.5 mM, 
NaMO4 1 mM, NaF 0.5 mM with protease inhibitors (Sigma), 1 mM DTT and 0.2 mM PMSF) and 
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distilled water, the fruits were dried on filter paper. Four different acetonic extracts were then 
prepared. For the first, 826 g of whole guava fruits were blended, freeze-dried and then extracted 
for 3 days with acetone at room temperature (3×5 l). Following filtration, the solvent was 
evaporated under reduced pressure and moderate temperature (35˚C) to give a gum (48 g). The 
same protocol was applied for the preparation of the other three extracts (peel, flesh and seed) after 
isolating the different parts of the fruit (14). In brief, 364 g of fresh guava peel gave 6 g of dry 
acetonic extract, 1,220 g of fresh guava flesh gave 50 g of dry acetonic extract and 31 g of seeds 
gave 300 mg of dry acetonic extract. All four extracts were freeze-dried and successively assayed 
for their anticancer potential. 
Cell lines, primary cells and culture conditions 
  NB4 cells were provided by M. Lanotte. All other cell lines were purchased from ATCC and 
routinely cultured. NB4 and U937 cells were grown at 37°C in air and 5% CO2 in RPMI-1640 
medium (GIBCO), supplemented with 10% heat-inactivated foetal bovine serum (FBS), 1% L-
glutamine, 1% ampicillin/streptomycin and 0.1% gentamicin.  U2OS osteosarcoma cells were 
grown at 37°C in air and 5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM, GIBCO) 
supplemented with 5% foetal bovine serum (FBS, GIBCO), 1% L-glutamine, 1% 
ampicillin/streptomycin and 0.1% gentamicin. MDA-MB231 breast cancer cells were grown at 
37°C in air and 5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM, GIBCO) supplemented 
with 5% foetal bovine serum (FBS, GIBCO), 1% L-glutamine, 1% ampicillin/streptomycin and 
0.1% gentamicin.  For the AML samples purifications and cultures were carried out as previously 
described (15). This study was approved by the Ethical Committee of the Second University of 
Naples. SAHA (kindly donated by Merck) and MS275 (Alexis) were resuspended in DMSO and 
used at a final concentration of 5µM. All Trans Retinoic Acid (ATRA, Sigma) was resuspended in 
100% ethanol and used at a final concentration of 1µM.   
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 Cell cycle analysis 
 2.5×105 cells were collected and resuspended in 500µl of a hypotonic buffer (0.1% Triton X-100, 
0.1% sodium citrate, 50µg/ml propidium iodide (PI), RNAse A). Cells were incubated in the dark 
for 30 min. Samples were acquired on a FACS-Calibur flow cytometer using Cell Quest software 
(Becton Dickinson) and analysed with standard procedures using Cell Quest software (Becton 
Dickinson) and the ModFit LT version 3 Software (Verity) as previously reported (16). All the 
experiments were performed in triplicate.  
FACS analysis of apoptosis 
Apoptosis was measured with Annexin V/PI double staining detection (Roche and Sigma–Aldrich 
respectively) as recommended by the suppliers; samples were analysed by FACS with Cell Quest 
software (Becton Dickinson) as previously reported (15,17). The apoptotic fraction was calculated 
by measuring Annexin V positive /PI negative cells. As second assays caspase 8, 9 and 7-3 
detection (B-Bridge) was performed as recommended by suppliers and quantified by FACS (Becton 
Dickinson).  
Granulocytic differentiation assay 
 Granulocytic differentiation was carried out as previously described (15,18). Briefly, NB4 cells 
were harvested and resuspended in 10µl phycoerythrine-conjugated CD11c (CD11c-PE) or 10µl 
FITC-conjugated CD14 (CD14- FITC) (Pharmingen). Control samples were treated with 10µl PE or 
FITC conjugated mouse IgG1, incubated for 30 min at 4°C in the dark, washed in PBS and 
resuspended in 500µl PBS containing PI (0.25µg/ml). Samples were analysed by FACS with Cell 
Quest software (Becton Dickinson). PI positive cells were excluded from the analysis. 
Western blot analysis 
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Forty µg of total protein extracts were separated on a 15% polyacrylamide gel and blotted as 
previously described (19). Western blots were performed for p21 (Transduction Laboratories, 
dilution 1:500) and for p16 (Santa Cruz, dilution 1:500) and total ERKs (Santa Cruz, dilution 
1:1000) were used to normalise for equal loading. For quantification of TRAIL protein, 100 µg of 
total protein extracts were separated on a 10% polyacrylamide gel and blotted. Western blots were 
performed for TRAIL (Abcam, diluition 1:200) and ERKs (Santa Cruz, dilution 1:1000) was used 
to normalise for equal loading. The same protocol was applied for DR5 (Millipore, dilution 1:1000). 
To determine FLIP levels, 35 µg of total protein extracts were separated on a 12% polyacrylamide 
gel and blotted. Western blots were performed for FLIP (Alexis, dilution 1:500) and total ERKs 
(Santa Cruz, dilution 1:1000) were used to normalise for equal loading. To determine BAD levels 
35 µg of total protein extracts were separated on a 12% polyacrylamide gel and blotted; the same 
was done for FASL (ProSci, dilution 1:500). For both proteins total ERKs (Santa Cruz, dilution 
1:1000) was used to normalise for equal loading.  
Morphology staining  
NB4 cells were spun onto glass slides with a cytospin centrifuge. Cell morphology was analysed 
after May-Grunwald Giemsa stain (SIGMA).  
 
Results 
 
Total acetonic Guajava fruit extract induces anticancer action in leukaemia NB4 cells 
 
That Guajava exerts anticancer action was initially confirmed by using the total acetonic Guajava 
fruit extract at different concentrations for a time of 48 hours in NB4 promyelocitic leukaemia cells. 
Trypan blue staining carried out in NB4 cells treated with the total acetonic Guajava fruit extract at 
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different concentrations indicated its strong anti-proliferative effect. Interestingly, the effect of 
Guajava total acetonic extract is linear and dose dependent (Fig. 1a, b). That two different time-long 
treatments (3 and 5 days) displayed the greatest effect in a dose-dependent manner in a 
concentration range of 5-1.5 mg/mL strongly suggested that the inhibition of cellular growth might 
be related to a ‘bona fide’ anti-proliferative dose-dependent effect rather than to drug toxicity. When 
cell cycle effects were analysed, treatment with total acetonic Guajava extract (in the range of the 
biological active dose) induced a G1 cell cycle block (Fig. 1c) of around 80% at concentrations of 
1.5 mg/mL and 3 mg/mL.  
 
Total acetonic Guajava fruit extract exerts anticancer action by inducing apoptosis and 
differentiation in cancer cells and primary leukaemia blasts. 
 
When apoptosis was measured upon treatment of NB4 cells with total acetonic Guajava extract, the 
percentage of apoptotic cells increased during treatment and the effect was already measurable at 
very low dose concentrations (around 0.4mg/ml) (Fig. 2a). When total acetonic Guajava fruit 
extract was tested for 48 hours ex vivo in primary leukaemia blasts deriving from a patient affected 
with acute myeloid leukaemia (AML) (AML #106), the induction of apoptosis was confirmed 
indicating that not only leukaemia cell lines, but also primary AML cells respond to Guajava extract 
treatment with apoptosis (Fig. 2b). As positive controls for induction of apoptosis two different 
HDAC inhibitors (HDACis), SAHA and MS275 were used. 
To establish whether Guajava fruit extract was also able to induce differentiation, the presence of 
CD11c, a specific marker for granulocytic differentiation, was evaluated in NB4 cells after 48 hours 
of treatment. CD11c expression increased even at a concentration of 0.75 mg/ml, and reached its 
maximum level at a concentration of 1.5 mg/ml (Fig. 2c). Nevertheless, the differentiative effect 
was lower than that of All Trans Retinoic Acid (ATRA), a well known anti-tumour and pro-
differentiative agent (17, 18,20). In full agreement with these data immunoistochemical staining 
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revealed that after 120 hours of treatment with Guajava total acetonic extract, NB4 cells assume the 
characteristic granulocytic morphology as bilobate nuclei and granules presence, as shown in Fig. 
2d. Interestingly, total acetonic Guajava extract exerted both an anti-proliferative effect and 
induction of cell death in MDA-MB 231 breast cancer cells (Fig. 2e), thus suggesting its anticancer 
activity in some solid cancer models as well.  
 
Guajava flesh extract is essential for cancer apoptotic action 
 
To better understand the biological action of Guajava extract, we fractioned the fruit parts aiming to 
identify which component(s) (peel [skin], flesh [pulp] and seeds) are actively responsible for its  
anti-cancer action. As shown in Fig. 3a, after the indicated treatments cell cycle progression was 
mainly altered by the flesh component, whereas peel and seed components only marginally affected 
cell cycle. Furthermore, the flesh component also proved to be mainly responsible for the induction 
of apoptosis, at around 65% (Fig. 3b). That the peel extract affected apoptosis to a lesser extent 
indicates a partial contribution of this component to cell death. When differentiation was measured 
by CD11c detection, the peel components were shown to be as significant for CD11c expression as 
the total extract. Morphology of NB4 cells upon May-Grunwald Giemsa staining after the indicated 
treatments further confirmed these data (Fig. 3c, d). Thus, flesh components mainly influenced 
apoptosis, whereas peel extract was responsible for differentiation. 
In order to understand to what extent the apoptotic effects can apply to different cancer cell models, 
we tested the total and component-specific Guajava extracts in breast, bone and leukaemia cancers. 
As shown in Fig. 4a, both total acetonic Guajava extract and flesh extract exerted an anti-
proliferative effect and induced cell death in MDA-MB 231 breast cancer cells. Differently, U937 
AML cells and U2OS osteosarcoma cells displayed neither cell cycle variations nor apoptosis at the 
time and concentrations tested, suggesting that only some cancer models are sensitive to Guajava 
treatment (Figure 4b, c). 
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Guajava flesh extract mediates caspase activation and apoptotic molecular events  
To better understand the molecular events underlying Guajava-induced cell death, caspase assay 
(caspase 8, 9 and caspase 3/7) were performed. As shown in Fig. 5a, caspase 8 and 9 are mainly 
activated by flesh extracts, thus suggesting that cell death is due to apoptosis and that the flesh 
component is the active anticancer part of the fruit. To confirm this hypothesis and to evaluate 
which molecular players could be involved in the anticancer action of Guajava flesh extract on NB4 
cells, the expression levels of different known key factors in cell cycle progression and apoptosis 
were analysed by Western blot analysis. As shown in figure 5b, after 48 hours of induction the total 
acetonic Guajava, peel, flesh and seed extracts induced the expression of p21 and p16, known cell 
cycle inhibitors. Taken together these data indicate that the most active Guajava fraction is the flesh 
component, confirming the observation on cell cycle block (Figure 5b and 1c). Under similar 
experimental conditions, the expression levels of pro- and anti-apoptotic proteins were analysed. 
Interestingly, DR-5, FASL and BAD appear to be induced after treatment with the total Guajava and 
flesh extracts, validating the pro-apoptotic action of both. In particular, only treatment with flesh 
fraction led to a significant decrease of the protein FLIP-L (a strong inhibitor of caspase 8-mediated 
apoptosis), although the expression level of the protein FLIP-S remained unchanged. (Figure 5b). 
 
Discussion  
Plants have long served as a useful and natural source of therapeutic agents. It is generally 
recognized that the consumption of a variety of local herbs and vegetables significantly contributes 
to the improvement of human health, in terms of prevention and treatment of diseases.  
Presently, in many developing countries, about 80% of available drugs derive from medicinal 
plants. Frequently in industrialized countries, the raw materials used to synthesize pure chemical 
derivatives have plant origin. 
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Psidium guajava L. belongs to the family of Myrtaceae (21). It is a tropical plant widely grown in 
Taiwan, Hawaii, Thailand, the Philippines and Malaysia, where Guajava fruits, leaves, and bark 
have been traditionally used as traditional herbal medicines and exhibit many therapeutic effects 
including amebicide, analgesic, vermifuge, anti-malarial, anti-bacterial, colic-relief, anti-spasmodic, 
astringent, anti-ulcerous, hypotensive, anti-inflammatory, anti-hyperglycemic and anti-diarrheal 
properties  as well as acting as a gastrototonic cough suppressant and combatting some psychic 
diseases. 
Psidium guajava anticancer activity has been thoroughly investigated in our study and data 
concerning the active anticancer parts of the fruit and their constituents are presented here. 
Guajava fruits are characterized by a low content of carbohydrates (13.2%), fats (0.53%), and 
proteins (0.88%) and by a high water content (84.9%) (22). Food value per 100 g is: calories 36–50 
kcal, moisture 77–86 g, crude fibre 2.8–5.5 g, ash 0.43–0.7 g, calcium 9.1–17 mg, phosphorus (23) 
17.8–30 mg, iron 0.30–0.70 mg (24), vitamin A 200–400 I.U., thiamine 0.046 mg, riboflavin 0.03–
0.04 mg, niacin 0.6–1.068 mg, ascorbic acid 100 mg, vitamin B3 40 I.U. (23,25,26). Manganese is 
also present in the plant in combination with phosphoric, oxalic and malic acids (27). Hexanal 
(65.9%), -butyrolactone (7.6%), (E)-2-hexenal (7.4%), (E,E)-2,4-hexadienal (2.2%), (Z)-3-
hexenal (2%), (Z)-2-hexenal (1%), (Z)-3-hexenyl acetate (1.3%) and phenol (1.6%) were reported 
from fresh white-flesh Guajava fruit oil. 3-caryophyllene (24.1%), nerolidol (17.3%), 3-
phenylpropyl acetate (5.3%) and caryophyllene oxide (5.1%) were isolated from essential oil 
extracted from the fruits (28). Subsequently, the active aromatic constituents in pink Guajava fruit, 
3-penten-2-ol and 2-butenyl acetate, were isolated (29). The fruit also contains glykosen 4.14%, 
saccharose 1.62%, and protein 0.3% (30, 31, 4, 32). The main constituents are, however, 
bioflavonoids. By analysing this list it is clear that Psidium guajava contains many substances 
normally employed in cancer research. That the crude acetonic extract was able to induce cell cycle 
arrest and cell death in NB4 cells confirmed our hypothesis that some of its components have 
anticancer activity. When acetonic extracts were prepared from Guajava peel, flesh and seed parts 
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the active parts were shown to be peel and flesh, capable of inducing CD11c expression and 
apoptosis in acute promyelocytic leukaemia cells respectively. The differential sensitivity shown by 
different cancer models, such as breast cancer and osteosarcomas, suggests both some cell-
selectivity and a very low toxic effect of the extract. 
This hypothesis was also confirmed by the evidence that cell death, occurring upon treatment, is 
caspase mediated and able to activate both cell cycle and molecular death programs. That not only 
caspase 8, but also FAS, DR-5 and BID were regulated mainly by the total and by the flesh extract 
(Fig. 5) strongly suggests the involvement of death receptor-mediated pathways in regulation of 
apoptosis. Though not fully understood, the abundance of flavonoids in the Guajava flesh extract 
indicates that they may play a key role in the anticancer action of the fruit. 
Taken together these data provide a new perspective for the analysis and use of natural products in 
the treatment of human pathologies and indicate that plant components exert anticancer activities. 
Given the need for new ‘smart’ anticancer drugs, the in-depth investigation of the properties of 
natural products with minor side effects and targeted action may represent a new approach for the 
future development of cancer-selective drugs. 
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Figure legends 
Figure 1: Total acetonic Guajava fruit extract exerts antiproliferative action in leukemia NB4 
cells. (a) Proliferation curve by Trypan blue assay in NB4 cells at day 3 after treatment with 
acetonic Guajava extract at the reported concentrations. (b) Proliferation curve by Trypan blue assay 
in NB4 cells at day 5. Results represent the average of triplicates. (c) Cell cycle analysis of NB4 
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cells after treatment with selected crude Guajava extracts for a period of 24 hours in comparison 
with ATRA (all trans retinoic acid). 
Figure 2. Total acetonic Guajava fruit extract exerts anticancer and differentiative action. (a) 
Percentage of apoptotic cells after 24 hours of treatment with indicated crude Guajava extracts. (b) 
Apoptosis evaluation carried out by FACS analysis in AML patient ex vivo blasts after 24 hours of 
treatment with indicated dose of total Guajava extract. MS275 and SAHA were used as controls. (c) 
CD11c expression levels measured by FACS after 48 hours of treatment with the indicated amounts 
of Guajava extract in NB4 cells. Note that PI positive cells were excluded from the analysis. ATRA 
was used as positive pro-differentiative compound. (d) Morphological analysis of granulocytes 
induction after the treatment with Guajava extract at day 4 in comparison with ATRA induction 
Figure 3. Flesh Guajava component is essential for apoptosis, peel  for differentiation. (a) Cell 
cycle analysis in NB4 cells after stimulation with total Guajava extract and the fractioned parts of 
Guajava fruits for a period of 24 hours and at a concentration of 1.5 mg/ml. (b) Apoptosis carried 
out by FACS analysis after 24 hours of induction with the same total and fractioned Guajava 
extracts. (c) FACS evaluation of CD11c in NB4 cells. The data show the average of triplicates. 
ATRA was used as positive control. (d) Morphological analysis of granulocyte induction after 
treatment with fractioned Guajava parts at day 4. The data are compared with ATRA effect. 
Figure 4. Guajava extract and flesh extract exerted anti-proliferative effect in different cancer 
cell model. (a) Morphological analysis of MDA-MB231 cells after treatment with total Guajava, 
peel, flesh and seed extracts at a concentration of 1.5mg/ml for a period of 4 days. (b) FACS cell 
cycle analysis in U937 and U2OS cells after induction with flesh and peel extracts for a period of 24 
hours and at a concentration of 1.5 mg/mL. The data show the average of triplicates. 
Figure 5. Flesh guajava extract mediates caspase activation and apoptotic molecular events. 
(a) FACS analysis of caspase 8, 3/7 and 9 in NB4 cells after 2 days of incubation with selected 
extracts at a concentration of 1.5mg/ml. Data represent the average of duplicates. (b) Western blot 
analysis of some proteins involved in cellular death. NB4 cells were treated with total Guajava, 
peel, flesh and seed extracts for a period of 24 hours and at a concentration of 1.5mg/ml. ERKs 
signal was used to normalize the loading cellular extracts. 
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a b s t r a c t
A novel class of KAT modulators (long chain alkylidenemalonates, LoCAMs) has been identified. Variations
of the alkyl chain length can change the activity profile from inhibition of both KAT3A/KAT2B (as deriv-
ative 2a) to the peculiar profile of pentadecylidenemalonate 1b, the first activator/inhibitor of histone
acetyltransferases. Together with the powerful apoptotic effect (particularly notable if considering that
anacardic acid and other KAT inhibitors are not cell permeable) appoint them as valuable biological tools
to understand the mechanisms of lysine acetyltransferases.
Ó 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Lysine acetylation is among the prominent posttranslational
modifications in eukaryotic cells. Crosstalking between this and
other identified posttranslational modifications1,2 such as methyl-
ation, ubiquitination, and phosphorylation give rise to a dense net-
work which constitutes the histone code2–4 and is crucial in
modulating chromatin-based transcriptional control and shaping
inheritable epigenetic programs. First identified nearly 50 years
ago,5 the acetylation state of histones within chromatin is corre-
lated with gene regulation, with hypoacetylated histones being
associated with transcriptionally repressed genes and hyperacety-
lated histones with transcriptionally active ones. Like histones,
many non-histone proteins are subject to acetylation6 and a simi-
lar crosstalk (named ‘protein modification code’)3,7 with other
posttranslational modifications is now known to occur in more
than 80 transcription factors (i.e., p53),8 many other nuclear regu-
lators (i.e., a-tubulin),9 and various cytoplasmic proteins.7,10 As a
result, lysine acetylation is not only crucial in the nucleus but also
appears to be important for the regulation of different cytoplasmic
processes, including cytoskeleton dynamics, energy metabolism,
endocytosis, autophagy, and even signaling from the plasma mem-
brane.11–13 In addition, reversible lysine acetylation may alter
enzymatic activity to allow the cell to respond to environmental
changes in metabolic demands and it has been proposed as an evo-
lutionarily conserved mechanism for the regulation of cell func-
tions.14–16
Protein acetylation level is a consequence of the balance be-
tween the opposite activities of protein acetyltransferases (KATs)17
and deacetylases (KDACs),18 and its deregulation has been linked
to several diseases,19,20 including cancer,21–29 inflammation30–33
and, probably, neurodegenerative diseases.34–38 Thus, lysine acety-
lation is a promising target for therapeutic development. As a mat-
ter of fact, a number of KDAC inhibitors are currently undergoing
clinical evaluation for efficacy in the treatment of human tu-
mours39,40 and two of them, suberoylanilide hydroxamic acid
(SAHA, vorinostat),41 and romidepsin (FR901228, Istodax)42 were
approved by the U.S. Food and Drug Administration (FDA) for the
treatment of advanced cutaneous T-cell lymphoma.
On the contrary, KATs are less validated as chemotherapeutic
targets. They can be organized into families based on primary-
structure homology within the catalytic domain and similarities
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in their biological function. Four of these families have been exten-
sively studied: the Gcn5-related N-acetyltransferase (GNAT) fam-
ily, the E1A-associated protein of 300 kDa (p300)/CREB-binding
protein (CBP) family, the MYST family; and the regulation of Ty1
transposition gene product 109 (Rtt109) family.7,17,43–46 Several
other KAT families have been identified, but they have been stud-
ied less extensively.6,14,17,47
Misregulation of the activity of KAT enzymes has been linked to
a broad set of diseases ranging from cancer to central nervous sys-
tem pathologies. Yet, at least in cancer, their role cannot be simply
generalized as they can function either as tumor suppressors or
promoters depending on different tumor types and development
stages.14,19 Therefore, cell-permeable, selective modulators of
these enzymes could be invaluable tools for reverse chemical
genetics studies48,49 and to assess the implication of KATs in sev-
eral pathologies. Moreover, they can represent starting points for
the design of novel epigenetic drugs.
Differently from KDAC proteins, just a few small molecule
inhibitors of KATs have been reported to date (Fig. 1), with various
degrees of selectivity and cell permeability. Peptide–CoA conju-
gates (Lys-CoA and H3-CoA-20) have been described as potent
and selective bisubstrate inhibitors for KAT3B (p300) and KAT2B
(PCAF), however the lack of cell permeability represents a draw-
back.34,50 A few natural products like anacardic acid,51 garcinol,52
curcumin,53 plumbagin,54 guttiferone A55 as well as some ana-
logues56–60 or semi-synthetic derivatives32 have also been reported
as inhibitors of different classes of KATs. Isothiazolones were dis-
closed as cell-permeable and potent inhibitors of KAT2B, but their
chemical reactivity limits their specificity.61–64 Cell-permeable
KAT2A (GCN5)-selective inhibitors like the c-butyrolactone MB-
365 and a few quinoline derivatives66 were also reported. On the
other side, only N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-
6-pentadecyl-benzamide (CTPB, Fig. 2)51 and nemorosone55 were
reported to selectively activate p300 HAT activity.
Recently we reported a unique activity profile for pentadecylid-
enemalonate 1b (Fig. 2), a simplified analogue of anacardic acid.
This compound exhibits a good inhibitory activity against KAT3A/
B (CBP/p300) and intriguingly, a significant increase of the acety-
lating activity of KAT2B.67 This observation suggests that it is the
first activator/inhibitor of histone acetyltransferases.
With the aim to derive structure–activity relationships, we
decided to explore the effect on the biological activity of the length
of the alkyl chain, the nature of the carbonyl function, the eventual
presence of substituents, and the rigidity/flexibility of the scaffold
(Fig. 3). Herein we thus report the synthesis of a number of ana-
logues of compound 1b, as well as the evaluation of their biological
effects on the activity of KAT enzymes. In addition, the effects of
tested compounds on cell cycle and apoptosis induction on U937
cells were also evaluated.
2. Chemistry
Most of the novel compounds were prepared by reacting a
1,3-dicarbonyl derivative with the proper electrophile. In fact,
derivatives 1–3 were prepared, respectively, (Scheme 1) by Knoe-
venagel condensation of diethyl malonate or pentane-2,4-dione
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with aldehydes 12a–e, commercially available or obtained from
the corresponding alcohols by oxidation with 1,1,1-triacetoxy-
1,1-dihydro-1,2-benziodoxol-3(1H)-one (Dess–Martin period-
inane, DMP).67,68 The monoalkylation of diethyl malonate with
the appropriate alkyl bromide in the presence of sodium hydride
in dry THF69 gave derivatives 4a–c,69–71 while the acylation of
the b-ketoester with tetradecanoyl, pentadecanoyl, or hexadeca-
noyl imidazolide in the presence of magnesium dichloride and tri-
ethylamine furnished derivatives 5a–c.67 The tetradecyl
substituted compound 5a was treated with phosphorus oxychlo-
ride or with ammonium acetate to obtain chloro-substituted or
amino-substituted derivatives 6 and 7, respectively (Scheme 1).
Similarly, when Meldrum’s acid was used as 1,3-dicarbonyl
compound in the Knoevenagel condensation or in the alkylation
in the presence of sodium hydride, derivatives 8 and 9 were
obtained, respectively (Scheme 2).
Alkan-2-ylidene malonates 10a,b were obtained by reacting the
corresponding alkan-2-ones with triethyl phosphonoacetate in the
presence of sodium hydride in the Horner–Wadsworth–Emmons
reaction conditions. The resulting mixture of E and Z a,b-unsatu-
rated esters was then treated with lithium diisopropylamide and
ethyl chloroformate to yield the desired derivatives (Scheme 3).
Finally, tridecylamino methylenemalonate 11 was obtained by
refluxing diethyl ethoxymethylenemalonate with tridecylamine
in anhydrous ethanol (Scheme 4).
3. Biology
3.1. KAT3A and KAT2B inhibitory assays
We previously reported that pentadecylidenemalonate 1b pos-
sess a peculiar activity profile against acetyltransferases.67 Thus,
compounds 1–11 were tested for inhibition of the recombinant
acetyltransferase enzymes KAT3A (CBP, Fig. 4A) and KAT2B
(Fig. 4B), using anacardic acid (AA)51 as reference compound
(at 50 lM). In agreement with what we previously reported, the
inferior homologues of 1b (with the exception of the tridecylidene
derivative 2c which resulted inactive) as well as the b-diketone 3
displayed a strong inhibition against recombinant KAT3A (in the
range 79–83%), thereby being more powerful than AA when tested
in the same conditions (62% of inhibition at 50 lM). Among the
other derivatives, only 5a exhibited a moderate enzyme inhibition
(52%), the others being scarcely active (Fig. 4A). Similarly to 1b,
derivative 1a induced an increase of the acetylating activity of
KAT2B (Fig. 4B). A slight increase of the enzymatic activity was also
detectable for compounds 5a and 11 (characterized by the pres-
ence on the double bond of the lead scaffold of a OH and a NH
group, respectively). All the other derivatives were inactive or dis-
played just a moderate inhibition, with the exception of the chloro-
substituted malonate 6 which displayed a strong activating effect.
3.2. Western blot analyses
The effect of compounds 1–11 on the acetylation levels of his-
tone (H3 terminal tails) or non-histone (a-tubulin) proteins was
assessed in human leukemia U937 cell line (Fig. 5A), and in human
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breast cancer MCF-7 cells (Fig. 5B), respectively. Cells were
incubated with vehicle, tested compounds or with the reference
compound suberoylanilide hydroxamic acid (SAHA, at 5 lM), a
well-known KDAC inhibitor41 able to increase histone H3 as well
as the non-histone substrate a-tubulin acetylation levels. As
shown by Western blot analysis (Fig. 5), the behavior of compound
1a in these assays was quite similar to what we previously
observed with 1b. In fact, both compounds produce an increase
of the H3 acetylation level, similar (even if less pronounced) to
the one induced by SAHA (Fig. 5A) but without affecting KDAC
activity (not shown). Moreover, while SAHA exhibited a marked
hyperacetylating effect on both substrates, compounds 1a and 1b
produced no detectable effect72 on the acetylation level of the
non-histone substrate a-tubulin (Fig. 5B). On the contrary, deriva-
tives 2a and 2b and, to a lesser extent, derivative 3 induced a sig-
nificant hypoacetylation of the H3 histone substrate in the same
conditions (Fig. 5A). No effect was detectable on a-tubulin acetyla-
tion. The effects of all the other derivatives were comparable to
control, with the exception of derivative 5b, which induced a
strong a-tubulin hyperacetylation at 15 lM, and derivative 11,
which shows a weak but distinct dose-dependent hyperacetylation
of the same substrate (Fig. 5B).
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3.3. In-cell evaluation. Effects on cell cycle and apoptosis
induction on human leukemia U937 cell line
As cell permeability is a crucial issue for modulators of his-
tone modifying enzymes,73 all the derivatives were then
screened for their effects on cell cycle, apoptosis induction, and
granulocytic differentiation in the human leukemia U937 cell
line, using anacardic acid (AA)51 as reference compound. After
30 h of treatment at 50 lM, compounds 1a,b and 2a,b were able
to arrest the cell cycle in the S phase (Fig. 6A)74 and, more
importantly, displayed a strong apoptosis-inducing effect
(51.8%, 94.4%, 25.4% and 60.2%, respectively; Fig. 6C). In the
same conditions, the effects on cell cycle and apoptosis induction
of derivative 3 were significantly lower, being barely detectable
for all the other compounds, particularly when the experiment
was repeated at lower concentration (25 lM, Fig. 6B and D).
For the most active derivatives, 1a,b and 2a,b, a dose–response
study was also performed. U937 cells were incubated for 30 h
at 37 °C in the absence (control) or presence of increasing con-
centrations (5–200 lM) of tested compounds. Interestingly, again
the length of the aliphatic side chain seems crucial for biological
activity, similarly to what reported by Giannis for analogues of
MB-3.65
In fact, as shown in Figure 6E, compounds 1a and 1b displayed
similar (42.90 lM and 44.91 lM, respectively) IC50 values (concen-
tration inducing 50% apoptosis, calculated using GraphPad Prism
5.0 software, GraphPad Software Inc., San Diego, CA), whereas
the shortening of the aliphatic chain (compounds 2a and 2b) re-
sulted in a 2–3-fold lower activity. This outcomes are consistent
with the effects exerted by tested compounds on the acetylation
levels of histone and non-histone proteins. None of the tested com-
pounds 1–11 showed any significant differentiating effect (see
Supplementary data).
3.4. SPR-based binding assay
We previously reported that 1b strongly inhibits (74% of inhibi-
tion at 50 lM) immunoprecipitated KAT3A/KAT3B from U937 cell
nuclear extracts.67 Thus, we resolved to ascertain if the long chain
alkylidenemalonates (LoCAMs) 1–3, the most active in cellular
experiments, besides KAT3A could bind also to KAT3B. To this
aim, we took advantage of a surface plasmon resonance-based
binding assay as implemented with Biacore technology, recently
set up and successfully employed by us to study kinetic and ther-
modynamic parameters of ligand–protein interactions between
KAT3B and a series of polyisoprenylated benzophenone deriva-
tives.55 This assay allowed us to assess in real time how com-
pounds associate and dissociate from the protein and provided
detailed information on the interaction. Thus, human recombinant
full-length KAT3B and KAT3B catalytic domain were immobilized
on different flow cells of the biosensor chip and the five LoCAMs
were injected at different concentrations (from 50–200 lM) over
the protein surface; the binding of each compound was read out
in real time as the change in mass at the sensor surface. After injec-
tion, running buffer was flowed over the surface and dissociation of
the compounds from the surface was observed (Fig. 7). Notewor-
thy, three out of the five tested LoCAMs (compounds 2a, 2b, and
3) interacted efficiently with the immobilized full-length protein,
as shown by the concentration-dependent responses and the
clearly evident exponential curves during both the association
and dissociation phases, but not with the immobilized catalytic do-
main (see Supplementary data). This seems to suggest an interac-
tion with a site different from the catalytic one. On the other hand,
SPR experiments carried out on compounds 1a and 1b on both pro-
teins also produced good sensorgrams, but showed very low and/or
concentration-independent responses, thus suggesting negligible
interactions of such molecules with p300. To evaluate possible
Figure 5. (A) Effects exerted by compounds 1–11 (50 lM) on H3 acetylation in histone extracts of U937 leukemia cells. (B) Effects exerted by compounds 1–11 (15 and
30 lM) on a-tubulin acetylation in MCF-7 breast cancer cells. Ponceau Red staining of histones (PR) and ERK1 (extracellular signal-regulated kinase-1) antibody were used,
respectively, to check for equal loading. SAHA (5 lM) was used as reference compound.
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unspecific bindings, compounds 1–3 were also injected on an
immobilized bovine serum albumin (BSA), and no interaction
was observed (data not shown).
The outcomes of SPR experiments were consistent with the re-
sults (see Supplementary data) of fluorescence-based assays, per-
formed to evaluate the ability of compounds 1–3 to modulate
Figure 6. Cell cycle analysis (A and B) and analysis of apoptosis induction (C and D) in U937 cells by fluorescence-activated cell sorting (FACS). The U937 cells were treated
with compounds 1–11 at 50 lM (top) or at 25 lM (bottom) for 30 h, then stained with propidium iodide and subjected to flow cytometric analysis to determine the cell
distributions at each phase of the cell cycle (A and B) or double-stained with Annexin V/propidium iodide and subjected to flow cytometric analysis to determine apoptotic
subpopulations (C and D). Caspase 3 was also detected and quantified (not shown). Anacardic acid (AA) was used as reference compound. Data are reported as mean ± SD of
three independent experiments. (E) IC50 (concentration inducing 50% apoptosis) values for 1a,b and 2a,b, obtained from dose–response experiments in U937 cells with
compounds tested at 5–200 lM.
Figure 7. SPR interaction analysis of compounds 1–3 binding to immobilized KAT3B full length. SPR response data (sensorgrams). Each compound was injected at four
different concentrations (50, 100, 150, and 200 lM).
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the acetyltransferase activity of KAT3B. As a matter of fact, all
tested compounds showed negligible effects on KAT3B (both full-
length and catalytic domain) biological activity.
3.5. Effect on the acetylation of specific lysine residues
We next examined the effects of compounds 1–3 on the acety-
lation of specific lysine residues of core histones H3 (K9, K14, K18,
K56) and H4 (K5, K8, K16). Thus, U937 cells were incubated (for
24 h) with vehicle, compounds 1–3 (50 lM) or with the reference
compound SAHA (5 lM), and the histone extracts were then
immunoblotted with antibodies to specific histone acetylation
sites (Fig. 8). This assay confirmed what we already observed that
small differences in the length of the aliphatic side chain of LoCAM
derivatives appear critical for biological activity. In fact, as shown
in Figure 8, compounds 1b and 2b were able to induce hyperacet-
ylation (in the case of 1b similar to that exerted by SAHA) of spe-
cific H3 lysine residues (in particular H3K9 and H3K18) as well as
the level of pan-acetylated H4, but while 1b was comparable to
control in all the other assays, dodecylidenemalonate 2b inhibited
the acetylation of all the other H3 and H4 lysines, with the excep-
tion of H4K8Ac.75 On the contrary, derivatives 1a and, even more
evidently, 2a exhibited a significant inhibition of the acetylation
of almost any lysine residue explored, again with the sole excep-
tion of H4K8. Both derivatives 2a and 2b reduced the level of
H4K5Ac and, more markedly, H4K16Ac. Tridecylidenemalonate
2c and the diketone 3 showed inhibition (at a different extent,
according to the specific antibody used in the Western blots)
against the acetylation of, respectively, H3K9/K18 and H3K9/K14,
being practically inactive in all the other assays. None of the com-
pounds tested exhibited a detectable effect the acetylation of
H4K8.
4. Conclusion
In this article, we have described the synthesis of compounds
1–11 as analogues of pentadecylidenemalonate 1b, recently re-
ported by us as the first activator/inhibitor of histone acetyltrans-
ferases.67 With the aim to identify the effects on the biological
activity of structural modifications such as length of the alkyl
chain, nature of the carbonyl function, occurrence of substituents,
and rigidity/flexibility of the scaffold, we tested the capability of
such derivatives to modulate the acetyltransferase activity of hu-
man recombinant KAT3A and KAT2B, and assayed their effects on
the acetylation of both histone- (H3) and non-histone proteins
(tubulin). Their effects on cell cycle, apoptosis induction, and gran-
ulocytic differentiation on U937 cells were also evaluated. In addi-
tion, we explored the binding capability of selected compounds to
KAT3B, using both the full length protein and the catalytic domain
in a SPR-based assay, and their effects on the acetylation of specific
histonic lysine residues, by immunoblotting histone extracts with
specific antibodies.
Taken together, the data resulting from biological assays
showed that, in general, major modifications introduced in the
Figure 8. Western blot analyses performed with compounds 1–3 (50 lM for 24 h) on the acetylation of specific lysine residues of histones H3 and H4 in histone extracts of
U937 leukemia cells. Acetylation was detected by immunoblotting with antibodies to specific histone acetylation sites as indicated. Ponceau Red staining of histones (PR) or
total H1 histone (in the case of pan-acH4) were used to check for equal loading. SAHA (5 lM) was used as reference compound.
3696 C. Milite et al. / Bioorg. Med. Chem. 19 (2011) 3690–3701
alkylidenemalonate scaffold were detrimental for the activity of
the resulting compounds. In fact, only the variation of alkyl chain
length (derivatives 1a and 2a–c) or the substitution of ester func-
tions with keto groups (derivative 3) yielded compounds display-
ing a strong inhibition against recombinant KAT3A (in the range
79–83%), thereby being more powerful than AA (62% of inhibition
at 50 lM) in this assay. On the other hand, only compound 1a, its
inferior homologue, was comparable to 1b in the activation of the
enzymatic activity of KAT2B, whereas the shorter malonates 2a–c
were inactive or displayed just a moderate inhibition. Accordingly,
western blot analyses showed that, similarly to 1b, compound 1a
was able to induce hyperacetylation of H3 in U937 cells, without
affecting tubulin acetylation (in MCF7 cells). On the contrary,
derivatives 2a and 2b and, to a lesser extent, derivative 3 induced
a significant hypoacetylation of the H3 histone substrate in the
same conditions. The effects of tested compounds on cell cycle
and apoptosis induction evidenced again that the shortening of
the aliphatic chain (compounds 2a and 2b) resulted in a 2–3-fold
lower activity, while compounds 1a and 1b displayed similar
(42.90 lM and 44.91 lM, respectively) concentration inducing
50% apoptosis (IC50) values. Interestingly, SPR-based assays
showed that the long chain alkylidenemalonates (LoCAMs) 2a
and 2b as well as the diketone 3 were able to interact with p300
full-length but not with the catalytic domain, whereas just negligi-
ble interactions were recorded for both 1a and 1b. It is noteworthy
that Giannis and co-workers previously reported that the length of
the aliphatic side chain seems crucial for biological activity of ana-
logues of MB-3.65 A few other derivatives exhibited various de-
grees of activity in one or both the enzymatic assays, but were
practically inactive in cellular assays.
In summary, we have identified LoCAMs as a novel, interesting
class of KAT modulators. Variations of the alkyl chain length can
change their activity profile from KAT3A/KAT2B inhibitors (as
derivative 2a) to the peculiar profile of pentadecylidenemalonate
1b, the first activator/inhibitor of histone acetyltransferases. To-
gether with the powerful apoptotic effect (particularly notable if
considering that anacardic acid and other KAT inhibitors are not
cell permeable) appoint them as valuable biological tools to under-
stand the mechanisms of lysine acetyltransferases. Further biolog-
ical in vitro and in vivo studies are in progress to better
characterize the observed properties of LoCAMs and to correlate
the effects on the acetylation of specific lysine residues with the
expression of particular genes. This may also prelude to a novel
group of compounds for antineoplastic therapeutics.
5. Experimental section
5.1. Chemistry
All chemicals were purchased from Aldrich Chimica (Milan,
Italy) or from Alfa Aesar GmbH (Karlsruhe, Germany) and were
of the highest purity. All solvents were reagent grade and, when
necessary, were purified and dried by standard methods. A sample
of suberoylanilide hydroxamic acid (SAHA) for biological assays
was prepared as previously reported by us.76 All reactions requir-
ing anhydrous conditions were conducted under a positive atmo-
sphere of nitrogen in oven-dried glassware. Standard syringe
techniques were used for anhydrous addition of liquids. Reactions
were routinely monitored by TLC performed on aluminum-backed
silica gel plates (Merck DC, Alufolien Kieselgel 60 F254) with spots
visualized by UV light (k = 254, 365 nm) or using a KMnO4 alkaline
solution. Concentration of solutions after reactions and extractions
involved the use of a rotary evaporator operating at a reduced pres-
sure of 10 Torr. Organic solutions were dried over anhydrous so-
dium sulfate. Chromatographic separations were performed on
silica gel (Silica Gel 60, 0.063–0.200 mm; Merck DC) columns.
Melting points were determined on a Gallenkamp melting point
apparatus in open capillary tubes and are uncorrected. 1H NMR
spectra were recorded at 300 MHz on a Bruker Avance 300 spec-
trometer; chemical shifts are reported in d (ppm) units relative
to the internal reference tetramethylsilane (Me4Si). Mass spectra
were recorded on a Finnigan LCQ DECA TermoQuest (San Jose,
CA, USA) mass spectrometer using an electrospray ion source
(ESI-MS). Combustion analysis on target compounds was per-
formed by our Analytical Laboratory at the University of Salerno.
All compounds showedP98% purity. When the elemental analysis
is not included, crude compounds were used in the next step with-
out further purification. As a rule, samples prepared for physical
and biological studies were dried in high vacuum over P2O5 for
20 h at temperatures ranging from 25 to 110 °C, depending on
the sample melting point.
5.1.1. General procedure for the synthesis of aldehydes 12a,b.
Example: tetradecanal (12a)67,77
To a solution of commercial tetradecan-1-ol (0.72 g, 3.37 mmol)
in DCM (20 mL) at 0 °C Dess–Martin periodinane (DMP) (1.53 g,
3.60 mmol) was added. After completion (45 min, TLC monitoring),
the reaction crude was directly purified by column chromatogra-
phy (silica gel, CHCl3/n-hexane, 3:1) to afford the required alde-
hyde as a waxy white solid (187 mg, 98% yield). 1H NMR (CDCl3):
d 0.88 (t, 3H, CH3), 1.26–1.29 (m, 20H, 10  CH2), 1.60–1.65 (m,
2H, CH2), 2.40–2.50 (m, 2H, CH2), 9.77 (t, 1H, H-1); MS (EI, 70 eV)
m/z (%): 212.
Pentadecanal 12b,78 was obtained following the same proce-
dure starting from commercial pentadecan-1-ol. 1H NMR (CDCl3):
d 0.86 (t, 3H, CH3), 1.26–1.30 (m, 22H, 11  CH2), 1.59–1.64 (m,
2H, CH2), 2.38–2.50 (m, 2H, CH2), 9.87 (t, 1H, H-1); MS (EI, 70 eV)
m/z (%): 226.
5.1.2. General procedure for the synthesis of derivatives 1–3.
Example: diethyl 2-tetradecylidenemalonate (1a)67
A stirred solution of the aldehyde 12a (3.98 mmol) and diethyl
malonate (4.38 mmol) in anhydrous methylene chloride (3 mL)
was treated with piperidine (0.08 mmol) and acetic acid
(0.08 mmol) at 0 °C. After 45 min of stirring, a small amount of
3-Å molecular sieves was added. Then the reaction mixture was
stirred at room temperature for another 15 min (TLC monitoring),
diluted with diethyl ether (50 mL), and washed with water (10 mL)
until the aqueous phase was neutral. The collected aqueous phases
were extracted with diethyl ether (3  10 mL). The combined ethe-
ral phases were successively washed with saturated sodium hydro-
gen carbonate solution (3  10 mL) and brine (3  10 mL) and
dried (Na2SO4). After removing the solvent, the crude was purified
by column chromatography (SiO2, n-hexane/AcOEt 8:2) to obtain
compound 1a as an oil, in a 83% yield. 1H NMR (CDCl3): d 0.90
(t, 3H, CH3), 1.27–1.36 (m, 26H, 10  CH2 and 2  OCH2CH3, over-
lapped signals), 1.47–1.51 (m, 2H, CH2CH2C@), 2.28–2.33 (m, 2H,
CH2C@), 4.23–4.34 (dm, 4H, 2  OCH2CH3, overlapped signals),
7.02 (t, 1H, CH); MS (EI, 70 eV) m/z (%): 354. Anal. Calcd for
C21H38O4 (354.52): C, 71.14; H, 10.80. Found: C, 71.07; H, 10.79.
Diethyl 2-pentadecylidenemalonate 1b,67 2-undecylmalonate
2a, 2-dodecylmalonate 2b, and 2-tridecylmalonate 2c were ob-
tained following the same procedure starting, respectively, from
pentadecanal (12b), undecanal, dodecanal (lauric aldehyde), and
tridecanal. 3-pentadecylidenepentane-2,4-dione 3 was prepared
following the same procedure starting from 2,4-pentanedione
(acetylacetone) and pentadecanal 12b.
Compound 1b: oil (yield 86%); 1H NMR (CDCl3): d 0.90 (t, 3H,
CH3), 1.27–1.36 (m, 28H, 11  CH2 and 2  OCH2CH3, overlapped
signals), 1.48–1.58 (m, 2H, CH2CH2C@), 2.29–2.33 (m, 2H, CH2C@),
4.24–4.34 (dm, 4H, 2  OCH2CH3, overlapped signals), 7.02 (t, 1H,
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CH); MS (EI, 70 eV)m/z (%): 368. Anal. Calcd for C22H40O4 (368.29):
C, 71.70; H, 10.94. Found: C, 71.63; H, 10.93.
Compound 2a: oil (yield 87%); 1H NMR (CDCl3): d 0.88 (t, 3H,
CH3), 1.25–1.35 (m, 20H, 7  CH2 and 2  OCH2CH3, overlapped
signals), 1.47 (m, 2H, CH2CH2C@), 2.27–2.30 (m, 2H, CH2C@),
4.20–4.31 (dm, 4H, 2  OCH2CH3, overlapped signals), 7.00 (t, 1H,
CH); MS (EI, 70 eV) m/z (%): 312. Anal. Calcd for C18H32O4
(312.23): C, 69.19; H, 10.32. Found: C, 69.01; H, 10.30.
Compound 2b: oil (yield 85%); 1H NMR (CDCl3): d 0.88 (t, 3H,
CH3), 1.25–1.35 (m, 22H, 8  CH2 and 2  OCH2CH3, overlapped
signals), 1.47 (m, 2H, CH2CH2C@), 2.27–2.30 (m, 2H, CH2C@),
4.22–4.31 (dm, 4H, 2  OCH2CH3, overlapped signals), 7.00 (t, 1H,
CH); MS (EI, 70 eV) m/z (%): 326. Anal. Calcd for C19H34O4
(326.25): C, 69.90; H, 10.50. Found: C, 69.77; H, 10.48.
Compound 2c: oil (yield 88%); 1H NMR (CDCl3): d 0.88 (t, 3H,
CH3), 1.25–1.35 (m, 24H, 9  CH2 and 2  OCH2CH3, overlapped
signals), 1.47 (m, 2H, CH2CH2C@), 2.25–2.32 (m, 2H, CH2C@),
4.20–4.33 (dm, 4H, 2  OCH2CH3, overlapped signals), 6.99 (t, 1H,
CH); MS (EI, 70 eV) m/z (%): 340. Anal. Calcd for C20H36O4
(340.26): C, 70.55; H, 10.66. Found: C, 70.41; H, 10.64.
Compound 3: oil (yield 83%); 1H NMR (CDCl3): d 0.90 (t, 3H,
CH3), 1.26–1.38 (m, 22H, 11  CH2), 1.51 (m, 2H, CH2CH2C@),
2.23–2.28 (m, 2H, CH2C@), 2.34 (s, 6H, 2  COCH3), 6.70 (t, 1H,
CH); MS (EI, 70 eV) m/z (%): 308. Anal. Calcd for C20H36O2
(308.27): C, 77.87; H, 11.76. Found: C, 77.69; H, 11.74.
5.1.3. General procedure for the synthesis of alkylmalonates
4a–c
Diethyl 2-tridecylmalonate 4a,71 tetradecylmalonate 4b,69 and
pentadecylmalonate 4c70 were prepared as previously reported69
from diethyl malonate and, respectively, tridecyl-, tetradecyl-,
and pentadecylbromide.
Compound 4a: oil (yield 75%); 1H NMR (CDCl3): d 0.88 (t, 3H,
CH3), 1.27–1.41 (m, 28H, 11  CH2 and 2  OCH2CH3, overlapped
signals), 1.75–1.80 (m, 2H, –CH2CH–), 3.28–3.34 (t, 1H, –CH2CH–),
4.12–4.18 (q, 4H, 2  OCH2CH3); MS (EI, 70 eV) m/z (%): 342. Anal.
Calcd for C20H38O4 (342.28): C, 70.13; H, 11.18. Found: C, 70.06;
H, 11.17.
Compound4b: oil (yield71%); 1HNMR(CDCl3):d0.88 (t, 3H,CH3),
1.26–1.40 (m, 30H, 12  CH2 and 2  OCH2CH3, overlapped signals),
1.76–1.81 (m, 2H, –CH2CH–), 3.28–3.34 (t, 1H, –CH2CH–), 4.12–4.18
(q, 4H, 2  OCH2CH3); MS (EI, 70 eV) m/z (%): 356. Anal. Calcd for
C21H40O4(356.29):C,70.74;H,11.31.Found:C,70.58;H,11.29.
Compound 4c: oil (yield 72%); 1H NMR (CDCl3): d 0.89 (t, 3H,
CH3), 1.26–1.42 (m, 32H, 13  CH2 and 2  OCH2CH3, overlapped
signals), 1.76–1.81 (m, 2H, –CH2CH–), 3.27–3.33 (t, 1H, –CH2CH–),
4.13–4.19 (q, 4H, 2  OCH2CH3); MS (EI, 70 eV) m/z (%): 370. Anal.
Calcd for C22H42O4 (370.31): C, 71.31; H, 11.42. Found: C, 71.15;
H, 11.39.
5.1.4. General procedure for the synthesis of derivatives 5a–c.
Example: diethyl 2-(1-hydroxyhexadecylidene)malonate 5b67
Triethylamine (1.30 mL, 9.36 mmol) and magnesium chloride
(0.71 g, 7.49 mmol) were added to a stirred solution of diethyl mal-
onate (1.00 g, 6.24 mmol) in dry acetonitrile (20 mL) while cooling
at 0 °C. The mixture was stirred at room temperature for 2 h. Then
a previously prepared mixture of palmitic acid (1.60 g, 6.24 mmol)
and N,N0-carbonyldiimidazole (1.11 g, 6.87 mmol) in dry acetoni-
trile (15 mL) was added, and the resulting slurry was stirred over-
night. After completion (TLC monitoring, SiO2/CHCl3), the mixture
was cautiously acidified with 13% HCl while keeping the tempera-
ture below 25 °C, and the resulting mixture was stirred for addi-
tional 15 min. The organic layer was separated and evaporated,
and the residue was treated with ethyl acetate (20 mL). The aque-
ous layer was extracted with ethyl acetate (2  20 mL), and the or-
ganic phases were combined, washed with saturated sodium
bicarbonate solution (2  30 mL) and brine (3  30 mL), dried,
and concentrated to give the crude diethyl 2-(1-hydroxyhexadecy-
lidene)malonates which was purified by column chromatography
(SiO2, CHCl3) to obtain compound 5b as a white solid (mp:
32–33 °C) in a 90% yield. 1H NMR (CDCl3) d 0.88 (t, 3H, CH3),
1.29–1.34 (m, 30H, 12  CH2 and 2  OCH2CH3, overlapped
signals), 1.57–1.62 (m, 2H, CH2CH2C(OH)@), 2.40–2.45 (m, 1H,
CH2CHHAC(OH)@), 2.58–2.63 (m, 1H, CH2CHHBC(OH)@),
4.21–4.30 (m, 4H, 2  OCH2CH3), 13.41 (s, 1H, OH, exchangeable
with D2O). MS (EI, 70 eV) m/z (%): 398. Anal. Calcd for C23H42O5
(398.30): C, 69.31; H, 10.62. Found: C, 69.18; H, 10.60.
Diethyl 2-(1-hydroxypentadecylidene)malonate 5a and diethyl
2-(1-hydroxyheptadecylidene)malonates 5cwere obtained follow-
ing the same procedure starting from diethyl malonates and,
respectively, pentadecanoic acid and heptadecanoic (margaric)
acid.
Compound 5a: oil (yield 93%). 1H NMR (CDCl3) d 0.88 (t, 3H,
CH3), 1.28–1.33 (m, 28H, 11  CH2 and 2  OCH2CH3, overlapped
signals), 1.58–1.63 (m, 2H, CH2CH2C(OH)@), 2.40–2.45
(m, 1H, CH2CHHAC(OH)@), 2.58–2.63 (m, 1H, CH2CHHBC(OH)@),
4.21–4.30 (m, 4H, 2  OCH2CH3), 13.41 (s, 1H, OH, exchangeable
with D2O). MS (EI, 70 eV) m/z (%): 384. Anal. Calcd for C20H40O5
(384.29): C, 68.71; H, 10.48. Found: C, 68.56; H, 10.46.
Compound 5c: oil (yield 91%). 1H NMR (CDCl3) d 0.89 (t, 3H,
CH3), 1.29–1.32 (m, 32H, 13  CH2 and 2  OCH2CH3, overlapped
signals), 1.57–1.62 (m, 2H, CH2CH2C(OH)@), 2.40–2.45
(m, 1H, CH2CHHAC(OH)@), 2.58–2.63 (m, 1H, CH2CHHBC(OH)@),
4.21–4.30 (m, 4H, 2  OCH2CH3), 13.41 (s, 1H, OH, exchangeable
with D2O). MS (EI, 70 eV) m/z (%): 412. Anal. Calcd for C24H44O5
(412.32): C, 69.86; H, 10.75. Found: C, 69.72; H, 10.73.
5.1.5. Preparation of diethyl 2-(1-chloropentadecylidene)-
malonate 6
A solution of compound 5a (2.16 g, 5.62 mmol) in phospho-
rus(V) oxychloride (4.79 g, 31.22 mmol) was cooled to 0 °C then
treated with triethylamine (0.87 mL, 6.24 mmol) dropwise. The
resulting mixture was stirred at room temperature overnight then
heated to 80 °C for additional 4 h. After completion (TLC monitor-
ing, SiO2, CHCl3/n-hexane 3:1), the mixture was evaporated and
the brownish residue was treated with saturated sodium carbonate
solution (30 mL) and extracted with petroleum ether (3  15 mL).
The organic phases were combined, washed with saturated sodium
bicarbonate solution (3  10 mL) and brine (3  30 mL), dried, and
evaporated and the residue was purified by column chromatogra-
phy (silica gel, CHCl3/n-hexane 1:1) to give the required ester 6 as a
pale yellow oil (yield: 80%). MS (EI, 70 eV) m/z: 402 (100.0%), 404
(35.6%). 1H NMR (CDCl3) d 0.88 (t, 3H, CH3), 1.26–1.34 (m, 28H,
11  CH2 and 2  OCH2CH3, overlapped signals), 1.66 (m, 2H,
CH2CH2C@), 2.89–2.94 (t, 2H, CH2C@), 4.19–4.34 (m, 4H,
2  OCH2CH3). Anal. Calcd for C22H39ClO4 (402.25): C, 65.57; H,
9.75; Cl, 8.80. Found: C, 65.44; H, 9.73; Cl, 8.79.
5.1.6. Preparation of diethyl 2-(1-aminopentadecylidene)-
malonate 7
A solution of compound 5a (0.61 g, 1.59 mmol) in anhydrous
ethanol (10 mL) was treated with ammonium acetate (1.23 g,
15.89 mmol) and the resulting mixture was stirred at room
temperature for 2 h. After completion (TLC monitoring, SiO2,
CHCl3/n-hexane 3:1), the mixture was evaporated and the residue
was treated with saturated sodium bicarbonate solution (10 mL)
and extracted with ethyl acetate (3  15 mL). The organic phases
were combined, washed with brine (3  30 mL), dried, and evapo-
rated to obtain the required aminoester 7 as a TLC pure pale yellow
oil (yield: 95%). MS (EI, 70 eV)m/z: 383 (100.0%). 1H NMR (CDCl3) d
0.90 (t, 3H, CH3), 1.29–1.34 (m, 28H, 11  CH2 and 2  OCH2CH3,
overlapped signals), 1.50–1.55 (m, 2H, CH2CH2C(NH2)@),
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2.20–2.25 (m, 1H, CH2CHHAC(NH2)@), 2.38–2.43 (m, 1H,
CH2CHHBC(NH2)@), 4.21–4.30 (m, 4H, 2  OCH2CH3), 8.51 (bs, 2H,
NH2, exchangeable with D2O). Anal. Calcd for C22H41NO4
(383.30): C, 68.89; H, 10.77; N, 3.65. Found: C, 68.74; H, 10.75;
N, 3.64.
5.1.7. Preparation of 2,2-dimethyl-5-pentadecylidene-1,3-
dioxane-4,6-dione 8
Title compound was prepared following the same procedure de-
scribed for derivatives 1–3, starting from Meldrum’s acid and pen-
tadecanal 12b, as an oil (yield 80%); 1H NMR (CDCl3): d 0.88 (t, 3H,
CH3), 1.26 (m, 22H, 11  CH2), 1.57–1.62 (m, 2H, CH2CH2C@), 1.75
(s, 6H, 2  CH3) 2.91–2.96 (m, 2H, CH2C@), 7.94 (t, 1H, CH); MS (EI,
70 eV) m/z (%): 352. Anal. Calcd for C21H36O4 (352.26): C, 71.55; H,
10.29. Found: C, 71.44; H, 10.27.
5.1.8. Preparation of 2,2-dimethyl-5-pentadecyl-1,3-dioxane-
4,6-dione 9
Title compound was prepared following the same procedure69
described for derivatives 4, starting from Meldrum’s acid and pen-
tadecylbromide, as an oil (yield 75%); 1H NMR (CDCl3): d 0.88 (t,
3H, CH3), 1.26 (m, 24H, 12  CH2), 1.43 (m, 2H, CH2CH2CH–),
1.76–1.78 (ds, 6H, 2  CH3) 2.07–2.17 (m, 2H, CH2CH–), 3.49 (t,
1H, CH); MS (EI, 70 eV) m/z (%): 354. Anal. Calcd for C21H38O4
(354.28): C, 71.14; H, 10.80. Found: C, 70.98; H, 10.78.
5.1.9. General procedure for the preparation of alkan-2-ylidene
malonates 10a,b
To a stirred and cooled (ÿ40 °C) suspension of pentane-washed
NaH (1.3 equiv, 60% suspension in oil) in dry THF (10 mL) was
added triethyl phosphonoacetate (1.3 equiv) in THF (10 mL). After
1 h at room temperature, the mixture was cooled again (ÿ40 °C),
then a solution of the proper ketone (1 equiv) in THF (10 mL)
was added dropwise and the mixture stirred for 18 h at room tem-
perature. After completion (TLC monitoring, SiO2, CHCl3/n-hexane
3:1), the mixture was cautiously diluted with saturated aqueous
ammonium chloride (20 mL) and diethyl ether (40 mL), the organic
layer separated and aqueous portion further extracted with ether
(2  10 mL). The combined organic extract was then washed with
water and brine and finally dried. Solvent removal followed by col-
umn chromatography of the residue (silica gel, CHCl3/n-hexane
1:1) afforded the mixture of E/Z diastereomers in 90% yield. A solu-
tion of this mixture (1 equiv) in dry THF (8 mL) was stirred at
ÿ78 °C under nitrogen and a solution of lithium diisopropylamide
(1.5 equiv) and HMPA (2 equiv) in dry THF (10 mL) was introduced
dropwise. The resulting mixture was stirred at ÿ78 °C for 2 h be-
fore ethyl chloroformate (1.2 equiv) was added. The reaction mix-
ture was warmed to room temperature gradually and stirred for
another 45 h. After completion (TLC monitoring, SiO2, CHCl3/n-hex-
ane 1:1), ether (100 mL) was added, and the reaction mixture was
washed with saturated aqueous NH4Cl and brine. The organic layer
was separated and the aqueous portion further extracted with
ether (2  10 mL). The combined organic extract was then washed
with water and brine and finally dried over Na2SO4. Solvent re-
moval furnished the TLC pure malonates.
Compound 10a: oil (yield 93%); 1H NMR (CDCl3): d 0.89 (t, 3H,
CH3), 1.22–1.28 (m, 26H, 10  CH2 and 2  OCH2CH3, overlapped
signals), 1.46 (m, 2H, CH2CH2C@), 2.02 (s, 3H, CH3C@), 2.26–2.31
(m, 2H, CH2C@), 4.14–4.22 (m, 4H, 2  OCH2CH3, overlapped sig-
nals); MS (EI, 70 eV) m/z (%): 368. Anal. Calcd for C22H40O4
(368.29): C, 71.70; H, 10.94. Found: C, 71.63; H, 10.93.
Compound 10b: oil (yield 92%); 1H NMR (CDCl3): d 0.88 (t, 3H,
CH3), 1.21–1.30 (m, 28H, 11  CH2 and 2  OCH2CH3, overlapped
signals), 1.50 (m, 2H, CH2CH2C@), 2.05 (s, 3H, CH3C@), 2.29–2.34
(m, 2H, CH2C@), 4.18–4.26 (m, 4H, 2  OCH2CH3, overlapped
signals); MS (EI, 70 eV) m/z (%): 382. Anal. Calcd for C23H42O4
(382.31): C, 72.21; H, 11.07. Found: C, 72.06; H, 11.05.
5.1.10. Preparation of diethyl 2-((tridecylamino)methylene)-
malonates 11
A solution of diethyl ethoxymethylenemalonate (500 lL,
2.45 mmol) in dry ethanol (2 mL) was added to a stirred solution
of tridecylamine (0.41 g, 2.00 mmol) in dry ethanol (8 mL) and
the resulting mixture was refluxed overnight. After completion
(TLC monitoring, SiO2, CHCl3/n-hexane 1:1), the solvent was re-
moved under reduced pressure to obtain title compound as a TLC
pure oil (yield 99%). 1H NMR (CDCl3): d 0.88 (t, 3H, CH3),
1.18–1.36 (m, 26H, 10  CH2 and 2  OCH2CH3, overlapped sig-
nals), 1.57 (m, 2H, CH2CH2NH@), 3.28–3.27 (m, 2H, CH2NH@),
4.14–4.27 (m, 4H, 2  OCH2CH3, overlapped signals), 7.97–8.01
(d, 1H, CH), 9.22 (br m, 1H, NH); MS (EI, 70 eV) m/z (%): 369. Anal.
Calcd for C21H39NO4 (369.29): C, 68.25; H, 10.64; N, 3.79. Found: C,
68.11; H, 10.62; N, 3.78.
5.2. Biology
5.2.1. Cell culture
Human leukemia cell lines U937 was propagated in RPMI med-
ium supplemented with 10% FBS (Foetal bovine serum; Hyclone)
and antibiotics (100 U/mL penicillin, 100 lg/mL streptomycin and
250 ng/mL amphotericin-B). MCF7 cells were grown in the same
condition but with D-MEM medium. Both cell lines were kept at
the constant concentration of 200,000 cells per mL of culture med-
ium, at the temperature of 37 °C and with 5% of CO2.
5.2.2. Ligands and materials
Anacardic acid (Alexis) and SAHA76 were dissolved in DMSO
and used at 50 and 5 lM, respectively.
5.2.3. Expression and purification of KAT3B (p300)
His6-tagged human p300 was expressed in Sf9 cells from a bac-
ulovirus-based plasmid (kind gift of Professor Alexandra Lusser
and Professor James T. Kadonaga) and purified by affinity chroma-
tography on Ni–NTA affinity resin (Qiagen) as described else-
where.79 Protein was eluted with buffer containing 250 mM
imidazole, frozen in liquid nitrogen, and stored at ÿ80 °C. p300
concentrations and purity were estimated by Bradford protein as-
says (Bio-Rad) and by comparison to BSA standards on SDS gels
stained with Coomassie Brilliant Blue G-250.
5.2.4. Human recombinant KAT3A (CBP) assay
The recombinant CBP was prepared in Escherichia coli BL21 and
purified by affinity chromatography. Recombinant CBP fraction
corresponded to amino acids 1098–1877. CBP was incubated in
HAT buffer (50 mM Tris–HCl pH 8.0, 10% glycerol, 0.1 mM EDTA,
1 mM DTT) with 10 lg of histone H4 peptide (corresponding to
amino acids 2–24) and 20 lM acetyl-CoA containing 0.5 lCi/mL
[3H]-acetyl-CoA in the presence of tested compounds at selected
concentrations. After 2 h a 37 °C, 5 lL of samples were spotted
onto Whatman P81 paper (in triplicate). The paper squares were
washed three times in 5% TCA and once in 100% acetone and then
placed into scintillation vials containing scintillation fluid to allow
the DPM reading. The DPM of enzyme samples was compared to
DPM of negative control. Data have been expressed as percentage.
5.2.5. KAT2B (PCAF)assays
PCAF radioactive assay was performed according to general
indications provided by UPSTATE radioactive KIT. Human PCAF
(200 ng) was incubated in KAT buffer (Upstate) with 10 lg of his-
tone H4 peptide substrate (corresponding to aminoacids 2–24)
and 20 lM acetyl-CoA containing 0.5 lCi/mL [3H] acetyl-CoA.
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The acetylation reaction was performed in a volume of 25 lL in the
presence of testing compounds at the desired final concentration.
After 2 h a 37 °C, 5 lL of samples were spotted onto chromato-
graphic Whatman P81 paper (in triplicate). After a washing session
(three times in 5% TCA and once in 100% acetone), the paper
squares were placed into scintillation vials containing scintillation
fluid to allow the DPM reading. The DPM of enzyme samples was
compared to DPM of negative and positive control and reported
as % of activity considering the untreated control as 100%.
5.2.6. Protein extraction protocol
MCF-7 and U937 cells were treated with reference compound or
tested derivatives and harvested by centrifugation. After PBS wash,
the samples were resuspended in a lysis buffer (50 mM Tris–HCl
pH 7.4, 150 mM NaCl, 1%NP40, 10 mM sodium fluoride, 1 mM
PMSF and protease inhibitor cocktail), and the lysis reaction was
carried out for 15 min at 4 °C. The samples were centrifuged at
13,000 rpm for 30 min at 4 °C, and the proteins were quantified
by the Bradford assay (Bio-Rad).
5.2.7. Histone extraction protocol
Cells were harvested and washed twice with ice-cold PBS and
lysed in Triton Extraction Buffer (TEB: PBS containing 0.5% Triton
X 100 (v/v), 2 mM phenylmethylsulfonyl fluoride (PMSF), 0.02%
(w/v) NaN3) at a cellular density of 10
7 cells per mL for 10 min
on ice, with gentle stirring. After a brief centrifugation at
2000 rpm at 4 °C, the supernatant was removed and the pellet
was washed in half the volume of TEB and centrifuged as before.
The pellet was resuspended in 0.2 M HCl at a cell density of
4  107 cells per mL and acid extraction was left to proceed over-
night at 4 °C on a rolling table. Next, the samples were centrifuged
at 2000 rpm for 10 min at 4 °C, the supernatant was removed and
its protein content was determined using the Bradford assay (Bio-
Rad).
5.2.8. Western blot analyses
Western Blot analyses were performed according to standard
procedures following suggestions of antibody suppliers. For
a-tubulin, an amount of 30 lg for MCF-7 cells of total protein
extracts was separated on 10% polyacrylamide gels and blotted.80
For the histone H3 and H4 acetylations in U937 and MCF7 cells,
10 lg of histone extract was separated on 15% polyacrylamide gels
and blotted.80 The blotted nitrocellulose was washed twice with
water and then blocked in freshly prepared PBS, containing 5%
nonfat dry milk (PBS-MLK) for one hour at room temperature with
constant agitation. The nitrocellulose was incubated with 1:1000
dilution of anti acetylated a-tubulin (Sigma), pan-acetylated his-
tone H3 (Upstate), H3K9ac (Abcam), H3K14ac (Abcam), H3K18ac
(Abcam), H3K56ac (Abcam), H4K5ac (Abcam), H4K8ac (Abcam),
H4K16ac (Abcam), and pan-acetylated H4 (Abcam). ERK-1 (extra-
cellular signal-regulated kinase-1, Santa Cruz) antibody, Ponceau
Red (Sigma) staining, and histone H1 (Abcam) were used, respec-
tively, to normalize for equal loading.
5.2.8.1. Cell cycle analysis. The 2.5  105 cells were collected
and resuspended in 500 lL of an hypotonic buffer (0.1% Triton X-
100, 0.1% sodium citrate, 50 lg/mL propidium iodide, RNAse A).
Cells were incubated in the dark for 30 min. Samples were acquired
on a FACS-Calibur flow cytometer using the Cell Quest software
(Becton Dickinson) and analyzed with standard procedures using
the Cell Quest software (Becton Dickinson) and the ModFit LT ver-
sion 3 software (Verity). All the experiments were performed three
times.
5.2.8.2. FACS analysis of apoptosis. Apoptosis was measured
with Annexin V/propidium iodide double-staining detection
(Roche and Sigma–Aldrich, respectively), as recommended by the
suppliers. Samples were analyzed by FACS with Cell Quest technol-
ogy (Becton Dickinson). As second assays, the caspase 3 detection
(B-Bridge) was performed and quantified by FACS (data not shown,
Becton Dickinson).
5.2.8.3. Kinetic study of the interaction with KAT3B. SPR
analyses were performed on a Biacore 3000 optical biosensor
equipped with research-grade CM5 sensor chips (Biacore AB).81
Using this platform, two separate KAT3B (p300, both the full
length protein and its KAT domain) surfaces, one BSA surface
and one unmodified reference surface were prepared for simul-
taneous analyses. Proteins (30 lg mLÿ1 in 10 mM sodium ace-
tate, pH 4.0) were immobilized on individual flow cells of the
sensor chip at a flow rate of 10 mL minÿ1 by using standard
amine-coupling protocols82 to obtain densities of 8–14 kRU.
Compounds 1–3 were dissolved in DMSO (100%) to obtain
50 mM solutions, and diluted in HBS (10 mM Hepes pH 7.4,
0.15 M NaCl, 0.005% NP40) with a final DMSO concentration of
0.5%. Binding experiments were performed at 25 °C, by using a
flow rate of 30 lL minÿ1, with 120 s monitoring of association
and 400 s monitoring of dissociation. Regeneration of the sur-
faces was performed, when necessary, by a 10 s injection of
5 mM NaOH.
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New Anacardic Acid-Inspired Benzamides: Histone Lysine
Acetyltransferase Activators
JosØ A. Souto,[a] Rosaria Benedetti,[b, d, e] Katharina Otto,[a] Marco Miceli,[b] Rosana lvarez,*[a]
Lucia Altucci,*[b, c] and Angel R. de Lera*[a]
Introduction
Data accumulated over the past decade clearly link cancer
onset and tumour progression to the deregulation of the enzy-
matic machinery responsible for epigenetic modifications of
both DNA and histone tails within the nucleosomes—the basic
units of chromatin.[1–5] The “epigenetic marks” on chromatin in-
clude methylation of DNA at CpG islands, as well as a variety
of covalent modifications (notably methylation, acetylation,
ADP-ribosylation, phosphorylation, sumoylation and ubiquityla-
tion) of basic amino acid residues located primarily at the tails
of histones H3 and H4.[6] These alterations become docking
sites for additional proteins that trigger the assembly of supra-
molecular structures,[7,8] which among other cellular processes
regulate chromatin remodelling, cell cycle, splicing, nuclear
transport and actin nucleation.[9–11] The reversible nature of
most of the epigenetic modifications[12] has been exploited for
the development of novel approaches to cancer[11, 13–15] and
therapies for other diseases as well.[16]
Histone lysine acetyltransferases1 (KATs)[17,18] are responsible
for the transfer of acetyl groups to lysine residues, whereas his-
tone deacetylases (HDACs) catalyse the reversal of this cova-
lent modification and remove acetyl substituents. Acetylation
(but not methylation) weakens the interactions of histone tails
with the negatively charged phosphate groups of DNA in the
nucleosome, converting the nontranscribed heterochromatin
to the more open euchromatin state, which is now accessible
to the transcriptional machinery.[19]
KATs have been recently grouped into seven families[17,18] al-
though only four of them have intrinsic KAT activities :[20] Gcn5
and PCAF, which are related to the yeast KAT; the cyclic adeno-
sine monophosphate response element-binding protein (CREB)
binding protein (CBP) and p300, which act as coactivators for a
number of transcription factor complexes;[21] TAF250, which is
part of the basic transcription complex TFIID that binds to the
TATA box; and finally SRC-1 and ACTR, which are coactivators
for the ligand-activated nuclear receptors, and their KAT activi-
ties are controversial.[21–23]
Although all KAT enzymes require acetyl-CoA as a cofactor,
the precise mechanism of acetyl transfer to the lysine residue
by the KAT enzyme[20,24] might vary with isoform. A ternary
complex, a “ping-pong” and a “hit and run” mechanism have
been proposed.[16] Regardless of the mechanistic details, dys-
function of acetyltransferase enzymatic activity has been asso-
ciated to several diseases, including cancer, Huntington’s dis-
ease, inflammatory disease, diabetes mellitus and AIDS.[17] Re-
storing the balance between acetylation and deacetylation via
small-molecule modulation might correct aberrant cell growth
and differentiation.[25] In fact, inhibitors of HDACs display anti-
cancer actions,[4, 26,27] and two drugs—SAHA (also known as
vorinostat or Zolinza) and FK228 (also known as romidepsin
or Istodax)—are in the clinic for the treatment of cutaneous
A series of N-(4-cyano-3-trifluoromethyl-phenyl)-2-ethoxy-6-
alkyl (and alkenyl) benzamides related to the anacardic acid
derivative CTPB have been prepared from 2,6-dihydroxybenzo-
ic acid with a Suzuki coupling and addition of the anion of 4-
cyano-3-trifluoromethylphenylamine to a benzodioxinone as
the key steps. In U937 cells, these analogues, in particular 7c,
7d, 7 f and 7 j, induced cell-cycle arrest in the G1 phase,
caused apoptosis in about 20% of the cells, and increased the
acetylation levels of H3. These activities correlate with the en-
zymatic activation of histone lysine acetyltransferases (KATs):
CBP and PCAF.
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T-cell lymphomas. Modulators of KATs (inhibitors or activators)
also have the potential to become new generation therapeu-
tics.[16]
KAT modulators of different structural classes, both of natu-
ral and synthetic origin, have been described in the literature
(Figure 1).[16] Bisubstrate analogues, such as LysCoA (1) and H3-
CoA-20 (2) act as inhibitors of p300 and PCAF/MYST Esa1/
Tip60, respectively.[28] Inhibitors discovered by virtual ligand
screening or rational drug design include isothiazolones, alkyli-
denemalonates, thiazol-2-yl hydrazones, quinolines, the curcu-
minoid multiple epigenetic ligands, or the methylenebutyrolac-
tone MB-3, among others.[16] Recently, C646 (3) was described
as a selective, linear, competitive inhibitor of p300 (86% inhibi-
tion of p300 at 10 mm compared with 10% inhibition for six
other KATs) versus acetyl-CoA with a Ki value of 400 nm.
[29] It is
the most potent KAT inhibitor reported, about 12-fold more
potent than LTK14 (4),[30] a synthetic phloroglucinol structurally
related to garcinol.[31]
6-Pentadecylsalicylic acid (anacardic acid, AA; 5), the main
component of the cashew nut-shell oil, was the first in vitro
noncompetitive inhibitor of both p300 and PCAF reported
(IC50=8.5 and 0.5 mm, respectively).
[32] It also inhibits the KAT
activity of recombinant pGcn5 from Plasmodium falciparum.[33]
Synthetic modifications of anacardic acid 1 have yielded com-
pounds with contrasting epigenetic profiles. In particular, CTPB
(N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-
benzamide) 6 was reported as a potent activator of p300/CBP,
and moreover, devoid of HDAC inhibitory activity.[32,34] Howev-
er, the related benzamides 7a,b (Figure 2) with a shorter satu-
rated side chain were characterised as p300 inhibitors with a
profile similar to the parent 5.[35] A series of novel derivatives
of CTPB, most notably 4-pyridylamides (8a,b ; Figure 2) were
shown to inhibit p300/CBP in the micromolar range.[36]
Since the strongest KAT inhibitors (7a, with an octyl group
being the most potent) had the shortest hydrophobic alkyl
chains of the series of CTPB analogues,[35] we decided to fur-
ther reduce the size of the chain and incorporate terminal
polar and/or unsaturated groups in the same position of the
C6-salicylic amide substituent, while preserving the ethoxy[32]
and the 4-cyano-3-trifluoromethylbenzamide functionali-
ties.[32,35]
Results and Discussion
Synthesis
Following the synthetic approach to the CTPB analogues that
uses a Suzuki cross-coupling reaction[37] between an aryl triflate
and different trialkylboranes,[38] known triflate 9[39,35] containing
a 1,3-benzodioxinone group[40–42] was coupled to the trialkyl-
borane obtained by hydroboration of the terminal alkene with
9-BBN in the presence of PdCl2(dppf), MeONa and KBr.
[42] Five
alkenes (1-heptene, 10c ; 1-hexene, 10d ; 4-penten-1-ol, 10e ;
3-buten-1-ol, 10 f ; 2-propen-1-ol, 10g) were selected as precur-
sors of the organoboranes. The combined yields for the hydro-
boration/coupling step ranged from 39 to 66%.
The acyl transfer/dioxinone deprotection step required the
treatment of the corresponding aniline 12 with nBuLi in DMPU
and heating with 11 at 80 8C, as reported for ester formation
starting from similar substrates.[43] Formation of the ethyl ether
from salicylamides 13 provided the final benzamides 7c,d and
the protected primary alcohols 14e–g, which were deprotect-
ed to afford 7e–g upon treatment with tetra-n-butylammoni-
um fluoride (TBAF) in THF (Scheme 1; Table 1).
Figure 1. Selected histone acetyltransferase modulators.
Figure 2. Anacardic acid-inspired amides.
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A reversal of the strategic key steps is also possible, and this
strategy was employed for the synthesis of the C6-unsaturated
salicylamides 7h–k. The 1,3-benzodioxinone 15 derived from
2,6-dihydroxybenzoic acid[40–42] (the precursor to triflate 9) was
converted into the ethyl ether 16 as described above (91%
yield). Addition of the anion derived from aniline 12 to 16 ef-
fected the acyl transfer/deprotection[43] in 88% yield. Triflate
18 was obtained in 87% yield upon treating 17 with trifluoro-
acetic anhydride (TFAA) in pyridine at 25 8C (Scheme 2).
The alkenylboron reagents required for the completion of
the series of C6-unsaturated salicylamides were acquired fol-
lowing complementary methods. (E)-Alkenyl boronates 20a,b
were obtained in high yield and excellent stereoselectivity
from commercially available benzaldehydes 19a,b using the
Takai–Utimoto condensation reaction,[44] after activation of 2-
(dichloromethyl)pinacolboronate with chromium(II) in the pres-
ence of lithium iodide.[45] Two previously described alkenylbor-
on reagents 21[46] and 22[47] were obtained by the hydrobora-
tion of the precursor alkynes and hydrolysis for 22.
The Suzuki coupling of triflate 18 and organoboranes 20–22
was complete after about 15 min in concentrated solutions
(0.2m) using microwave irradiation.[48,49] Unfortunately, the in-
stability of pinacolboronates 20 under the reaction conditions
decreased the yield of the corresponding products 7h and 7 i.
Biological evaluation
To evaluate whether these novel CTPB-inspired benzamides
are able to have an effect on KAT activity, we tested the com-
pounds in enzymatic and whole-cell assays. In particular, cell-
based assays were performed in U937 leukaemia cells to deter-
mine the antiproliferative potential and the ability of the syn-
thetic compounds to alter the cell cycle. Compared with the
vehicle-treated cells (negative control) and to the cells treated
with the pan-HDAC inhibitor SAHA, used as a positive control
for its known actions on cell cycle and apoptosis,[50] at 5 mm
the test compounds did not significantly alter the cell cycle. In
contrast to SAHA, which accumulates the cell population in
the S phase after 24 h of treatment, at the same concentration
the synthetic salicylamides showed only a modest effect
(~10% increase of U937 cells in the S phase; Figure 3a). How-
ever, after 24 h of induction, compounds 7c–e and 7k at
50 mm induced a time-dependent accumulation of U937 cells
in the G1 phase that reached 70% (Figure 3b), doubling the
effect of the controls SAHA and AA (5). The parent compound
CTPB (6) had no effect on the cell cycle at the tested concen-
trations of 5 and 50 mm. The failure of 5 to influence the cell
cycle regardless of its concentration (see Figure 3a and 3b) is
consistent with reports on its inability to pass through the cell
membrane.[51] In contrast, some of the salicylamides altered
the cell cycle, entering cells most likely due to the presence of
functionalities that provide greater membrane permeability. In
addition, the series of compounds induced a ~20% apoptosis
in U937 cells (Figure 3).
Scheme 1. Reagents and conditions : a) 10c–g, 9-BBN, MeONa, PdCl2(dppf),
KBr, 70 8C, THF; b) Aniline 12, nBuLi, DMPU, 80 8C, 2 h; c) Et2SO4, K2CO3,
acetone; d) TBAF, THF. The yield for each step is given in Table 1.
Table 1. Yields for the steps a–d of the synthesis (Scheme 1).[a]
R1 Step a Step b Step c Step d
P [%] P [%] P [%] P [%]
C5H11 11c 39 13c 76 7c 76 –
C4H9 11d 41 13d 65 7d 46 –
(CH2)2CH2OTBS 11e 32 13e 35 – 7e 61
[b]
CH2CH2OTBS 11 f 66 13 f 50 – 7 f 51
[b]
CH2OTBS 11g 32 13g 37 – 7g 97
[b]
[a] The product (P) and associated yield (%) is given for each step. R1 in-
troduced using compounds 10 (see Scheme 1). [b] Combined yield for
steps c and d.
Scheme 2. Reagents and conditions : a) EtI, K2CO3, acetone, 25 8C, 12 h, 91%;
b) 12, nBuLi, DMPU, 80 8C, 2 h, 88%; c) TFAA, pyridine, 25 8C, 87%; d) 20a,b,
21 or 22, Pd(PPh3)4, K2CO3, dioxane, microwave, 85 8C, 15 min (7h, 43%; 7 i,
27%; 7j, 80%; 7k, 92%); e) 2-(Dichloromethyl)pinacolboronate, CrCl2, LiI,
THF, 25 8C, 16 h (20a, 81%; 20b, 91%).
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To confirm the general involvement of these CTPB analogues
in the modulation of KAT activity; we analysed the acetylation
status of the representative histone protein H3, which is de-
pendent upon the opposing activities of HDAC and KAT en-
zymes (Figure 4a). The activities of these AA-derived benza-
mides were compared to those of AA (50 mm), CTPB (50 mm),
and the HDAC inhibitors SAHA (5 mm) and MS-275 (5 mm). The
inhibition of HDACs is demonstrated by an increase in the
global level of acetyl groups on H3 lysine tails after treatment
of U937 cells for 24 h (Figure 4a), in comparison to the control
experiments using SAHA and MS-275. Despite the reported
low cell permeability, CTPB 6 is able to induce an increase in
the acetylation of H3 lysine tails due to its action on KAT en-
zymes (Figure 4a). Interestingly, a similar effect was observed
with most of the salicylamides at 50 mm (Figure 4a). This effect
can most likely be ascribed to the increase of KAT activity and
the up-regulation of the acetylation reaction. Compounds 7c,
7e, 7 f and 7k, which showed induction of KAT activity, also
caused significant cell-cycle arrest in the G1 phase (see Fig-
ure 3a and 3b, and Figure 4a). The insensitivity of the intracel-
lular acetylation status to the presence of AA, as deduced from
Western blot analysis, further confirms its well-known inability
to enter the cells.
To evaluate the effective induction of KAT activity, two enzy-
matic assays were performed: a PCAF and a CBP radioactive
assay. Figure 4 shows the correlation between the enzymatic
and whole-cell assay results. The CTPB analogues, in particular
7e, 7 f, 7h, 7k, enhanced the CBP acetyltransferase activity by
30–40% relative to the control (Figure 4b). In our previous
report, we determined that benzamides 7a and 7b, with an
n-octyl and n-decyl chains at C6, respectively, behaved as
modest inhibitors of p300. Indeed, the shorter homologue 7c
is a rather weak inhibitor of CBP, but the n-hexyl derivative 7d
is inactive, thus signalling the lower limit for modifications at
that position with saturated groups.[35]
Likewise, all the compounds in the series induced activation
of PCAF in the radioactive enzymatic assay. Indeed these com-
pounds enhanced the PCAF activity by at least 150%, and in
particular 7e, 7 f, 7g and 7k induced a 200–250-fold activation
relative to the control (Figure 4c). In both assays, AA behaves
as a very potent enzymatic inhibitor,[32,51] whereas benzamide
CTPB 6 is a selective activator of p300/CBP (Figure 4b, 4c and
4d) as previously described.[32,34] On the contrary, benzamides
7 activate KATs and, moreover, exhibit a preference for the
PCAF family. These experiments confirm that the analogues are
able to modulate the acetylation balance inside the cell by the
direct activation of KAT enzymes.
Conclusions
The development of chemical probes and modulators of KATs
has provided valuable insights into the catalytic features of
this enzyme class and revealed their roles in various cellular
pathways.[16] The great majority of these modulators are KAT
inhibitors with various degrees of potency, selectivity and cell
permeability. As far as we know, only the AA-derived benz-
amide CTPB is an activator of the p300/CBP KAT. However, no
drugs have been described that selectively distinguish be-
tween the subtypes p300 and CBP or PCAF and GCN5. As a
follow-up of our previous studies on the activities of AA-de-
rived CTPB analogues,[35] we have designed and synthesised a
new series of compounds, which carry polar terminal groups
to improve the permeability and enhance their activity. From
the analysis of the biological readouts, we conclude that these
amides act specifically on KAT enzymes both in enzymatic and
whole-cell assays. The increase in KAT activity was ~30% for
CBP and ~200% for PCAF when the compounds, in particular
those with a primary alcohol on the side chain 7e and 7k,
Figure 3. a) Cell-cycle analysis of U937 cells treated with the indicated com-
pounds at 5 mm for 24 h. b) Cell-cycle analysis of U937 cells treated with the
indicated compounds at 50 mm for 24 h. Cell-cycle phases (G1, S and S2) and
apoptosis (Apo) are shown. The data represent the mean of three independ-
ent experiments.
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were used at 50 mm. At the same concentration they also
showed cell-cycle arrest in the G1 phase and a strong induc-
tion of acetylation of H3 tails.
From the limited number of CTPB-related compounds re-
ported,[32,34–36] the modifications at the C6-position have
proved most informative:
1) Shorter saturated side chain benzamides 7a,7b (Figure 2)
revert the modulatory profile of the parent CTPB (6)[32,34] and
behave as p300 inhibitors similar to anacardic acid (5).[35]
2) Further reduction in the size
of the alkyl chain (7c, 7d)
was inconsequential, thus
demonstrating a lower limit
for modifications at that posi-
tion.
3) The incorporation of hydroxy
groups at the terminus of
the C6-group (7e, 7 f, 7g,
7k) modified the KAT inhibi-
tory activities of the alkylben-
zamide analogues 7a, 7b
and provided activators of
both p300 and PCAF
(Figure 4).
4) In contrast to CTPB (6), these
compounds (most notably 7 f
and 7g) exhibit a preference
for the activation of PCAF
over p300, thus modifying
the selectivity of parent 6.
An examination of the biologi-
cal results indicates the lack of a
linear correlation between the
enzymatic and whole-cell data
for every compound. In fact,
some of the CTPB analogues
show a strong G1 phase block-
ade but not a direct activation
of PCAF and/or CBP. The exis-
tence of ancillary mechanisms
and additive pathways by which
the balance of acetylated/deace-
tylated histones within a cell is
maintained, in addition to the
chemical structure of the com-
pound itself, might partially ex-
plain some of the differences.
Given that the compounds
showing a well-defined KAT acti-
vation profile (7e, 7 f, 7g, 7k)
act at a quite high concentration
(50 mm), additional chemical
modifications of the general
scaffold might provide more
potent activators that could
become valuable tools for understanding the correlation be-
tween the acetylation status of histones and nonhistone pro-
teins, and transcriptional activation.
Experimental Section
Chemistry
General Procedures : Solvents were dried according to published
methods and distilled before use. All other reagents were commer-
Figure 4. a) Western Blot analysis of histone H3 acetylation carried out in U937 cells after 24 h induction with
compounds at 50 mm. b) CBP radioactive assay performed with 1 mg of recombinant CBP enzyme. The compounds
were tested at 50 mm and the CBP activity (%) was compared in each case to anacardic acid (AA; 5) and CTPB (6)
at the same concentration. c) PCAF radioactive assay performed with 200 ng of recombinant PCAF enzyme. The
compounds were tested at 50 mm and the inhibition value was reported as a percentage of residual activity in
comparison to the control, to anacardic acid (AA; 5) and to CTPB (6). The data represent the mean of three inde-
pendent experiments. d) PCAF dose–response assay with the selected compounds (5 and 6 as reference com-
pounds) at three different concentrations (50 mm, 10 mm and 1 mm).
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cial compounds of the highest purity available. All reactions were
carried out under argon atmosphere, and those not involving
aqueous reagents were carried out in oven-dried glassware. Analyt-
ical thin-layer chromatography (TLC) was performed on aluminium
plates with Merck kieselgel 60 F254 and visualised by UV irradiation
(254 nm) or by staining with solution of phosphomolibdic acid.
Flash column chromatography was carried out using Merck kiesel-
gel 60 (230–400 mesh) under pressure. UV/VIS spectra were record-
ed on a Cary 100 bio-spectrophotometer. Infrared (IR) spectra were
obtained on a JASCO FTIR 4200 spectrophotometer from a thin
film deposited onto a NaCl glass. Mass Spectra (MS) were obtained
on a Hewlett–Packard HP59970 instrument operating at 70 eV by
electron ionisation. High-resolution mass spectra (HRMS) were
taken either on a VG Autospec instrument, a Micromass GC-TOF or
a Bruker FT-MS apex-Qe. 1H NMR spectra were recorded in CDCl3
and (CD3)2CO at room temperature on a Bruker AMX-400 spec-
trometer at 400 MHz with residual protic solvent as the internal ref-
erence (CDCl3, dH=7.26 ppm; (CD3)2CO, dH=2.05 ppm); chemical
shifts (d) are given in parts per million (ppm), and coupling con-
stants (J) are given in Hertz (Hz). The proton spectra are reported
as follows: d (multiplicity, coupling constant J, number of protons).
13C NMR spectra were recorded in CDCl3 and (CD3)2CO at room
temperature on the same spectrometer at 100 MHz, with the cen-
tral peak of CDCl3 (dC=77.0 ppm) or (CD3)2CO (dC=30.8 ppm) as
the internal reference. Although DEPT 135 was used to aid the as-
signment of signals in the 13C NMR spectra, the multiplicity is only
shown for fluorine–carbon bonds, with the JCÿF values measured.
2,2-Dimethyl-5-heptyl-4H-1,3-benzodioxin-4-one (11c): General
procedure for the alkyl Suzuki coupling reaction (Method A). A solu-
tion of 10c (0.09 mL, 0.65 mmol) in THF (0.6 mL) was treated with
9-BBN (1.3 mL, 0.5m in THF, 0.65 mmol) and the reaction was
stirred at 25 8C for 24 h. The mixture was transferred to a flask con-
taining MeONa (0.035 g, 0.65 mmol) and the solution was stirred
for 2 h. A mixture of dichloro-1,1’-bis-(diphenylphosphino)ferrocene
palladium (0.006 g, 0.018 mmol), KBr (0.087 g, 0.728 mmol) and 9
(0.2 g, 0.61 mmol) in THF (4 mL) was added and the mixture was
stirred at 70 8C for 4 h. Hexane (1 mL), aq NaOH (1 mL, 2m) and
H2O2 (1 mL, 30% w/w) were then added and the mixture was
stirred at 25 8C. The aqueous layer was extracted with Et2O (3)
and the combined organic layers were washed with a saturated aq
NaHCO3 (3) and dried (Na2SO4), and the solvent was evaporated.
The residue was purified by column chromatography (90:10,
hexane/EtOAc) to afford 11c as a yellow oil (70 mg, 39%): 1H NMR
(400 MHz, CDCl3): d=7.37 (t, J=7.9 Hz, 1H), 6.91 (d, J=7.6 Hz, 1H),
6.78 (d, J=8.2 Hz, 1H), 3.07 (t, J=7.7 Hz, 2H), 1.67 (s, 6H, 2CH3),
1.6–1.5 (m, 2H), 1.5–1.2 (m, 8H), 0.85 ppm (t, J=6.5 Hz, 3H);
13C NMR (100 MHz, CDCl3): d=160.2, 157.1, 148.5, 135.0, 125.1,
115.0, 112.1, 104.9, 34.4, 31.8, 31.2, 29.6, 29.1, 25.6 (2C), 22.6,
14.1 ppm; IR (NaCl): n˜=2998 (w, CÿH), 2954 (m, CÿH), 2926 (s, Cÿ
H), 2856 (m, CÿH), 1738 (s, C=O), 1605 (m, C=C), 1582 cmÿ1 (C=C);
MS (ESI+ ): m/z (%): 276 [M]+ (7), 219 (12), 218 (100), 176 (14), 162
(38), 161 (20), 148 (13), 147 (43), 134 (77), 133 (11), 105 (34), 91
(11), 77 (11); HRMS (ESI+ ): m/z [M]+ calcd for C17H24O3 : 276.1725,
found: 276.1733.
N-(4-Cyano-3-trifluoromethylphenyl)-6-heptyl-2-hydroxybenz-
amide (13c): General procedure for the amidation of dioxinones. A
cooled (0 8C) solution of 12 (0.4 g, 2.15 mmol) and 1,3-dimethyl-
3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU; 0.38 mL, 3.14 mmol)
in THF (8.3 mL) at 0 8C was treated with nBuLi (1.5 mL, 1.40m in
hexane, 2.15 mmol). After stirring for 30 min at 25 8C a solution of
11c (0.12 g, 0.43 mmol) in THF (8.3 mL) was added and the reac-
tion was stirred at 80 8C for 2 h. Water was added, the layers were
separated and the aqueous layer was extracted with EtOAc (3).
The combined organic layers were washed with 10% aq HCl (1),
water (2) and brine (1), dried (Na2SO4) and the solvent was
evaporated. The residue was purified by column chromatography
(85:15, hexane/EtOAc) to afford 13c as a yellow oil (133 mg, 76%);
mp: 147 8C (hexane/acetone); 1H NMR (400 MHz, (CD3)2CO): d=
10.08 (s, 1H), 8.83 (s, 1H), 8.54 (s, 1H), 8.30 (d, J=8.4 Hz, 1H), 8.07
(d, J=8.4 Hz, 1H), 7.21 (t, J=7.9 Hz, 1H), 6.82 (d, J=7.6 Hz, 1H),
6.81 (d, J=8.2 Hz, 1H), 2.68 (t, J=8.2 Hz, 2H), 1.7–1.5 (m, 2H), 1.3–
1.2 (m, 8H), 0.82 ppm (t, J=6.4 Hz, 3H); 13C NMR (100 MHz,
(CD3)2CO): d=167.3, 154.0, 144.0, 142.0, 136.3, 132.7 (
2JCÿF=
32.1 Hz), 130.4, 124.6, 122.7 (1JCÿF=273.1 Hz), 121.9, 120.7, 116.7
(3JCÿF=5.6 Hz), 115.5, 113.3, 102.8, 32.9, 31.5, 31.3, 29.2, 28.8, 22.4,
13.4 ppm; IR (NaCl): n˜=3600–3000 (br, NÿH and OÿH), 2929 (m,
CÿH), 2855 (m, CÿH), 1651 (m, C=O), 1588 (s, C=C), 1535 (s, C=C),
1426 (s), 1188 cmÿ1 (s) ; MS (ESI+ ): m/z (%): 404 [M]+ (8), 273 (11),
220 (15), 219 (100), 218 (21), 186 (37), 134 (20), 108 (21), 107 (24);
HRMS (ESI+ ): m/z [M]+ calcd for C22H23F3N2O2 : 404.1712, found:
404.1731; Anal. calcd for C22H23F3N2O2 : C, 65.34; H, 5.73; found: C,
64.79; H, 5.74.
N-(4-Cyano-3-trifluoromethylphenyl)-2-ethoxy-6-heptylbenz-
amide (7c): General procedure for the alkylation of phenols. A solu-
tion of 13c (0.1 g, 0.25 mmol) in acetone (10 mL) was treated se-
quentially with K2CO3 (0.085 g, 0.617 mmol) and Et2SO4 (0.071 mL,
0.54 mmol). After stirring for 3 h, saturated aq NH4Cl was added
(1.5 mL) and the aqueous layer was extracted with Et2O (3). The
combined organic layers were washed with brine (2), dried
(Na2SO4) and the solvent was evaporated. The residue was purified
by column chromatography (90:10, hexane/EtOAc) to afford 7c as
a white solid (82 mg, 76%); mp: 80 8C (hexane/EtOAc); 1H NMR
(400 MHz, (CD3)2CO): d=10.04 (s, 1H), 8.51 (s, 1H), 8.26 (d, J=
8.5 Hz, 1H), 8.06 (d, J=8.5 Hz, 1H), 7.32 (dd, J=8.3, 7.6 Hz, 1H),
6.90 (d, J=8.3 Hz, 1H), 6.89 (d, J=7.6 Hz, 1H), 4.07 (q, J=6.9 Hz,
2H), 2.66 (t, J=7.7 Hz, 2H), 1.7–1.6 (m, 2H), 1.4–1.2 (m, 11H),
0.81 ppm (t, J=6.8 Hz, 3H); 13C NMR (100 MHz, (CD3)2CO): d=
168.9, 157.6, 145.8, 143.8, 138.2, 134.7 (2JCÿF=31.8 Hz), 132.3, 128.2,
124.7 (1JCÿF=272.7 Hz), 123.6, 123.5, 118.5 (
3JCÿF=5.7 Hz), 117.4,
111.5, 104.8, 65.9, 34.7 (2C), 33.4, 33.1, 31.4, 24.2, 16.0, 15.3 ppm; IR
(NaCl): n˜=3300–3100 (br, NÿH), 2928 (s, CÿH), 2856 (m, CÿH), 1668
(m, C=O), 1587 (s, C=C), 1528 (s, C=C), 1326 (s), 1269 (s), 1179 (s),
1140 cmÿ1 (s) ; MS (ESI+ ): m/z (%): 432 [M]+ (3), 248 (60), 247 (100),
147 (19), 145 (16), 135 (19), 133 (15), 107 (14), 105 (11); HRMS
(ESI+ ): m/z [M]+ calcd for C24H27F3N2O2 : 432.2025, found:
432.2024; Anal. calcd for C24H37F3N2O2 : C, 66.65; H, 6.29; found: C,
66.81; H, 6.66.
2,2-Dimethyl-5-hexyl-4H-1,3-benzodioxin-4-one (11d): Following
the general procedure described for the Suzuki cross coupling
(Method A), the reaction of 9 (0.25 g, 0.07 mmol), 10d (0.06,
0.65 mmol), 9-BBN (1.3 mL, 0.65 mmol), MeONa (0.04 g, 0.65 mmol),
PdCl2(dppf) (6 mg, 0.02 mmol) and KBr (0.09 g, 0.73 mmol) in THF
(5.4 mL) afforded, after purification by column chromatography
(90:10, hexane/EtOAc), 11d as a colourless oil (71 mg, 41%);
1H NMR (400 MHz, CDCl3): d=7.40 (t, J=7.9 Hz, 1H), 6.94 (d, J=
7.6 Hz, 1H), 6.80 (d, J=8.2 Hz, 1H), 3.09 (t, J=7.9 Hz, 2H), 1.70 (s,
6H, 2CH3), 1.6–1.5 (m, 2H), 1.4–1.3 (m, 6H), 0.89 ppm (t, J=6.2 Hz,
3H); 13C NMR (100 MHz, CDCl3): d=160.2, 157.1, 148.5, 135.0,
125.0, 115.0, 112.0, 104.9, 34.3, 31.6, 31.1, 29.3, 25.6 (2C), 22.6,
14.0 ppm; IR (NaCl): n˜=2998 (w, CÿH), 2925 (s, CÿH), 2855 (m, Cÿ
H), 1739 (s, C=O), 1605 (m, C=C), 1582 (m, C=C), 1312 (m), 1213
(m), 1042 cmÿ1 (m); MS (ESI+ ): m/z (%): 262 [M]+ (8), 204 (100),
162 (32), 147 (22), 134 (57), 105 (25); HRMS (ESI+ ): m/z [M]+ calcd
for C16H22O3 : 262.1569, found: 262.1572.
ChemMedChem 2010, 5, 1530 – 1540  2010 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim www.chemmedchem.org 1535
Anacardic Acid-Derived Histone Lysine Acetyltransferase Activators
N-(4-Cyano-3-trifluoromethylphenyl)-6-hexyl-2-hydroxybenz-
amide (13d): Following the general procedure described for
amide formation, the reaction of 11d (0.06 g, 0.23 mmol), 12
(0.21 g, 1.15 mmol), nBuLi (0.82 mL, 1.40m in hexane, 1.15 mmol)
and DMPU (0.2 mL, 1.68 mmol) in THF (8.8 mL) afforded, after pu-
rification by column chromatography (80:20, hexane/EtOAc), 13d
as a white solid (58 mg, 65%); mp: 161 8C (hexane/acetone);
1H NMR (400 MHz, (CD3)2CO): d=10.07 (br, 1H), 8.54 (s, 1H), 8.29
(d, J=8.4 Hz, 1H), 8.07 (d, J=8.5 Hz, 1H), 7.21 (t, J=7.9 Hz, 1H),
6.82 (d, J=7.7 Hz, 1H), 6.81 (d, J=8.1 Hz, 1H), 2.85 (br, 1H), 2.68 (t,
J=7.9 Hz, 2H), 1.7–1.6 (m, 2H), 1.4–1.3 (m, 2H), 1.3–1.2 (m, 4H),
0.82 ppm (t, J=6.7 Hz, 3H); 13C NMR (100 MHz, (CD3)2CO): d=
167.2, 154.0, 143.9, 142.0, 136.3, 132.7 (2JCÿF=31.3 Hz), 130.4, 124.5,
123.0 (1JCÿF=273.0 Hz), 121.9, 120.7, 116.7 (
3JCÿF=5.7 Hz), 115.5,
113.3, 102.9, 32.9, 31.4, 31.2, 28.9, 22.2, 13.3 ppm; IR (NaCl): n˜=
3600–3000 (br, NÿH and OÿH), 3020 (m, CÿH), 2931 (m, CÿH),
2857 (w, CÿH), 1654 (m, C=O), 1588 (s, C=C), 1534 (s, C=C), 1426
(s), 1331 (s), 1217 cmÿ1 (s) ; MS (ESI+ ): m/z (%): 390 [M]+ (7), 212
(29), 205 (100), 186 (54), 108 (31), 107 (34), 77 (18); HRMS (ESI+ ):
m/z [M]+ calcd for C21H21F3N2O2 : 390.1555, found: 390.1552.
N-(4-Cyano-3-trifluoromethylphenyl)-2-ethoxy-6-hexylbenz-
amide (7d): Following the general procedure described for the al-
kylation of phenols, the reaction of 13d (0.03 g, 0.08 mmol), Et2SO4
(0.02 mL, 0.17 mmol) and K2CO3 (0.03 g, 0.19 mmol) in acetone
(3.2 mL) afforded, after purification by column chromatography
(90:10, hexane/EtOAc), 7d as a white solid (15 mg, 46%); mp:
109 8C (hexane/EtOAc); 1H NMR (400 MHz, CDCl3): d=8.1–8.0 (m,
3H), 7.81 (d, J=8.2 Hz, 1H), 7.31 (t, J=8.0 Hz, 1H), 6.89 (d, J=
7.7 Hz, 1H), 6.80 (d, J=8.3 Hz, 1H), 4.08 (q, J=6.9 Hz, 2H), 2.71 (t,
J=7.7 Hz, 2H), 1.6–1.5 (m, 2H), 1.4–1.2 (m, 9H), 0.85 ppm (t, J=
6.5 Hz, 3H); 13C NMR (100 MHz, CDCl3): d=166.5, 155.5, 143.6,
142.4, 136.0, 134.1 (2JCÿF=33.0 Hz), 131.2, 124.6, 122.6, 122.2
(1JCÿF=274.0 Hz), 121.7, 117.0 (
3JCÿF=4.8 Hz), 115.6, 109.7, 104.1,
64.5, 33.4, 31.6, 31.5, 29.2, 22.5, 14.8, 14.0 ppm; IR (NaCl): n˜=3500–
3100 (br, NÿH), 2929 (s, CÿH), 2857 (m, CÿH), 1668 (m, C=O), 1587
(s, C=C), 1528 (s, C=C), 1327 (s), 1179 (s), 1140 cmÿ1 (s) ; MS (ESI+ ):
m/z (%): 418 [M]+ (6), 234 (99), 233 (100), 205 (22), 147 (47), 145
(63), 135 (58), 134 (29), 133 (52), 107 (52), 105 (35), 91 (29), 77 (28);
HRMS (ESI+ ): m/z [M]+ calcd for C23H25F3N2O2 : 418.1868, found:
418.1870; Anal. calcd for C23H25F3N2O2 : C, 66.02; H, 6.02; found: C,
66.21; H, 6.07.
2,2-Dimethyl-5-(tert-butyldimethylsilyloxypent-1-yl)-4H-1,3-ben-
zodioxin-4-one (11e): Following the general procedure described
for the Suzuki cross coupling (Method A), the reaction of 9 (0.25 g,
0.07 mmol), 10e (0.13 g, 0.65 mmol), 9-BBN (1.3 mL, 0.5m in THF,
0.65 mmol), MeONa (0.04 g, 0.65 mmol), PdCl2(dppf) (6 mg,
0.02 mmol) and KBr (0.09 g, 0.73 mmol) in THF (5.4 mL) afforded,
after purification by column chromatography (90:10, hexane/
EtOAc), 11e as a colourless oil (80 mg, 32%); 1H NMR (400 MHz,
CDCl3): d=7.40 (t, J=7.9 Hz, 1H), 6.93 (d, J=7.6 Hz, 1H), 6.81 (d,
J=8.2 Hz, 1H), 3.61 (t, J=6.5 Hz, 2H), 3.09 (t, J=7.7 Hz, 2H), 1.70
(s, 6H, 2CH3), 1.6–1.4 (m, 6H), 0.89 (s, 9H, SiC(CH3)3, 0.04 ppm (s,
6H, 2SiCH3) ;
13C NMR (100 MHz, CDCl3): d=160.2, 157.1, 148.3,
135.1, 125.1, 115.1, 112.0, 104.9, 63.1, 34.3, 32.7, 30.9, 26.0 (3C),
25.8, 25.6 (2C), 18.4, ÿ5.2 ppm (2C); IR (NaCl): n˜=2929 (m, CÿH),
2857 (m, CÿH), 1740 (s, C=O), 1606 (m, C=C), 1582 (s, C=C),
1476 cmÿ1 (s, C=C); MS (ESI+ ) 401 [M+Na]+ (100), 379 [M+H]+
(76), 287 (9), 201 (20); HRMS (ESI+ ): m/z [M+H]+ calcd for
C21H35O4Si : 379.2299, found: 379.2300.
N-(4-Cyano-3-trifluoromethylphenyl)-6-(5-tert-butyldimethylsilyl-
oxypent-1-yl)-2-hydroxybenzamide (13e): Following the general
procedure described for amide formation, the reaction of 11e
(0.08 g, 0.21 mmol), 12 (0.20 g, 1.05 mmol), nBuLi (0.75 mL, 1.40m
in hexane, 1.05 mmol) and DMPU (0.19 mL, 1.54 mmol) in THF
(8.1 mL) afforded, after purification by column chromatography
(80:20, hexane/EtOAc), 13e as a colourless oil (37 mg, 35%);
1H NMR (400 MHz, (CD3)2CO): d=10.00 (br, 1H), 8.86 (s, 1H), 8.54 (s,
1H), 8.30 (d, J=8.2 Hz, 1H), 8.07 (d, J=8.3 Hz, 1H), 7.21 (t, J=
8.0 Hz, 1H), 6.82 (d, J=7.6 Hz, 1H), 6.81 (d, J=8.2 Hz, 1H), 3.59 (t,
J=6.2 Hz, 2H), 2.69 (t, J=7.9 Hz, 2H), 1.7–1.4 (m, 6H), 0.86 (s, 9H,
SiC(CH3)3), 0.01 ppm (s, 6H, 2SiCH3) ;
13C NMR (100 MHz, (CD3)2CO):
d=167.2, 154.1, 144.0, 141.9, 136.3, 132.8 (2JCÿF=32.1 Hz), 130.4,
124.5, 122.8 (1JCÿF=273.0 Hz), 121.9, 120.7, 116.7 (
3JCÿF=4.9 Hz),
115.5, 113.3, 102.9, 62.5, 33.0, 32.4, 31.1, 25.5, 25.4 (3C), 17.9,
ÿ6.1 ppm (2C); IR (NaCl): n˜=3500–3000 (br, NÿH and OÿH), 2931
(s, CÿH), 2858 (m, CÿH), 1656 (m, C=O), 1588 (s, C=C), 1533 (s, C=
C), 1426 (s), 1330 cmÿ1 (s) ; MS (ESI+ ): 507 [M+H]+ (24), 371 (56),
197 (100); HRMS (ESI+ ): m/z [M+H]+ calcd for C26H34F3N2O3Si :
507.2285, found: 507.2298.
N-(4-Cyano-3-trifluoromethylphenyl)-2-ethoxy-6-(5-hydroxypent-
1-yl)benzamide (7e): Following the general procedure described
for the alkylation of phenols, the reaction of 13e (0.03 g,
0.05 mmol), Et2SO4 (0.02 mL, 0.12 mmol), K2CO3 (0.02 g, 0.13 mmol)
in acetone (2.1 mL) afforded, after purification by column chroma-
tography (90:10, hexane/EtOAc), a colourless oil (16 mg) that was
used in the next step without further purification. General proce-
dure for the deprotection of silyl ethers. A solution of the residue ob-
tained above (0.02 g, 0.03 mmol) in THF (0.5 mL) at 0 8C was treat-
ed with TBAF (0.05 mL, 1m in THF, 0.055 mmol) and stirred at RT
for 5 h. The mixture was diluted with EtOAc and washed with satu-
rated aq NaHCO3 (3). The aqueous layer was extracted with
EtOAc (3) and the combined organic layers were washed with
brine (3), dried (Na2SO4) and the solvent was evaporated. The res-
idue was purified by column chromatography (50:50, hexane/
EtOAc) to afford 7e as a colourless oil (8 mg, 61% combined
yield); 1H NMR (400 MHz, CDCl3): d=8.27 (s, 1H), 8.06 (s, 1H), 8.04
(d, J=8.1 Hz, 1H), 7.82 (d, J=8.2 Hz, 1H), 7.32 (t, J=8.0 Hz, 1H),
6.90 (d, J=7.7 Hz, 1H), 6.81 (d, J=8.3 Hz, 1H), 4.09 (q, J=6.6 Hz,
2H), 3.60 (t, J=6.3 Hz, 2H), 2.74 (t, J=7.6 Hz, 2H), 1.7–1.4 ppm (m,
9H); 13C NMR (100 MHz, CDCl3): d=166.6, 155.6, 143.0, 142.4,
136.0, 134.1 (2JCÿF=33.0 Hz), 131.2, 124.8, 122.5, 122.2 (
1JCÿF=
273.1 Hz), 121.7, 117.1 (3JCÿF=4.8 Hz), 115.6, 109.8, 104.1, 64.5, 62.7,
33.2, 32.3, 30.9, 25.4, 14.8 ppm; IR (NaCl): n˜=3500–3000 (br, NÿH
and OÿH), 2932 (s, CÿH), 2859 (m, CÿH), 1679 (m, C=O), 1588 (s,
C=C), 1529 (s, C=C), 1327 (s), 1138 cmÿ1 (s) ; MS (ESI+ ): 443
[M+Na]+ (33), 421 [M+H]+ (100); HRMS (ESI+ ): m/z [M+H]+ calcd
for C22H24F3N2O3 : 421.1734, found: 421.1736.
2,2-Dimethyl-5-(tert-butyldimethylsilyloxybut-1-yl)-4H-1,3-ben-
zodioxin-4-one (11 f): Following the general procedure described
for the Suzuki cross coupling (Method A), the reaction of 9 (0.25 g,
0.07 mmol), 10 f (0.12 g, 0.65 mmol), 9-BBN (1.3 mL, 0.5m in THF,
0.65 mmol), MeONa (0.04 g, 0.65 mmol), PdCl2(dppf) (6 mg,
0.02 mmol) and KBr (0.09 g, 0.73 mmol) in THF (5.4 mL) afforded,
after purification by column chromatography (90:10, hexane/
EtOAc), 11 f as a colourless oil (160 mg, 66%); 1H NMR (400 MHz,
CDCl3): d=7.39 (t, J=7.9 Hz, 1H), 6.93 (d, J=7.6 Hz, 1H), 6.80 (d,
J=8.2 Hz, 1H), 3.63 (t, J=5.8 Hz, 2H), 3.11 (t, J=7.0 Hz, 2H), 1.69
(s, 6H, 2CH3), 1.7–1.6 (m, 4H), 0.88 (s, 9H, SiC(CH3)3), 0.03 ppm (s,
6H, 2SiCH3) ;
13C NMR (100 MHz, CDCl3): d=160.2, 157.1, 148.1,
135.1, 125.1, 115.2, 112.1, 104.9, 63.1, 34.0, 32.7, 27.3 , 26.0 (3C),
25.6 (2C), 18.3, ÿ5.2 ppm (2C); IR (NaCl): n˜=2929 (s, CÿH), 2857
(m, CÿH), 1739 (s, C=O), 1605 (m, C=C), 1582 (m, C=C), 1312 (m),
1217 cmÿ1 (m); MS (ESI+ ): 387 [M+Na]+ (42), 365 [M+H]+ (100);
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HRMS (ESI+ ): m/z [M+H]+ calcd for C20H33O4Si: 365.2143, found:
365.2142.
N-(4-Cyano-3-(trifluoromethyl)phenyl)-6-(4-tert-butyldimethylsi-
lyloxybut-1-yl)-2-hydroxybenzamide (13 f): Following the general
procedure described for amide formation, the reaction of 11 f
(0.16 g, 0.44 mmol), 12 (0.41 g, 2.20 mmol), nBuLi (1.57 mL, 1.40m
in hexane, 2.20 mmol) and DMPU (0.39 mL, 3.20 mmol) in THF
(17 mL) afforded, after purification by column chromatography
(80:20, hexane/EtOAc), 13 f as a colourless oil (109 mg, 50%);
1H NMR (400 MHz, (CD3)2CO): d=10.06 (br, 1H), 8.54 (s, 1H), 8.30
(d, J=8.5 Hz, 1H), 8.06 (d, J=8.6 Hz, 1H), 7.21 (t, J=7.9 Hz, 1H),
6.82 (d, J=7.6 Hz, 1H), 6.81 (d, J=7.6 Hz, 1H), 3.61 (t, J=6.3 Hz,
2H), 2.71 (t, J=7.4 Hz, 2H), 1.7–1.4 (m, 4H), 0.84 (s, 9H, SiC(CH3)3),
ÿ0.01 ppm (s, 6H, 2SiCH3) ;
13C NMR (100 MHz, (CD3)2CO): d=167.3,
154.1, 144.0, 141.9, 136.3, 132.8 (2JCÿF=32.1 Hz), 130.4, 124.6, 122.8
(1JCÿF=273.0 Hz), 121.9, 120.6, 116.7 (
3JCÿF=4.1 Hz), 115.6, 113.4,
102.8, 62.5, 32.7, 32.5, 27.6, 25.4 (3C), 17.9, ÿ6.1 ppm (2C); IR
(NaCl): n˜=3500–3000 (br, NÿH and OÿH), 2953 (s, CÿH), 2931 (s,
CÿH), 2857 (m, CÿH), 1656 (m, C=O), 1588 (s, C=C), 1533 (s, C=C),
1426 (s), 1329 (s), 1187 cmÿ1 (m); MS (ESI+ ): 515 [M+Na]+ (38),
493 [M+H]+ (100); HRMS (ESI+ ): m/z [M+H]+ calcd for
C25H32F3N2O3Si : 493.2129, found: 493.2128.
N-(4-Cyano-3-trifluoromethylphenyl)-2-ethoxy-6-(4-hydroxybut-
1-yl)benzamide (7 f): Following the general procedure described
for the alkylation of phenols, the reaction of 13 f (0.08 g,
0.16 mmol), Et2SO4 (0.05 mL, 0.36 mmol), K2CO3 (0.06 g, 0.41 mmol)
in acetone (6.5 mL) afforded, after purification by column chroma-
tography (80:20, hexane/EtOAc), a colourless oil (67 mg) that was
used in the next step without further purification. Following the
general procedure described for the deprotection of silyl ethers,
the reaction of the residue obtained above (67 mg, 0.129 mmol)
and TBAF (0.19 mL, 1m in THF, 0.19 mmol) in THF (2.2 mL) afford-
ed, after purification by column chromatography (60:40, hexane/
EtOAc), 7 f as a colourless oil (27 mg, 51%); 1H NMR (400 MHz,
(CD3)2CO): d=10.07 (br, 1H), 8.51 (s, 1H), 8.26 (d, J=7.1 Hz, 1H),
8.07 (d, J=8.5 Hz, 1H), 7.33 (t, J=8.0 Hz, 1H), 6.92 (d, J=7.4 Hz,
2H), 4.08 (q, J=7.0 Hz, 2H), 3.50 (t, J=6.0 Hz, 2H), 3.39 (t, J=
5.2 Hz, 1H), 2.70 (t, J=7.8 Hz, 2H), 1.7–1.5 (m, 4H), 1.30 ppm (t, J=
6.9 Hz, 3H); 13C NMR (100 MHz, (CD3)2CO): d=167.0, 155.8, 143.9,
141.7, 136.3, 132.8 (2JCÿF=31.3 Hz), 130.4, 126.3, 122.7 (
1JCÿF=
273.9 Hz), 121.9, 121.6, 116.7 (3JCÿF=4.8 Hz), 115.5, 109.6, 102.9,
63.9, 61.3, 32.6, 32.5, 27.6, 14.1 ppm; IR (NaCl): n˜=3500–3000 (br,
NÿH and OÿH), 2933 (m, CÿH), 1678 (m, C=O), 1588 (s, C=C), 1529
(s, C=C), 1327 cmÿ1 (s) ; MS (ESI+ ): 429 [M+Na]+ (23), 407 [M+H]+
(100); HRMS (ESI+ ): m/z [M+H]+ calcd for C21H22F3N2O3 : 407.1577,
found: 407.1585.
2,2-Dimethyl-5-(3-tert-butyldimethylsilyloxyprop-1-yl)-4H-1,3-
benzodioxin-4-one (11g): Following the general procedure de-
scribed for the Suzuki cross coupling (Method A), 9 (0.25 g,
0.07 mmol), 10g (0.11 g, 0.65 mmol), 9-BBN (1.3 mL, 0.5m in THF,
0.65 mmol), MeONa (0.04 g, 0.65 mmol), PdCl2(dppf) (6 mg,
0.02 mmol) and KBr (0.09 g, 0.73 mmol) in THF (5.4 mL) afforded,
after purification by column chromatography (90:10, hexane/
EtOAc), 11g as a colourless oil (74 mg, 32%); 1H NMR (400 MHz,
CDCl3): d=7.41 (t, J=7.9 Hz, 1H), 6.96 (d, J=7.6 Hz, 1H), 6.81 (d,
J=8.2 Hz, 1H), 3.69 (t, J=6.4 Hz, 2H), 3.14 (t, J=7.7 Hz, 2H), 1.84
(t, J=6.6 Hz, 2H), 1.70 (s, 6H, 2CH3), 0.91 (s, 9H, SiC(CH3)3),
0.07 ppm (s, 6H, 2SiCH3) ;
13C NMR (100 MHz, CDCl3): d=160.2,
157.1, 147.8, 135.1, 125.2, 115.2, 112.1, 105.0, 62.8, 34.0, 30.7, 26.0
(3C), 25.6 (2C), 18.3, ÿ5.3 ppm (2C); IR (NaCl): n˜=2952 (m, CÿH),
2928 (m, CÿH), 2887 (w, CÿH), 2857 (m, CÿH), 1739 (s, C=O), 1606
(m, C=C), 1582 (m, C=C), 1476 (s), 1313 (s), 1271 cmÿ1 (s) ; MS
(ESI+ ): 373 [M+Na]+ (71), 351 [M+H]+ (100); HRMS (ESI+ ): m/z
[M+H]+ calcd for C19H31O4Si : 351.1986, found: 351.1989.
N-(4-Cyano-3-(trifluoromethyl)phenyl)-6-(3-tert-butyldimethylsi-
lyloxyprop-1-yl)-2-hydroxybenzamide (13g): Following the gener-
al procedure described for amide formation, the reaction of 11g
(0.11 g, 0.17 mmol), 12 (0.16 g, 0.85 mmol), nBuLi (0.57 mL, 1.50m
in hexane, 0.85 mmol) and DMPU (0.15 mL, 1.24 mmol) in THF
(6.5 mL) afforded, after purification by column chromatography
(80:20, hexane/EtOAc), 13g as a colourless oil (30 mg, 37%);
1H NMR (400 MHz, (CD3)2CO): d=10.07 (br, 1H), 8.57 (s, 1H), 8.27
(d, J=8.5 Hz, 1H), 8.06 (d, J=8.5 Hz, 1H), 7.22 (t, J=7.9 Hz, 1H),
6.9–6.8 (m, 2H), 3.65 (t, J=6.1 Hz, 2H), 2.75 (t, J=7.8 Hz, 2H), 1.9–
1.8 (m, 2H), 0.83 (s, 9H, SiC(CH3)3), 0.00 ppm (s, 6H, 2SiCH3) ;
13C NMR (100 MHz, (CD3)2CO): d=167.2, 154.1, 144.0, 141.5, 136.2,
132.7 (2JCÿF=34.5 Hz), 130.4, 124.7, 122.7 (
1JCÿF=272.5 Hz), 121.9,
120.7, 116.7 (3JCÿF=5.6 Hz), 115.6, 113.3, 102.8, 62.3, 34.5, 29.5, 25.3
(3C), 17.8, ÿ6.1 ppm (2C); IR (NaCl): n˜=3500–3000 (br, NÿH and
OÿH), 2928 (m, CÿH), 2858 (m, CÿH), 1652 (m, C=O), 1588 (s, C=C),
1534 (s, C=C), 1427 (s), 1330 cmÿ1 (s) ; MS (ESI+ ): 501 [M+Na]+
(100), 479 [M+H]+ (14) ; HRMS (ESI+ ): m/z [M+H]+ calcd for
C24H30F3N2O3Si : 479.1972, found: 479.1984.
N-(4-Cyano-3-trifluoromethylphenyl)-2-ethoxy-6-(3-hydroxyprop-
1-yl)benzamide (7g): Following the general procedure described
for the alkylation of phenols, the reaction of 13g (0.03 g,
0.07 mmol), Et2SO4 (0.02 mL, 0.16 mmol) and K2CO3 (0.03 g,
0.18 mmol) in acetone (2.8 mL) afforded, after purification by
column chromatography (80:20, hexane/EtOAc), a colourless oil
(25 mg) that was used in the next step without further purification.
Following the general procedure described for the deprotection of
silyl ethers, the reaction of the residue obtained above (24 mg,
0.047 mmol) and TBAF (0.071 mL, 1m in THF, 0.071 mmol) in THF
(0.8 mL) afforded, after purification by column chromatography
(60:40, hexane/EtOAc), 7g as a colourless oil (18 mg, 97%);
1H NMR (400 MHz, (CD3)2CO): d=10.08 (s, 1H), 8.49 (s, 1H), 8.25 (d,
J=8.4 Hz, 1H), 8.05 (d, J=8.5 Hz, 1H), 7.33 (t, J=8.0 Hz, 1H), 6.9–
6.8 (m, 2H), 4.07 (q, J=7.0 Hz, 2H), 3.6–3.5 (m, 2H), 2.74 (t, J=
8.5 Hz, 2H), 1.9–1.8 (m, 2H), 1.29 ppm (t, J=6.9 Hz, 3H); 13C NMR
(100 MHz, (CD3)2CO): d=169.0, 157.7, 145.8, 143.3, 138.2, 134.7
(2JCÿF=31.0 Hz), 132.4, 128.4, 125.1 (
1JCÿF=270.6 Hz), 123.9, 123.5,
118.7 (3JCÿF=4.9 Hz), 117.4, 111.6, 104.8, 65.9, 62.7, 36.2, 31.1,
16.0 ppm; IR (NaCl): n˜=3500–3200 (br, NÿH and OÿH), 2928 (m,
CÿH), 1671 (m, C=O), 1589 (s, C=C), 1526 (s, C=C), 1327 (s),
1220 cmÿ1 (s) ; MS (ESI+ ): 415 [M+Na]+ (100), 393 [M+H]+ (65) ;
HRMS (ESI+ ): m/z [M+H]+ calcd for C20H20F3N2O3 : 393.1421, found:
393.1419.
5-Ethoxy-2,2-dimethyl-4H-1,3-benzodioxin-4-one (16): Following
the general procedure described for the alkylation of phenols, the
reaction of 15 (0.10 g, 0.51 mmol), K2CO3 (0.18 g, 1.28 mmol) and
ethyl iodide (0.09 mL, 1.13 mmol) in acetone (16 mL), afforded,
after purification by column chromatography (90:10, hexane/
EtOAc), 16 as a white solid (0.106 g, 91%); mp: 101 8C (hexane/ace-
tone); 1H NMR (400 MHz, CDCl3): d=7.42 (t, J=8.4 Hz, 1H), 6.62 (d,
J=8.4 Hz, 1H), 6.55 (d, J=8.4 Hz, 1H), 4.19 (q, J=6.8 Hz, 2H), 1.72
(s, 6H, 2CH3), 1.53 ppm (t, J=6.8 Hz, 3H);
13C NMR (100 MHz,
CDCl3): d=160.7, 158.0, 157.6, 136.2, 108.8, 106.3, 105.0, 103.3,
64.8, 25.5 (2C), 14.4 ppm; IR (NaCl): n˜=2988 (w, CÿH), 2938 (w, Cÿ
H), 2888 (w, CÿH), 1736 (s, C=O), 1582 (m, C=C), 1461 (s), 1254 (s),
1081 cmÿ1 (s) ; MS (ESI+ ): 245 [M+Na]+ (100), 223 [M+H]+ (46) ;
HRMS (ESI+ ): m/z [M+Na]+ calcd for C12H14NaO4 : 245.0784; found
245.0779; Anal. calcd for C12H14O4 : C, 64.85; H, 6.35; found: C,
64.76; H, 6.38.
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N-(4-Cyano-3-trifluoromethylphenyl)-6-ethoxy-2-hydroxybenz-
amide (17): Following the general procedure described for amide
formation, the reaction of 16 (0.34 g, 1.51 mmol), 12 (0.703 g,
3.78 mmol), nBuLi (3.10 mL, 1.22m in hexane, 3.78 mmol) and
DMPU (4.15 mL, 34.50 mmol) in THF (56 mL) afforded, after purifi-
cation by column chromatography (60:10:30, hexane/EtOAc/
CH2Cl2), 17 as a white solid (0.47 g, 88%); mp: 167 8C (hexane/ace-
tone); 1H NMR (400 MHz, (CD3)2CO): d=11.06 (s, 1H), 8.40 (s, 1H),
8.1–8.0 (m, 2H), 7.43 (t, J=8.4 Hz, 1H), 6.67 (d, J=8.4 Hz, 1H), 6.61
(dd, J=8.4, 0.9 Hz, 1H), 4.38 (q, J=7.0 Hz, 2H), 1.66 ppm (t, J=
7.0 Hz, 3H); 13C NMR (100 MHz, (CD3)2CO): d=171.3, 166.4, 160.0,
144.1, 138.1, 137.0, 134.7 (2JCÿF=32.5 Hz), 125.6, 124.5 (
1JCÿF=
273.4 Hz), 120.2 (3JCÿF=5.6 Hz), 117.2, 113.2, 106.0 (
4JCÿF=2.6 Hz),
105.7, 104.6, 67.8, 15.8 ppm; IR (NaCl): n˜=3600–3000 (br, NÿH and
OÿH), 1648 (m, C=O), 1585 (s, C=C), 1544 (s, C=C), 1451 (m), 1430
(m), 1326 (s), 1234 (s), 1136 cmÿ1 (s) ; MS (ESI+ ): 373 [M+Na]+ (20),
351 [M+H]+ (92), 209 (100); HRMS (ESI+ ): m/z [M+H]+ calcd for
C17H14F3N2O3 : 351.0951; found 351.0965; Anal. calcd for
C17H13F3N2O3 : C, 58.29; H, 3.74; found: C, 58.25; H, 3.76.
2-(4-Cyano-3-trifluoromethylphenylcarbamoyl)-3-ethoxyphenyl
trifluoromethanesulfonate (18): Following the general procedure
described for the synthesis of triflates, the reaction of 17 (0.15 g,
0.43 mmol) and trifluoromethanesulfonic anhydride (0.07 mL,
0.43 mmol) in pyridine (0.75 mL) afforded, after purification by
column chromatography (70:30, hexane/EtOAc), 18 as a white
solid (0.18 g, 87%); mp: 148 8C (hexane/EtOAc); 1H NMR (400 MHz,
CDCl3): d=8.52 (s, 1H), 8.02 (d, J=9.2 Hz, 1H), 7.96 (s, 1H), 7.79 (d,
J=8.4 Hz, 1H), 7.49 (t, J=8.4 Hz, 1H), 7.03 (d, J=8.8 Hz, 1H), 6.98
(d, J=8.4 Hz, 1H), 4.19 (q, J=7.2 Hz, 2H), 1.46 ppm (t, J=7.2 Hz,
3H); 13C NMR (100 MHz, CDCl3): d=161.0, 157.0, 147.6, 141.7,
136.0, 134.1 (2JCÿF=33.2 Hz), 132.8, 122.2, 122.1 (
1JCÿF=274.0 Hz),
118.6, 118.5 (1JCÿF=320.6 Hz), 117.3 (
3JCÿF=4.9 Hz), 115.5, 114.9,
112.5, 104.8, 65.7, 14.6 ppm; IR (NaCl): n˜=3286 (m, NÿH), 2979 (w,
CÿH), 1650 (m, C=O), 1582 (s, C=C), 1545 (s, C=C), 1431 (s, C=C),
1322 cmÿ1 (s) ; MS (ESI+ ): 505 [M+Na]+ (91), 483 [M+H]+ (100);
HRMS (ESI+ ): m/z [M+H]+ calcd for C18H13F6N2O5S: 483.0444,
found: 483.0446; Anal. calcd for C18H12F6N2O5S: C, 44.82; H, 2.51;
found: C; 44.63; H, 1.98.
(E)-4,4,5,5-Tetramethyl-2-(4-trifluoromethylphenyl-vin-1-yl)-1,3,2-
dioxaborolane (20a): General procedure for the Takai–Utimoto reac-
tion. A suspension of CrCl3 (2.76 g, 22.43 mmol) in THF (30 mL) was
treated with 19a (0.38 mL, 2.80 mmol) and 3-(dichloromethyl)-
4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.18 g, 5.60 mmol) in THF
(6 mL). Then LiI (1.50 g, 11.20 mmol) in THF (6 mL) was added and
the suspension was stirred for 16 h at RT. The mixture was poured
into water, extracted with EtOAc (3), and the solvent was evapo-
rated. The residue was purified by column chromatography (95:5,
hexane/EtOAc) to afford 20a as a white solid (0.68 g, 81%); mp:
60 8C (hexane/EtOAc) ; 1H NMR (400 MHz, CDCl3): d=7.6–7.5 (m,
4H), 7.39 (d, J=18.4 Hz, 1H), 6.25 (d, J=18.4 Hz, 1H), 1.28 ppm (s,
12H, 4CH3) ;
13C NMR (100 MHz, CDCl3): d=147.6, 140.8, 130.4
(2JCÿF=32.5 Hz), 127.1 (2C), 125.5 (
3JCÿF=4.2 Hz, 2C), 124.1 (
1JCÿF=
274.7 Hz), 119.5, 83.5 (2C), 24.7 ppm (4C); IR (NaCl): n˜=2923 (s, Cÿ
H), 2853 (m, CÿH), 1623 cmÿ1 (w, C=C); MS (ESI+ ): 321 [M+Na]+
(72), 299 [M+H]+ (100), 279 (20); HRMS (ESI+ ): m/z [M+H]+ calcd
for C15H19BF3O2 : 299.1427, found: 299.1438; Anal. calcd for
C15H18BF3O2 : C, 60.43; H, 6.09; found: C, 60.49; H, 6.09.
(E)-4,4,5,5-Tetramethyl-2-(3-bromophenyl)ethen-1-yl-1,3,2-dioxa-
borolane (20b): Following the general procedure described for the
Takai–Utimoto reaction, 19b (0.33 mL, 2.80 mmol), 3-(dichloro-
methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.18 g, 5.60 mmol),
CrCl3 (2.76 g, 22.43 mmol) and LiI (1.50 g, 11.20 mmol) in THF
(42 mL) afforded, after purification by column chromatography
(95:5, hexane/EtOAc), 20b as a yellow oil (0.78 g, 91%); 1H NMR
(400 MHz, CDCl3): d=7.63 (t, J=1.7 Hz, 1H), 7.42 (td, J=8.0, 1.6 Hz,
2H), 7.32 (d, J=18.4 Hz, 1H), 7.23 (t, J=7.6 Hz, 1H), 6.18 (d, J=
18.4 Hz, 1H), 1.33 ppm (s, 12H); 13C NMR (100 MHz, CDCl3): d=
147.5, 139.5, 131.5, 129.9 (2C), 129.7, 125.4, 122.6, 83.3 (2C),
24.7 ppm (4C); MS (ESI+ ): 429 [M+Na]+ (23), 407 [M+H]+ (100);
IR (NaCl): n˜=2979 (m, CÿH), 1626 (m, C=O), 1563 (w, C=C), 1471
(w), 1345 (s), 1210 (m), 1145 cmÿ1 (s) ; MS (ESI+ ): 333 [M+Na]+
(51), 331 [M+Na]+ (62), 311 [M+H]+ (100), 309 [M+H]+ (100);
HRMS (ESI+ ): m/z [M+H]+ calcd for C14H19B
79BrO2 : 309.0659,
found: 309.0667.
(E)-N-(4-Cyano-3-trifluoromethylphenyl)-2-ethoxy-6-phenyl-
ethen-1-yl Benzamide (7 j): General procedure for the Suzuki cross
coupling (Method B). 21 (41.9 mg, 0.19 mmol), 18 (0.05 g,
0.11 mmol), Pd(PPh3)4 (6 mg, 5.2 mmol) and K3PO4 (0.04 g,
0.19 mmol) were suspended in dioxane (0.55 mL). The suspension
was irradiated in a microwave reactor for 15 min at 100 8C (90 W).
Benzene (1 mL), aq NaOH (100 mL, 3m) and H2O2 (30%, 100 mL)
were added and the mixture was stirred at RT for 1 h. Water was
added and the aqueous layer was extracted with EtOAc (3). The
combined organic layers were dried (Na2SO4) and the solvent was
evaporated. The residue was purified by column chromatography
(-NH2 silica gel; 90:10, hexane/EtOAc) to afford 7 j as a white solid
(36.8 mg, 80%); mp: 182 8C (hexane/acetone); 1H NMR (400 MHz,
(CD3)2CO): d=10.16 (s, 1H), 8.50 (s, 1H), 8.29 (dd, J=8.5, 1.4 Hz,
1H), 8.07 (d, J=8.5 Hz, 1H), 7.6–7.4 (m, 4H), 7.4–7.2 (m, 5H), 7.03
(dd, J=7.7, 1.3 Hz, 1H), 4.12 (q, J=7.0 Hz, 2H), 1.31 ppm (t, J=
7.0 Hz, 3H); 13C NMR (100 MHz, (CD3)2CO): d=168.4, 158.0, 145.8,
139.0, 138.3, 138.2, 134.7 (2JCÿF=34.6 Hz), 133.5, 132.6, 130.6 (2C),
129.9, 128.6 (2C), 127.7, 126.7, 124.6 (1JCÿF=272.0 Hz), 123.9, 119.3,
118.7 (3JCÿF=5.6 Hz), 117.4, 113.1, 105.0, 66.1, 16.0 ppm; IR (NaCl):
n˜=3292 (br, NÿH), 2964 (s, CÿH), 1668 (s, C=O), 1587 (s, C=C),
1530 (s, C=C), 1426 (m), 1260 (s), 1137 cmÿ1 (s) ; MS (ESI+ ): 459
[M+Na]+ (38), 437 [M+H]+ (100), 391 (38); HRMS (ESI+ ): m/z
[M+H]+ calcd for C25H20F3N2O2 : 437.1471, found: 437.1468.
(E)-N-(4-Cyano-3-trifluoromethylphenyl)-2-ethoxy-6-(4-trifluoro-
methylphenyl-ethen-1-yl benzamide (7h): Following the general
procedure described for the Suzuki cross coupling (Method B), the
reaction of 20a (0.06 g, 0.19 mmol), 18 (0.05 g, 0.11 mmol),
Pd(PPh3)4 (6 mg, 5.19 mmol) and K3PO4 (0.04 g, 0.19 mmol) in diox-
ane (0.55 mL) afforded, after purification by column chromatogra-
phy (-NH2 silica gel; 90:10!85:15, hexane/EtOAc), 7h as a white
solid (22.7 mg, 43%); mp: 180 8C (hexane/acetone); 1H NMR
(400 MHz, (CD3)2CO): d=10.19 (s, 1H), 8.50 (s, 1H), 8.28 (dd, J=8.5,
1.0 Hz, 1H), 8.07 (d, J=8.5 Hz, 1H), 7.71 (d, J=8.4 Hz, 2H), 7.67 (d,
J=8.4 Hz, 2H), 7.5–7.4 (m, 3H), 7.36 (d, J=16.3 Hz, 1H), 7.08 (d, J=
7.9 Hz, 1H), 4.13 (q, J=7.0 Hz, 2H), 1.32 ppm (t, J=7.0 Hz, 3H);
13C NMR (100 MHz, (CD3)2CO): d=168.2, 158.1, 145.7, 142.9, 138.3,
137.8, 134.7 (2JCÿF=32.5 Hz), 132.8, 131.9, 130.7 (
2JCÿF=32.5 Hz),
129.7, 129.1 (2C), 127.9, 127.5 (3JCÿF=3.9 Hz, 2C), 126.3 (
1JCÿF=
271.7 Hz), 124.6 (1JCÿF=273.8 Hz), 124.0, 119.6, 118.7 (
3JCÿF=4.9 Hz),
117.4, 113.8, 105.1, 66.2, 16.0 ppm; IR (NaCl): n˜=3500–3200 (br, Nÿ
H), 2963 (m, CÿH), 2931 (m, CÿH), 1666 (m, C=O), 1588 (s, C=C),
1531 (s, C=C), 1326 (s), 1121 cmÿ1 (s) ; MS (ESI+ ): 527 [M+Na]+
(48), 505 [M+H]+ (71), 391 (100); HRMS (ESI+ ): m/z [M+H]+ calcd
for C26H19F6N2O2 : 505.1345, found: 505.1343.
(E)-N-(4-Cyano-3-trifluoromethylphenyl)-2-ethoxy-6-(3-bromo-
phenyl)ethen-1-yl benzamide (7 i): Following the general proce-
dure described for the Suzuki cross coupling (Method B), the reac-
tion of 20b (58.4 mg, 0.19 mmol), 18 (50 mg, 0.11 mmol), Pd(PPh3)4
(6 mg, 5.19 mmol) and K3PO4 (40.1 mg, 0.19 mmol) in dioxane
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(0.55 mL) afforded, after purification by column chromatography
(-NH2 silica gel; 90:10!85:15, hexane/EtOAc), 7 i as a white solid
(15 mg, 27%); mp: 144 8C (hexane/acetone); 1H NMR (400 MHz,
(CD3)2CO): d=10.17 (s, 1H), 8.49 (d, J=1.6 Hz, 1H), 8.28 (dd, J=
8.4, 1.6 Hz, 1H), 8.07 (d, J=8.6 Hz, 1H), 7.68 (t, J=1.7 Hz, 1H), 7.52
(d, J=7.8 Hz, 1H), 7.5–7.4 (m, 3H), 7.39 (d, J=16.3 Hz, 1H), 7.30 (t,
J=7.9 Hz, 1H), 7.25 (d, J=16.3 Hz, 1H), 7.06 (dd, J=6.7, 2.4 Hz,
1H), 4.12 (q, J=7.0 Hz, 2H), 1.31 ppm (t, J=7.0 Hz, 3H); 13C NMR
(100 MHz, (CD3)2CO): d=168.2, 158.0, 145.7, 141.5, 138.3, 138.0,
134.6 (2JCÿF=31.2 Hz), 132.7, 132.6, 132.5, 131.9, 131.4, 128.6, 127.8,
127.3, 124.6 (1JCÿF=272.7 Hz), 124.3, 124.0, 119.6, 118.7 (
3JCÿF=
4.9 Hz), 117.4, 113.6, 105.0, 66.1, 16.0 ppm; IR (NaCl): n˜=3500–3200
(br, NÿH), 2980 (w, CÿH), 2937 (w, CÿH), 2891 (w), 1654 (s, C=O),
1584 (s, C=C), 1510 (s, C=C), 1424 (s), 1271 (s), 1178 (s), 1133 cmÿ1
(s) ; MS (ESI+ ): 539 [M+Na]+ (28), 537 [M+Na]+ (28), 515 [M+H]+
(31), 515 [M+H]+ (31), 38 (100); HRMS (ESI+ ): m/z [M+H]+ calcd
for C25H19BrF3N2O2 : 515.0577, found: 515.0585; Anal. calcd for
C25H18BrF3N2O2 : C, 58.27; H, 3.52; found: C, 58.03; H, 3.62.
(E)-N-(4-Cyano-3-trifluoromethylphenyl)-2-ethoxy-6-(6-hydroxy-
hex-1-enyl)benzamide (7k): Following the general procedure de-
scribed for the Suzuki cross coupling (Method B), the reaction of
22 (27.2 mg, 0.19 mmol), 18 (50 mg, 0.11 mmol), Pd(PPh3)4 (6 mg,
5.19 mmol) and K3PO4 (40.1 mg, 0.19 mmol) in dioxane (0.55 mL) af-
forded, after purification by column chromatography (-NH2 silica
gel; 90:10!55:45, hexane/EtOAc), 7k as a colourless oil (43.5 mg,
92%); 1H NMR (400 MHz, (CD3)2CO): d=10.09 (s, 1H), 8.50 (s, 1H),
8.25 (d, J=8.5 Hz, 1H), 8.05 (d, J=8.5 Hz, 1H), 7.34 (t, J=8.1 Hz,
1H), 7.22 (d, J=7.9 Hz, 1H), 6.94 (d, J=8.2 Hz, 1H), 6.53 (d, J=
15.7 Hz, 1H), 6.32 (td, J=15.6, 7.0 Hz, 1H), 4.08 (q, J=6.9 Hz, 2H),
3.49 (q, J=5.7 Hz, 2H), 3.4–3.3 (m, 1H), 2.18 (q, J=6.6 Hz, 2H), 1.6–
1.5 (m, 4H), 1.28 ppm (t, J=6.9 Hz, 3H); 13C NMR (100 MHz,
(CD3)2CO): d=168.6, 157.8, 145.8, 138.7, 138.2, 136.1, 134.6 (
2JCÿF=
32.5 Hz), 132.3, 128.2, 127.1, 125.0 (1JCÿF=272.7 Hz), 123.8, 119.4,
118.6 (3JCÿF=4.9 Hz), 117.4, 112.4, 104.8, 66.0, 63.1, 34.6, 34.1, 27.3,
16.0 ppm; IR (NaCl): n˜=3500–3200 (br, NÿH and OÿH), 2935 (m,
CÿH), 1675 (m, C=O), 1591 (s, C=C), 1532 (s, C=C), 1329 (s), 1266
(s), 1177 cmÿ1 (s) ; MS (ESI+ ): 455 [M+Na]+ (61), 433 [M+H]+ (100);
HRMS (ESI+ ): m/z [M]+ calcd for C23H24F3N2O3 : 433.1734, found:
433.1731.
Biology
Ligands and materials : SAHA (Merck; Rome, Italy), MS-275 (Bayer
Schering AG; Berlin, Germany), and anacardic acid and CTPB
(Alexis–Enzo Life Sciences; New York, USA) were dissolved in
DMSO and used at 510ÿ6 m. All other compounds described
were dissolved in DMSO (Sigma–Aldrich; Milan, Italy) and used at
5 mm and 50 mm.
Cell Culture : Human U937 and HL60 leukaemia cell lines were
propagated in RPMI medium supplemented with 10% fetal bovine
serum (FBS; Hyclone, Milan, Italy) and antibiotics (100 UmLÿ1 peni-
cillin, 100 mgmLÿ1 streptomycin and 250 ngmLÿ1 amphotericin-B).
Cells were kept at the constant concentration of 200000 cells per
mL of culture medium.
Cell Cycle Analysis : 2.5105 U937 cells were collected and resus-
pended in 500 mL of hypotonic buffer (0.1% Triton X-100, 0.1%
sodium citrate, 50 mgmLÿ1 propidium iodide, RNAse A). Cells were
incubated in the dark for 30 min. Data were acquired on a FACS-
Calibur flow cytometer using the CellQuest software (Becton, Dick-
inson & Co.) and analysed with standard procedures also using
CellQuest and the ModFit LT v3 software (Verity) as previously re-
ported.[27] Nuclear fragmentation (the so-called “sub-G1 DNA
peak”), monitored by FACS and analysed by CellQuest technology,
was used as an indicator of apoptosis.
Histone Extraction Protocol : Cells were harvested and washed twice
with ice-cold phosphate-buffered saline (PBS) and lysed in Triton
extraction buffer (TEB; PBS containing 0.5% Triton X-100 (v/v),
2 mm phenylmethylsulfonyl fluoride (PMSF), 0.02% (w/v) NaN3) at a
cellular density of 107 cells per mL for 10 min on ice, with gentle
stirring. After brief centrifugation at 2000 rpm at 4 8C, the superna-
tant was removed and the pellet was washed in half the volume of
TEB and centrifuged as before. The pellet was resuspended in
0.2m HCl at a cell density of 4107 cells per mL, and acid extrac-
tion was left to proceed overnight at 4 8C on a rolling table. Next,
the samples were centrifuged at 2000 rpm for 10 min at 4 8C, the
supernatant was removed and the protein content was determined
using the Bradford assay.
Western Blot analyses : Western Blot analyses were performed ac-
cording to standard procedures following the suggestions of the
antibody suppliers.
Determination of Histone H3 Specific Acetylation : For histone H3
acetylation in U937 cells, 5 mg of histone extract were separated on
15% polyacrylamide gels and blotted. Western blots were shown
for pan-acetylated histone H3 (Upstate Biotechnology; Milan, Italy).
Human recombinant CBP assay : The recombinant cyclic adenosine
monophosphate response element-binding protein (CREB) binding
protein (CBP) was prepared in E. coli BL21 and purified by affinity
chromatography. The recombinant CBP fraction corresponded to
amino acids 1098–1877. CBP was incubated in KAT buffer x 5
(250 mm TRIS base pH 8.0, 50% glycerol, 0.5 mm EDTA, 5 mm DTT)
with 10 mg of histone H4 peptide (corresponding to amino acids
2–24) and 20 mm acetyl-CoA containing 0.5 mCimLÿ1 [3H]acetyl-CoA
in the presence of inhibitors and putative KAT activators. After 2 h
a 37 8C, 5 mL of samples were spotted onto Whatman P81 paper (in
triplicate). The paper squares were washed in 5% TCA (3) and
100% acetone (1) and then placed into scintillation vials contain-
ing scintillation fluid to allow the disintegrations per minute (dpm)
reading. The dpm value of enzyme samples was compared with
the dpm value of negative and positive controls. Data have been
expressed as the percentage of activity considering the control
without treatment as 100%.
PCAF radioactive assay : 200 ng of human PCAF were incubated in
KAT buffer (Upstate Biotechnology) with 10 mg of histone H4 pep-
tide substrate (corresponding to amino acids 2–24) and 20 mm
acetyl-CoA containing 0.5 mCimLÿ1 [3H]acetyl-CoA. The acetylation
reaction was performed in a volume of 25 mL in the presence of
test compounds at the desired final concentration. After 2 h a
37 8C, 5 mL of samples were spotted onto chromatographic What-
man P81 paper (in triplicate). After a washing session (35% TCA;
1100% acetone), the paper squares were placed into scintillation
vials containing scintillation fluid to allow the dpm reading. The
dpm value of enzyme samples was compared to the dpm value of
the negative and positive controls and reported as the percentage
of activity considering the untreated control as 100%.
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Abstract
Background: BPA (bisphenol A or 2,2-bis(4-hydroxy-phenol)propane) is present in the
manufacture of polycarbonate plastic and epoxy resins, which can be used in impact-resistant safety
equipment and baby bottles, as protective coatings inside metal food containers, and as composites
and sealants in dentistry. Recently, attention has focused on the estrogen-like and carcinogenic
adverse effects of BPA. Thus, it is necessary to investigate the cytotoxicity and apoptosis-inducing
activity of this compound.
Methods: Cell cycle, apoptosis and differentiation analyses; western blots.
Results: BPA is able to induce cell cycle arrest and apoptosis in three different acute myeloid
leukemias. Although some granulocytic differentiation concomitantly occurred in NB4 cells upon
BPA treatment, the major action was the induction of apoptosis. BPA mediated apoptosis was
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caspase dependent and occurred by activation of extrinsic and intrinsic cell death pathways
modulating both FAS and TRAIL and by inducing BAD phosphorylation in NB4 cells. Finally, also
non genomic actions such as the early decrease of both ERK and AKT phosphorylation were
induced by BPA thus indicating that a complex intersection of regulations occur for the apoptotic
action of BPA.
Conclusion: BPA is able to induce apoptosis in leukemia cells via caspase activation and
involvement of both intrinsic and extrinsic pathways of apoptosis.
Background
The Endocrine Disrupting Compounds are defined as
"exogenous substances that cause adverse health effects in an
intact organism, or its progeny, secondary to changes in endo-
crine function" (EEC, 1996). Their effects on humans, wild-
life and the environment have been subject of high
attention by the scientific community, since concerns
were first raised about them by Colborn [1]. Recently, the
potential of certain pesticides to act as EDCs has been con-
firmed. These include organometallic compounds, and
many other organochlorine compounds that are also toxic
and persistent [2,3], and many have been banned as a
result [2]. Other pesticides such as organophosphates, car-
bamates, triazines and pyrethroids that are less persistent
and less toxic than the organochlorines, were used to
replace them, but many are now confirmed or suspected
EDCs [4]. Conventional toxicological testing of pesticides
can miss the potential of a substance to disrupt the endo-
crine system, especially at the low concentrations likely to
be found in the environment. It is generally assumed that
chemical substances will show a simple monotonic dose-
response curve, but some ED pesticides have j-type dose-
response curves [5], whereby the toxic effects decrease as
the dose decreases, until at very low doses (often as low as
parts per billion or even trillion) their effects increase [5].
Of the more than 2,000 high-production volume chemi-
cals that are manufactured in or imported many are
widely used in consumer products. Among the many
chemicals is bisphenol A [BPA; 2,2-bis(4-hydroxyphe-
nyl)propane]. BPA is used in the manufacture of polycar-
bonate plastic and epoxy resins, which can be used in
impact-resistant safety equipment and baby bottles, as
protective coatings inside metal food containers, and as
composites and sealants in dentistry. Exposure to BPA is
thought to result primarily from ingestion of food con-
taining BPA [6,7]. At high doses, BPA demonstrates estro-
gen-like effects on uterine and prostate organ weights in
experimental animals. At doses below the putative lowest
observed adverse effect level, exposure to BPA has resulted
in decreased sperm production, increased prostate gland
volume, altered development and tissue organization of
the mammary gland, altered vaginal morphology and
estrous cycles, disruption of sexual differentiation in the
brain, and accelerated growth and puberty [8-16]. BPA is
of concern to environmental public health because of the
high potential for exposure of humans to these phenols
and their demonstrated animal toxicity. Recently, atten-
tion has focused on the carcinogenic adverse effects of
BPA. Thus, it is important to investigate the cytotoxicity
and apoptosis-inducing activity of these compounds
[17,18]. In the present manuscript, we decided to investi-
gate the effects of different doses of BPA on acute myeloid
leukemia models to understand the mechanism(s) of BPA
action in systems not directly related to the endocrine sys-
tem. We show indeed that BPA is able to induce apoptosis
in leukemia cells by activation of the initiator caspases 8,
9 and the effector caspases 37. Moreover we show that
many genomic and non-genomic players are influenced
by the action of BPA and contribute to its adverse effects.
Methods
Cell lines
All cell lines have been obtained from ATCC and routinely
cultured. NB4, U937, k562, and cells HL60, were grown at
37°C in air and 5% CO2 in RPMI 1640 medium
(GIBCO), supplemented with 10% heat-inactivated foetal
bovine serum (FBS), 1% l-glutamine, 1% ampicillin/
streptomycin and 0, 1% gentamicin. BPA (SIGMA) was
resuspended in ethanol and at the final concentration of
1  M. All trans retinoic acid (SIGMA) (RA) was resus-
pended in ethanol and at the final concentration of 1  M.
To understand the potential role of BPA leukemia cell
lines were treated with different concentrations of BPA
(10, 30, 60, 100  M) for different times.
Cell cycle analysis
2.5 × 105 cells were collected and resuspended in 500  l of
a hypotonic buffer (0.1% Triton X-100, 0.1% sodium cit-
rate, 50  g/ml propidium iodide (PI), RNAse A). Cells
were incubated in the dark for 30 min. Samples were
acquired on a FACS Calibur flow cytometer using the Cell
Quest software (Becton Dickinson) and analysed with
standard procedures using the Cell Quest software (Bec-
ton Dickinson) and the ModFit LT version 3 Software
(Verity) as previously reported [19]. All the experiments
were performed in triplicate.
FACS analysis of apoptosis
Apoptosis was measured with Annexin V/PI double stain-
ing detection (Roche and Sigma-Aldrich, respectively) as
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BPA induces dose dependent apoptosis and cell cycle block in acute myeloid leukemia cellsFigure 1
BPA induces dose dependent apoptosis and cell cycle block in acute myeloid leukemia cells. (A) Cell cycle and 
apoptosis in NB4 cells after treatment with 10,30,60 and 100  M BPA, ATRA (all-trans-retinoic acid) 1  M and the combination 
of ATRA 1  M and BPA, at the indicated concentrations for 48 hrs. (B) Cell cycle analysis and apoptosis in K562 cells after 48 
hrs of treatment with 60 and 100  M BPA. (C) Cell cycle analysis and apoptosis in HL60 cells after treatment with 10, 30, 60 
and 100  M BPA for 48 hrs.
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recommended by the suppliers; samples were analysed by
FACS with Cell Quest technology (Becton Dickinson) as
previously reported [20,21]. We measured as apoptotic
fraction the Annexin V positive, PI negative cells. As sec-
ond assays the caspase 8, 9 and 7, 3 detection (B-Bridge)
was performed as recommended by suppliers and quanti-
fied by FACS (Becton Dickinson). NB4 cells were treated
for 48 h with 10-60-100  M BPA.
Granulocytic differentiation assay
Granulocytic differentiation was carried out as previously
described [22]. Briefly, NB4 cells, treated for 48 h with 10-
30-60-100  M BPA, ATRA 1  M or with ATRA 1  M and
BPA at the indicate prima concentrations, were harvested
and resuspended in 10  l phycoerythrine-conjugated
CD11c (CD11c-PE) (Pharmingen). Control samples were
incubated with 10  l PE or FITC conjugated mouse IgG1,
incubated for 30 min at 4°C in the dark, washed in PBS
and resuspended in 500  l PBS containing PI (0.25  g/
ml). Samples were analysed by FACS with Cell Quest tech-
nology (Becton Dickinson). PI positive cells have been
excluded from the analysis.
Western blot analyses
40 micrograms of total protein extracts were separated on a
15% polyacrylamide gel and blotted as previously
described [23]. Western blots were shown for p21 (Trans-
duction Laboratories, dilution 1:500), p27 c-19 (Santa
Cruz sc-528 rabbit, dilution 1:500), p16 (Santa Cruz sc-468
rabbit, dilution 1:500). For determination of Rb, pRb, p53,
ERalpha and cyclin D 35  g of total protein extracts were
separated on a polyacrylamide gel and blotted. Antibodies
were: cyclin D (Zymed), pRb, p53, RB and ERalpha (Santa
Cruz). Total ERKs (Santa Cruz) were used to normalise for
equal loading. For quantification of TRAIL protein, 100  g
of total protein extracts were separated on a 10% polyacry-
lamide gel and blotted. Western blots were shown for
TRAIL (Abcam Ab 16963-1). For determination of FAS,
FLIP-L and FLIP-S, BAD, pBAD and BCL2, 35  g of total
protein extracts were separated on a 12% polyacrylamide
gel and blotted. Antibodies used were: FAS (ProSci xw-
7192, dilution 1:500), Flip (Alexis 804-429-C100, dilution
1:500), BAD (Cell signalling #9292, dilution 1:500), pBAD
(p-Bad ser 136, #9295 cell signalling, dilution 1:500), Bcl2
(Bcl2 (Ab-1) Oncogene Science, dilution 1:500). Total
ERKs were used to normalise for equal loading.
For determination of ERK2, pERK, Akt and pAkt, 35  g of
total protein extracts were separated on a 12% polyacryla-
mide gel and blotted. Antibodies used were: ERK2 (Santa
Cruz sc-154, dilution 1:500), pERK (Santa Cruz sc-7383,
dilution 1:200), pAkt (Cell signalling cod 9271, dilution
1:1000) and Akt (Cell signalling Akt cod 9272, dilution
1:1000). For quantification of histone H3 acetylation, 40  g
of total protein extracts were separated on a 15% polyacryla-
mide gel and blotted. Antibodies used were: acetylated his-
tone H3 (Upstate cat. 06-599, dilution 1:500). Total ERKs
were used to normalise for equal loading.
Results
BPA induces dose dependent apoptosis in acute myeloid 
leukemia cells
To understand the potential role of BPA in biological sys-
tems of leukemias we tested the action of BPA in three
different acute myeloid leukemia models such as NB4,
BPA induces dose dependent differentiation in NB4 cellsFigure 2
BPA induces dose dependent differentiation in NB4 
cells. (A) CD11c expression levels measured by FACS after 
48 h of treatment with 10,30,60 and 100  M BPA. (B) CD11c 
expression levels after treatment with ATRA 1  M or with 
the combination of ATRA 1  M and BPA at the indicated 
concentrations for 48 hrs. Note that PI positive cells have 
been excluded from the analysis.
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HL60 and K562 cells. As it is shown in Fig. 1, different
concentrations of BPA are able to induce an increase of
the sub-G1 peack in all the cell lines tested, HL60 being
the most resistant one. In NB4 cells, a model from pro-
myelocytic leukemia containing the fusion protein PML-
RAR! and sensitive to retinoids, the highest concentra-
tion of BPA used induces around 38% of apoptosis after
48 hrs. This apoptosis is not synergistically modulated
by the double treatment with 1  M Retinoic Acid (RA) as
shown in Fig. 1A. Differently, cell cycle arrest seems to be
affected by the double treatment, showing an increase of
the G1 peack at low dose BPA (30  M) and an increase
of the G2-M fraction of cells at the highest concentration
of BPA (100  M). Differently, in the K562 cells, a model
of AML derived from a CML containing the Philadelphia
chromosome, the treatment with BPA showed an
increase of cell death proportional to the dose increase of
BPA, together with a G1 peack at the lower dose and a
G2-M increase at the higher dose (Fig. 1B). Finally, HL60
cells showed an increase of apoptosis at the higher dose
of BPA (100  M) in agreement with what reported previ-
ously [17]. This increase is directly proportional with the
enrichment in G1 phase of HL60 cells upon treatment
with increasing doses of BPA (Fig. 1C).
BPA induces dose dependent differentiation in NB4 cells
That BPA was able to induce apoptosis and to influence
the cell cycle of NB4 cells, prompted us to check its effects
on granulocytic differentiation of these cells. As shown in
Fig. 2A by FACS analyses, BPA is able to differentiate NB4
cells versus granulocytes in a dose dependent manner.
However, the effect was weak if compared with the one of
RA at the same time in the NB4 cells (Fig. 2B), thus show-
ing that BPA preferentially activates apoptotic actions in
respect to differentiative effects in these cells.
BPA induces apoptosis via caspase activation in NB4 cells
To better identify which apoptotic pathway is activated by
BPA, we tested by FACS analyses the initiator and effector
caspases activation in NB4 cells after 48 h treatment with
BPA. As it is shown in Fig. 3, both caspase 8 (Fig. 3A) and
9 (Fig. 3B) are cleaved and active upon BPA treatment.
Note that caspase 8 resulted more active, suggesting a
prior activity of BPA on the extrinsic pathway of apoptosis
BPA induces apoptosis via caspase activation in NB4 cellsFigure 3
BPA induces apoptosis via caspase activation in NB4 cells. Caspase 8, 9 and 37 assays have been carried out by FACS 
analysis in NB4 cells after 48 h of incubation with the indicated concentrations of BPA.
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BPA induces modulation of cell cycle regulators and apop-totic player in NB4 cellsFigure 4
BPA induces modulation of cell cycle regulators and 
apoptotic players in NB4 cells. (A) Western blot analysis 
showing p21, p27, p16, cyclin D1 and RB expression levels in 
NB4 cells treated with 60  M BPA for 2, 4 and 6 days. (B) 
Western blot analysis showing TRAIL, FAS, Flip-L and Flip-S 
expression levels in NB4 cells treated with 60  M BPA for 
the indicated days. (C) Western blot analysis showing BCL2 
and pBAD expression levels after treated with 60  M BPA 
for the indicated days. Total ERKs expression levels account 
for equal loading.
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BPA induces modulation of ERK and AKT phosphorylation and increase of histone acetylation in NB4 cellFigure 5
BPA induces modulation of ERK and AKT phosphor-
ylation and increase of histone acetylation in NB4 
cells. (A) Western blot analysis showing ERK and AKT phos-
phorylation in NB4 cells treated with 60  M BPA at the 
times indicated times; (B) Western blot analysis of the 
acetylation levels of Histone H3 in NB4 cells treated for 2, 4 
and 6 days with 60  M BPA. ERKs expression levels account 
for equal loading); (C) Western blot analysis of the phospho-
rylation levels of Rb and p53 expression in NB4 cells treated 
for 2, 4 and 6 days with 60  M BPA. ERKs expression levels 
account for equal loading); (D) Western blot analysis of the 
expression levels of ER alpha in NB4 cells treated for 2, 4 and 
6 days with 60  M BPA. As positive control for the ER alpha 
detection (indicated as +) 25  g of MCF7 protein extracts 
have been used. ERKs expression levels account for equal 
loading.
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at least as time scale. As expected, caspase 37, which are
downstream of caspase 8 and 9, resulted activated by
medium (60) and high doses (100) of BPA.
BPA induces modulation of cell cycle regulators and 
apoptotic players in NB4 cells
That BPA influenced both cell cycle progression and apop-
tosis of acute myeloid leukemias has been clarified by
these results. To understand which molecular events
underlie to these effects, we have tested its action on
known cell cycle regulators in NB4 cells in a time depend-
ent manner. As shown in Fig 4A, p21, p27 and p16
together with RB are up-regulated by BPA at the 60  M
dose, whereas cyclin D1 which is known to modulate pro-
liferation gets decreased. This scenario is reminiscent of a
cell cycle block regulated at the molecular level. At the
same time, checking for apoptotic key players we found
that both FAS and TRAIL are up-regulated already at day 2
of treatment, while Flip-L is transiently up-regulated and
then down-regulated, whereas Flip-S is down regulated
(Fig. 4B). At the mitochondria cell death level, we could
not find modulation of BCL2, but we could see increased
phosphorylation of BAD (Fig. 4C) thus confirming that
both pathways (extrinsic and intrinsic) gets activated by
BPA in NB4 cells.
BPA induces modulation of ERK, AKT and Rb 
phosphorylation and increase of histone acetylation in 
NB4 cells
To better focus the activity of BPA in acute myeloid leuke-
mia models, we decided to check whether BPA can also
modulate non genomic actions. As shown in Fig. 5, BPA
induce a decrease of ERK, Rb and AKT phosphorylation
thus indicating that anti-proliferative actions occur by
induction of non genomic pathways by 60  M of BPA in
NB4 cells. Note that p53 expression levels stayed
unchanged (Fig. 5c). In agreement with these findings,
histone H3 acetylation is increased upon BPA treatment
suggesting an effect (direct or indirect) on chromatin
accessibility of BPA (Fig. 5B).
Discussion
The Endocrine Disrupting Compounds have been subject
of high attention by the scientific community, since con-
cerns have been raised about their actions and potential
toxicities. Among the many chemicals, BPA is used in the
assemble of polycarbonate plastic and epoxy resins, used
in impact-resistant safety equipment and baby bottles, as
protective coatings inside metal food containers, and as
composite and sealant in dentistry. Exposure to BPA is
thought to result primarily from ingestion of food con-
taining BPA [6,7]. BPA is of concern to environmental
public health because of its toxicity. At high doses, BPA
demonstrates estrogen-like effects in experimental ani-
mals, but effects independent from its endocrine modu-
lating function have been poorly investigated. Thus, it is
central to investigate the cyto-toxicity and apoptosis-
inducing activities of BPA at the molecular level. The fact
that BPA is able to induce effects on cell cycle and apopto-
sis in AML models indicates that BPA actions can go
beyond the endocrine interference. This is also demon-
strated by the fact that NB4 cells do not display detectable
levels of ER alpha. Thus suggesting that effects of BPA in
this cells are largely ER independent (Fig. 5d). This notion
is a key point considering that BPA is industrially used and
that its effects can cumulate. Although the properties seen
on granulocytic differentiation are minor when compared
to those of RA, the fact that BPA is used in equipments and
baby bottles makes also these weak effects of significance.
Even more interesting is the induction of cell death which
is clearly specifically regulated at the molecular level.
Indeed, the fact that three different cell lines respond with
apoptosis to BPA treatment and that this effect seems to be
dose dependent indicates that this is a general feature of
BPA treatment and that this might be reproduced in many
other cells. These evidences are exciting from several point
of view: if from one side we might consider the induction
of apoptosis as an interesting anti-cancer action, on the
other side we have to keep in mind that these effects might
also be elicited in normal cells in the different compart-
ments of the human body and thus might contribute to
the toxicity of BPA. The regulation of caspase-dependent
pathways of apoptosis suggests a specific action on the
extrinsic and intrinsic pathways of apoptosis which is con-
firmed by the clear induction of Fas and TRAIL and by Flip
down regulation in NB4 cells. Even if our data would sup-
port a model in which the extrinsic pathway of apoptosis
is more active, we do not exclude the importance of the
mitochondria de-regulation of apoptosis which is indeed
confirmed by caspase 9 activation and BAD phosphoryla-
tion. Considering that many clinical treatments target
apoptosis at the present, our data suggest that the contact
or the assumption of BPA might increase the effects of a
on-going treatment in humans, apart, of course, having
effects on its own. Finally, the fact that BPA decreases the
activity of ERK and AKT well integrates with its anti-prolif-
erative and apoptotic actions suggesting that the cross-talk
of different molecular actions contribute to the cell cycle
arrest and to the apoptosis in human biological systems.
The hyperacetylating effect shown on histone H3 con-
firms the property of BPA to modulate the chromatin in a
more accessible state thus corroborating the hypothesis
that BPA contributes with a plethora of different effects to
the induction of cell cycle arrest, weak differentiation and
apoptosis in a specific and molecularly defined manner. If
the hyperacetylation upon BPA treatment is a direct or
indirect effect on chromatin, remains to be established.
More characterized studies on BPA exposed population in
healthy or unhealthy status will decipher in the future the
real impact of these molecular actions.
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Conclusion
Our data strongly indicate that BPA has molecular activi-
ties that go much beyond its ED function. These actions
have been well focused as cell cycle arrest and apoptosis
and the molecular pathways involved have been identi-
fied. This knowledge clearly shows that BPA effects have to
be considered independently of its ED action and might
help in the understanding of the adverse effects caused in
humans.
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A collection of analogues of the dimeric natural product psammaplin A that differ in the substitution on
the (halo)tyrosine aryl ring, the oxime and the diamine connection has been synthesized. The effects on
cell cycle, induction of differentiation and apoptosis of the natural-product inspired series were measured
on the human leukaemia U937 cell line. Epigenetic profiling included induction of p21WAF1, effects on glo-
bal H3 histone and tubulin acetylation levels as well as in vitro enzymatic assays using HDAC1, DNMT1,
DNMT3A, SIRT1 and a peptide domain with p300/CBP HAT activity. Whereas the derivatives of psamma-
plin A with modifications in the length of the connecting chain, the oxime bond and the disulfide unit
showed lower potency, the analogues with changes on the bromotyrosine ring exhibited activities com-
parable to those of the parent compound in the inhibition of HDAC1 and in the induction of apoptosis.
The lack of HDAC1 activity of analogues modified on the disulfide bond suggests that its cleavage must
occur in cells to produce the monomeric Zn2+-chelating thiol. This assumption is consistent with the
molecular modelling of the complex of psammaplin A thiol with h-HDAC8. Only a weak inhibition of
DNMT1, DNMT3A and residual activities with SIRT1 and a p300/CBP HAT peptide were measured for
these compounds.
Ó 2010 Elsevier Ltd. All rights reserved.
1. Introduction
Psammaplin A (1, PsA, Scheme 1) is a symmetrical disulfide di-
mer derived from the condensation of modified tyrosine and cys-
teine units1 (for a proposal of its biogenesis, see 2,3). Although it
was first isolated in 1987 from an unidentified sponge4 and from
Psammaplysilla sp.,5,6 PsA is found, together with biogenetically-re-
lated congeners, in several Verongidas2,3,6–10 and in some associa-
tions of these species.11,12
Antibacterial and antitumor activities have been reported for
PsA. The in vitro antibacterial activity of PsA against both Staphylo-
coccus aureus (SA) and methicillin-resistant Staphylococcus aureus
(MRSA) was considered the result of the inhibition of DNA gyrase13
and induced arrest of bacterial DNA synthesis. PsA also inhibits
topoisomerase II (topo II),14 farnesyl protein transferase,8 leucine
aminopeptidase,8 mycothiol-S-conjugate amidase,15 chitinase,10
Pol a-primase,16 PPARc17–20 and mammalian aminopeptidase N
(APN).21 Targeting multiple proteins that impact on DNA topology,
DNA replication, transcription, apoptosis, tumor invasion, and
angiogenesis likely contributes to the significant cytotoxicity dis-
played by PsA in human lung (A549), ovarian (SKOV- 3), skin
(SK-MEL-2), CNS (XF498), and colon (HCT15) cancer cell lines.12
PsA was also reported to inhibit in vitro the chromatin-modify-
ing enzymes histone deacetylase (HDAC) and DNAmethyl transfer-
ase (DNMT).3 HDAC and DNMT are epigenetic enzymes that
catalyze the covalent modifications of histone proteins and DNA
in chromatin,22 and therefore they are considered prime new tar-
gets23 for the treatment and prevention of cancer24–34 and other
diseases.35 The modification of chromatin is thus an addition to
the list of potential mechanisms involved in the anticancer actions
of the natural product PsA.
Histone acetylation is a dynamic process in which a cellular
steady state is maintained by the opposing activities of histone
acetyltransferases (HATs) and deacetylase enzymes (HDAC) acting
at the e-amino groups of evolutionally conserved lysine residues lo-
cated at the histone N-termini. HATs transfer the acetyl moiety
from acetyl CoA to the histone lysine residues whereas HDACs cat-
alyze their removal. Individual HATs and HDACs display distinct
0968-0896/$ - see front matter Ó 2010 Elsevier Ltd. All rights reserved.
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specificities for certain individual lysine residues and particular
histones. Although the factors responsible for the specificity are
poorly understood they might reflect different biological functions
of the various enzymes. Regardless of the details, it is widely
accepted that histone acetylation is essential to establish a trans-
criptionally competent state of chromatin22 and consequently
contributes to the gene activation/gene repression transcriptional
status of cells. Two histone deacetylase inhibitors (HDACis), sube-
roylanilide hydroxamic acid (SAHA, vorinostat, ZolinzaÒ), and
FK228 (romidepsin, IstodaxÒ) are used as therapy for cutaneous
T-cell lymphoma,36 and several others are currently undergoing
clinical trials as potential targeted cancer chemotherapeutic
agents.37–41
In eukaryotes DNMTs catalyze the addition of methyl groups
from S-adenosyl-L-methionine (SAM) to the C5 position of cytosine
bases within the CpG-rich islands in DNA. Methylation of DNA is an
epigenetic mark associated to a repressed chromatin state which
inhibits gene transcription.42,43 Several tumour supressor genes
are hypermethylated in tumours, which suggest a link between
aberrant DNA methylation and cancer.44–47 DNA methyl transfer-
ase inhibitors (DNMTis)48 structurally related to cytidine (5-aza-
cytidine, VidazaÒ and 5-aza-deoxycytidine, DacogenÒ) are already
in the clinic for the treatment of myelodysplastic syndrome.49
Since histone acetylation and DNA methylation play a key role
in the pathophysiology of cells, dual inhibitors of HDAC or DNMT
are therapeutically more appealing than combination of these
drugs.50,51 We thus became intrigued by the reports on the potent
activity of psammaplin A (1) in the inhibition of these two epige-
netic enzymes (HDAC: IC50 = 4.2 nM; DNMT: IC50 = 18.6 nM using
in vitro cell-free enzyme assays)3 as well as by the in vitro and
in vivo inhibition of tumour growth induced by this natural prod-
uct.20 Despite the reports indicating some drawbacks for the devel-
opment of 1 as a drug due to its poor physiological stability,15,21,52
we undertook the synthesis of a family of analogues with the aim
to discover more potent and selective derivatives of 1 as well as to
shed light into the mechanism of epigenetic inhibition by 1. Apart
from the work of Nicolaou focused on antibacterial activities, no
structure–activity relationship studies of the anticancer activities
of PsA analogues have been reported, which are necessary for an
eventual lead optimization project within this class of modified
tetrapeptides.
2. Chemistry. Synthesis of psammaplin A and derivatives
All previous synthetic approaches to 1 have focused on the final
construction of the dimeric disulfide structure by condensation of
the corresponding carboxylic acid with the symmetrical diamine
cystamine. Both Hoshino et al.53 and Nicolaou et al.54,55 installed
the oxime function after the synthesis of the corresponding pyruvic
acid derived from L-tyrosine, in a sequence that afforded 1 in mod-
erate overall yields. Nicolaou then screened in antibacterial assays
a 3828-membered library of heterodimeric psammaplin A ana-
logues15 obtained from symmetrical precursors by combinatorial
scrambling via catalytically-induced disulfide exchange reactions.
A recently described three-step (43% overall yield) synthesis of
PsA 1 starts from the considerably more expensive and less versa-
tile 4-hydroxyphenylpyruvic acid.56
We modified the above synthesis of 1 by performing the bro-
mination of the phenol ring on the corresponding oxime 3 (Scheme
1).57 As shown on Scheme 1, the amino group of L-tyrosine 2 was
oxidized to the hydroxyimino ester 3 in 60% yield using Na2WO4
and H2O2 in ethanol.
58 A monobrominated product 4 was obtained
by treatment of 3 with one equivalent of NBS in CH3CN at
25 °C,58,59 with no evidence of formation of the dibromo derivative
or the dibrominated spirocyclic isoxazoline.57 After saponification
of 4 the carboxylic acid 5 was coupled with cystamine using Hosh-
ino’s conditions.53 The overall yield for the synthetic sequence is
29%, with a slight improvement over the two routes previously de-
scribed from L-tyrosine 2. The synthetic scheme is advantageous
for the preparation of diverse PsA analogues starting from com-
mercial tyrosine derivatives.
Using the methodology depicted on Scheme 1, the synthesis of
PsA homologues containing from three to six methylene units was
completed, albeit in low yields (Scheme 2), using the non-commer-
cial diamines 6a–d, which were synthesized following a general
methodology.60
Similarly, PsA analogues that preserve the native connecting
cystamine unit but differ in the substituents at the aryl ring
(Scheme 3) were synthesized using either commercially available
tyrosine derivatives or the synthetic halogenated analogues (with
bromine or iodine at C3) after oxidation of the amine to the oxime
(Scheme 3). Some compounds of the series (11a, 11c, 11d and 11e)
have previously been described by Nicolaou on his search for new
antibacterial agents.55 Bromopsammaplin A 11f is also a natural
product isolated from an association of the sponges Jaspis wondo-
ensis and Poecillastra wondoensis.12
Condensation of acid 5 with amines 12 and 14a–c (Scheme 4)
provided analogues 13 and 15a–c which were designed to further
our understanding of the mechanism underlying the biological
activity of the parent PsA as HDAC inhibitor. The dimer 13 contains
an ethylene group replacing the disulfide bond functionality. Prod-
ucts 15b,c are monomers that have, respectively, methyl ether and
methyl sulfide as end groups. The primary alcohol 16was obtained
by acidic (7:2:1 THF/HCO2H/H2O) deprotection of silyl ether 15a.
The derivative lacking the oxime was also of interest to reveal
whether this functional group is critical for the epigenetic activity
of 1. Compound 20 was prepared as described on Scheme 5. The
bromination of methyl 3-(4-hydroxyphenyl)propanoate using the
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conditions described for oxime 4 (NBS in CH3CN) yielded a mixture
of mono- and dibromo derivatives, 18a and 18b, respectively, in a
3:1 ratio. Hydrolysis of the former followed by the coupling of 19
with cystamine led to the desired disulfide 20 in moderate yield
(Scheme 5).
Lastly the spirocyclic hexadienyl-isoxazoline 21, a potential
metabolite of PsA1 could only be obtained, albeit in very low yield
(5%), by the oxidative-induced cyclization61 of PsA 1 with manga-
nese(III) tris(acetylacetonate) (MTA)62 (Scheme 6) after many other
methods failed.
3. Biological characterization
Firstly, we focused on the reported inhibition of HDAC by PsA
and the synthetic analogues, as well as on their effects on cell cycle,
induction of differentiation and apoptosis on the U937 human
acute myeloid leukemia cell line. In vitro tests of the compounds
at 5 lM on human recombinant HDAC1, using SAHA as a positive
control, confirmed the enzymatic inhibition of PsA 1 (Fig. 1A). In
addition, some analogues (11a–e, 11g) reduced the activity of
HDAC1 more efficiently than 1. The other compounds of the series
(7a–d, 11f, 13, 15b–c, 16, 20 and 21) did not noticeably affect
HDAC1 activity. Compounds with longer chain connecting the
disulfide to the hydroxyimino amide (7a–d) lack significant
inhibitory activity. A similar result was observed for compounds
having the disulfide replaced by methylene units (13) and for the
monomers with either methyl ether –OMe, methyl thioether
(–SMe) or alcohol (–OH) functionalities (15b, 15c and 16, respec-
tively). In contrast, the inhibitory activity is maintained and even
increased with compounds that preserve the general modified tet-
rapeptide scaffold of PsA regardless of the nature and pattern of the
substituents at the aryl ring (11a–f). The more drastic change of
the overall aryl ring structure imparted by the spirocycle together
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with the reduction of flexibility and the lack of free oxime in deriv-
ative 21 led to substantial loss of HDAC inhibitory activity.
Cell-based assays were performed on the U937 myeloid leuke-
mia cells to determine the anti-proliferative potential and the abil-
ity of the compounds to revert myeloid tumor cells to
differentiated granulocytes. Cell cycle progression, differentiation
and amount of cells that undergo apoptosis following treatment
with PsA 1 and analogues (5 lM) for 30, 40, and 48 h were deter-
mined (Figs. 1B and 2). Compared to the vehicle-treated cells and
relative to the positive control represented by the known HDACis
MS275 (HDAC1,2,3-selective) and SAHA (also HDAC6 inhibi-
tor),63,64 only PsA 1 and some analogues induced cell cycle arrest
in G1 (Fig. 1, panels B–D). In particular after 30 h PsA induced a
time-dependent accumulation of U937 cells in the G1 phase
(60%), and analogues 11a–g and 20 showed even greater arrest
(80%), with values comparable to MS-275 (Fig. 1C). A clear correla-
tion between the in vitro HDAC1 inhibition and the in vivo efficacy
to induce cell cycle arrest was noticed for the most active com-
pounds. Compound 21, on the other hand, appears to block cell cy-
cle at G2/M. The remaining analogues gave no detectable activities
on cell cycle progression even after longer (48 h) treatment re-
gimes (Fig. 1B and D).
The percentage of apoptotic cells (measured as caspase 3 acti-
vation by FACS analysis) increased when U937 cells were treated
with 1 and series 11a–g for 30 h (Fig. 2A). After 30 h induction
with compounds 11a–e and 11g the percentage of apoptotic cells
varied between 30% and 40%. Other compounds, including bro-
mopsammaplin A (11f), and the derivative lacking the oxime
function 20, exhibited only minor effects even at longer incuba-
tion times (40 h). The results confirmed the in vitro findings since
the most potent inducers of differentiation and apoptosis in
U937 cells are the 11a–g series of ring-modified PsA analogues
(with the exception of bromopsammaplin A 11f). Modifications
in the chain length and the disulfide led to lower values of apop-
tosis, in agreement with the enzymatic assays. Interestingly,
spiro derivative 21 showed comparable induction of apoptosis to
parent 1.
The differentiation of myeloid precursors to granulocytes was
determined by measuring the presence on the cell membrane of
the granulocytic differentiation marker CD11c antigen, which is
highly expressed only on mature granulocytes, monocytes and
certain lymphocytes, but not significantly on myeloid committed
precursor cells. After treating the U937 cells with the PsA
analogues at 5 lM for 30 and 40 h, low differentiation levels
Figure 1. (A) HDAC1 fluorescent assay with the indicated compounds at 5 lM. The inhibition is reported as percentage of activity relative to the control (100%). (B–D) Cell
cycle analysis and apoptosis in U937 cells treated with the indicated compounds at 5 lM for 30 h. The data represent the media of independent duplicates.
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were measured (with the exception of parent 1 and methyl sulfide
15c) relative to control (Fig. 2B) and to the class I-selective HDACi
MS-275.
We next determined the expression levels of p21WAF1, which is
involved in the mechanism of tumor suppression, as well as the
global acetylation status of histone (histone H3) and non-histone
proteins (tubulin), that are substrates of HDACs family members.
The up-regulation of p21WAF1 and the increase of tubulin acetyla-
tion levels were evaluated by Western blot analyses on total
extracts after treating the U937 cells for 24 h with the compounds
at 5 lM (Fig. 3A–C). Compounds 7a–d, 13, 15b, 16 and 21 failed to
increase both p21WAF1 and tubulin acetylation expression levels.
Methyl sulfide 15c increased weakly these levels in line with its
noticeable effect on the induction of differentiation. While the
11a–g series did not show a significant effect on tubulin acetyla-
tion, some members (11b–e) up-regulated p21WAF1 to levels even
higher than those of SAHA. The effect of the analogues on the level
of histone acetylation was also analyzed by Western blot (Fig. 3D).
After treating U937 cells for 24 h all compounds of the series 11a–
g displayed the ability to increase the level of acetylated histone
H3, present in the histonic extract, as shown using the specific
antibody.
In order to determine if the most potent analogues are endowed
with additional epigenetic modulation activities, the series 11a–g
and 20 were also used in in vitro human SIRT1 fluorescent assay
and in a radioactive assay on a peptide fragment having p300/
CBP histone acetyl transferase (HAT) enzyme activity. As shown
in Figure 4B, very weak SIRT1 inhibition was noted (ca. 30% relative
to the control) for the majority of compounds at 50 lM, far lower
than the activity of the SIRT1 inhibitor suramin at the same con-
centration. In addition, none of the analogues displayed modula-
tion of a peptide fragment of CBP containing the enzymatically
active HAT domain (Fig. 4A) relative to the control and to the
effects of the known inhibitor anacardic acid (AA) at the same con-
centration,65,66 thus confirming the specificity of the HDAC among
other epigenetic inhibitory activities.
DNMT inhibition has also been reported for PsA.3 To verify the
effective physical interaction between PsA and its analogues and
DNA methyl transferase enzymes, two in vitro radioactive assays
were performed using DNMT1 and DNMT3A (Fig. 4C and D).
DNMT1 was immunoprecipitated from K562 cells and used in
radioactive assay that employs [3H]-adenosyl-L-methionine as
methyl donor and Poly dI-dC as methyl acceptor. The same condi-
tions have been used for the DNMT3A radioactive assay, but the
Figure 2. (A) Induction of apoptosis after treatment of U937 cells with the indicated compounds at 5 lM, for 30 h (for the series 11a–11g) and 40 h. (B) Differentiation
analysis in U937 cells after 30 h treatment with the indicated compounds at 5 lM. The percent value of CD11c positive/propidium iodide (PI) negative cells is represented.
The data shown is the media of independent quadruplicates.
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recombinant enzyme was produced in Escherichia coli BL21, as GST
fused protein. In neither assay compounds 11a–g and 20 showed
significant inhibition at 50 lM (see Fig. 4C), in contrast to
RG10867 and SGI102768 at the same concentration for the DNMT1
assay.
Taken together, the enzymatic profiling suggests that the
epigenetic activities of PsA are mainly restricted to the inhibition
of the HDAC family in this context. Moreover, the HDAC activity
of the series is likely linked to the formation of the monomeric
thiol that originates from –S  S– bond cleavage (Scheme 7, vide
infra), a known potent metal chelator. The Zn2+-dependent his-
tone deacetylase subfamily is composed of Class I HDACs (HDAC
1–3, 8 and 11) and Class II HDACs (HDAC 4–7, 9 and 10). In con-
trast, Class III (sirtuins), with seven members (SIRT1-7), require
NAD+ as a cofactor and release O-acetyl-ADP ribose and nicotin-
amide as a consequence of acetyl transfer from the acetylated
lysine.69
Metalloproteinase-targeted HDAC inhibitors are typically
substrate mimics of the linear acetyl-lysine side chain with a
Zn2+-chelating ‘warhead’ group that replaces the scissile acet-
amide, a connector chain and a ‘cap’ at the other end that extend
beyond the enzyme substrate-binding channel. These features
are exhibited by the thiol derived from PsA (Scheme 7), in which
the active site binding/inactivating group is connected via a
hydroxyimino amide linker to the HDAC recognition aryl group.
In order to address the nature of the interaction between the
inhibitor and HDAC, the ab initio calculated structure of thiol 22
was docked into the active site of the human HDAC8-trichostatin
A (TSA) crystal structure70 after removal of the TSA ligand. The
catalytic domain of about 390 amino acids responsible for the
deacetylation is highly conserved among the metal-dependent
HDACs, in particular the residues lining the ligand-binding pocket,
but some differences can be exploited for the designed of selective
Class I/Class II HDAC inhibitors.71
The highest scores using automated docking method for the
interaction of the ligand with the Zn2+ ion in the active site, vali-
dated by the GRID maps, agree in having the thiol chelated to
the metal, whereas the linker domain occupies the channel and
the o-bromophenol is stabilized through interaction with Tyr100
and Phe152 at the rim of the active site entrance (Fig. 5 and Figs.
S1–S3). This positioning facilitates the formation of a hydrogen
bond between the oxime group and Asp101, which remains at a
constant distance along the energy minimization and the simula-
tion of the dynamic behaviour using unrestrained MD (Fig. S3).
The Zn2+ ion is kept firmly coordinated to the four ligands
(Asp178, Asp267, His180 and the thiol group of the inhibitor),
Figure 3. (A–C) Western blot analyses of p21WAF1/CIP1 expression and a-tubulin acetylation in U937 cells after treatment with the indicated compounds at 5 lM for 24 h.
ERK1 expression is shown as loading control. (D) Western blot analyses of histone H3 acetylation carried out in U937 cells, after 24 h induction with the compounds at 5 lM.
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and the electrostatic term (ÿ59.2191 ± 1.7841 kcal/mol) makes an
important contribution to the overall energy. Favourable van der
Waals interactions of the ligand with Phe152 and Phe208
residues also account for a fraction of the intermolecular energy
component (Fig. S2).
4. Discussion
Psammaplin A 1 is the prototype of a collection of metabolites
isolated from sponges1 that are biosynthesized by linear connec-
tions of (bromo)tyrosines and modified cysteines.12 Their biologi-
cal activities, common to most of the bromotyrosine/cysteine
constructs, range from antimicrobial54 to anticancer.1,6 The inhibi-
tion of several enzymes that impact different stages on the onset
and progression of cancer such as topoisomerase II (growth),14
the zinc-dependent metalloproteinase aminopeptidase N (APN,
tumor cell invasion or angiogenesis),21 HDAC and DNMT (chroma-
tin remodeling),3 among others, likely conspire to account for the
reported anticancer activities of PsA in several cancer cell lines
and in the A549 lung xenograft mouse model.3,12 PsA was reported
to activate Wnt signalling in a cell-based assay but the effect is
likely due to HDAC inhibition rather than to an specific Wnt signal-
ling pathway.72
More recent molecular and cellular studies73 confirmed the
potent inhibitory activity of PsA in enzymatic (HDAC inhibition)
and in anti-proliferation assays, and also the selective induction
of histone hyperacetylation. The anti-proliferative effects were
linked to the overexpression of genes related to cell cycle arrest
and apoptosis (p53-independent p21WAF1 expression).74
A series of PsA analogues modified at the aryl ring, with varying
lengths of the amino thiol connecting unit, and some exchanges/
deletions of functional groups have been prepared. These ana-
logues have been characterized with regard to their enzymatic
inhibitory potential and for their effects on cell cycle, differentia-
Figure 4. (A) CBP radioactive assay performed with 1 lg of recombinant CBP enzyme peptide fragment and the psammaplin A analogues at 50 lM. (B) SIRT1 fluorescence
assay to measure the lysine deacetylase activity of the compounds at 50 lM on human recombinant SIRT1 enzyme (1 U). (C) DNMT1 radioactive assay with synthetic poly dI-
dC as methyl acceptor (0.1 lg) and [3H]-adenosyl-L-methionine (1 lCi) as methyl donor. DNMT1 was immunoprecipitated from K562 cells and the compounds 11a–g were
used at 50 lM. (D) DNMT1 radioactive assay to measure the inhibition of recombinant DNMT3a (1 lg, produced in E. coli BL21, as GST fused protein) by the compounds at
50 lM. In each panel the inhibition/activation of the enzyme is reported as percentage of activity relative to the control.
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Scheme 7. Bioactivation of PsA 1 to thiol 22 by the reductive environment of the
cells.
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tion and apoptosis on the U937 acute myeloid leukemia cell line.
For 1 and the most potent analogues, functional assays have also
been carried out on the same cell line.
Enzymatic HDAC1 inhibition data for the series of analogues
having chain lengths spanning from two to six methylene units (
7a–d) established that the derivative of natural cystamine (the
decarboxylated cysteine) present in psammaplin A was the most
potent, and also that both the oxime and the disulfide functional-
ities were required for the HDAC inhibition activity, since ana-
logues 13, 15b–c, 16 and 20 proved to be inactive (Fig. 1A). We
then addressed the modifications of the aryl ring with analogues
that preserve the same connecting diamine unit of the parent nat-
ural product. The substitution at the ring is well tolerated, and a
general improvement in potency relative to PsA was noted when
the ring was mono- (11a–b) or disubstituted (11d,e,g). The unsub-
stituted compound (the phenylalanine-derived 11c) and the tri-
substituted bromopsammaplin A 11f were less active than 1.
Conversely the series of halogenated analogues 11d,e,g exhibited
greater potency than PsA and followed the order Br < F < Cl < I.
The activities of the spiro derivative 21 are most intriguing, since
it is the only compound showing a G2/M block (Fig. 1B) and strong
induction of apoptosis (Fig. 2B), which appears not to be correlated
with HDAC inhibition. A promising pro-differentiation profile is
also noted for the methylsulfide 15c (Fig. 2B), which merit further
investigation.
It has previously been reported that human endometrial Ishik-
awa cancer cells treated with PsA showed accumulation of cells
in the G1 phase and a significant decrease in the number of cells
in the S phase,74 a result in keeping with the effect of known HDAC
inhibitors.75 Our data confirm the time-dependent accumulation of
cells in G1 upon treatment of human leukaemia U937 cells with
PsA and analogues. Moreover, 1 and the 11a–g series of related
compounds induced apoptosis of U937 cells (Fig. 2B), an effect
likely associated to their more selective inhibition of class I HDACs.
The majority of these compounds (with the exception of 15c) failed
to induce tubulin acetylation (Fig. 3), which is a target of HDAC6
enzymes, and this finding is in agreement with previous reports
for PsA in HeLa cells.73 Although the result might suggest that
psammaplin A show selectivity for histone proteins in preference
to tubulin, it cannot be considered as a selective class I HDAC
inhibitor, since it also inhibits HDAC4, a class II HDAC, in enzymatic
assays (results not shown). Important differences between class I
and class II metalo-HDACs are noticeable in their size (with class
II being from two to three times larger), their cellular localization,
the conservation of sequence motifs in the catalytic domains, the
identity of the protein–protein interaction complexes and the tis-
sue distribution.76
Western blot analysis of U937-treated cells confirmed the accu-
mulation of acetylated histones using antibodies against acetylated
H3 (Fig. 3D), in agreement with similar findings for PsA in endome-
trial cancer Ishikawa cells.74 PsA and several analogues up-regu-
lated cyclin-dependent kinase inhibitor p21WAF1 (Fig. 3), which is
one of the genes induced by HDAC inhibitors,76 and this effect
might be related to the suppression of cell proliferation and induc-
tion of apoptosis.
PsA and its 5-bromo derivative have been reported to inhibit
the bacterial methyltransferase SssI. However, cultured HCT116
human colon carcinoma cells treated with 1 lM PsA did not reduce
global genomic DNA methylation (the level of which was deter-
mined using a mass spectrometry assay) and failed to induce the
hypomethylation or reactivation of cancer-testis antigen genes,
known as methylation silenced genes.56 Here, two different assays
were performed on DNMT1 and DNMT3A (see Fig. 4C and D) to
evaluate the inhibition of DNMT enzymes by PsA and derivatives
(11a–g). Differently from expected, these compounds at 50 lM
failed to inhibit DNMT1 and DNMT3a, thus indicating their inabil-
ity to alter DNMT in vitro. Therefore, the action of these com-
pounds on cell cycle progression and induction of apoptosis can
be better correlated with the HDAC inhibitory activities. It is likely
that the absence of hypomethylation is not due to the low affinity
of PsA (and its analogues) for DNMT, but instead to the inefficient
transport of these compounds through the nuclear membrane.
Inefficient transportation of the compound into the nucleus or poor
cell membrane penetration might also explain the much greater
concentration of 1 (1800 times) required to obtain similar poten-
cies in cell-based assays relative to the HDAC enzymatic inhibition
assay.52
Lastly, no significant inhibition of SIRT1 and p300/CBP HAT
enzymes was seen for the PsA-related series of analogues (Fig. 4A
and B).
Other natural products of the depsipeptide class that act as
inhibitors of HDAC also contain disulfide bonds, namely FK228
23, spiruchostatins 25 and FR901375 26 (Fig. 6).39,71 FK228 (romi-
Figure 5. Proposed docking pose of biocleaved psammaplin A (thiol 22) with
HDAC8. The Ca trace of the enzyme is displayed as a ribbon, colored in green. The
side chains of His142, His143, Asp178, Asp267, His180, Met274, Tyr306 are shown
as sticks, with carbon atoms colored in green. The Zn2+ ion at the catalytic site is
shown as a magenta sphere. The inhibitor is displayed also as sticks, but with
carbon atoms colored in gray and the bromine atom colored in brown.
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(24, redFK) is shown by analogy with the reduced form of psammaplin A, 22.
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depsin, IstodaxÒ) currently approved for T cell lymphoma is under-
going phase II clinical trials for the treatment of non-Hodgkin’s
lymphoma, acute myelogeneous leukemia, and pancreatic cancer
(www.clinicaltrials.gov). It has been shown that the disulfide bond
of FK228 becomes cleaved in the cells by the reducing activity of
glutathione to afford redFK 24, and the thiol then interacts with
the Zn2+ ion in the active site of HDAC.77Moreover, mass spectrom-
etry analysis of blood samples identified the thiol and glutathione
conjugates of FK228.78 Upon bio-reduction depsipeptides 25 and
26 must also release the Zn2+-binding butenylthiol.79 From an
structural point of view both redFK 25 and PsA thiol 22 have
Zn2+ ion connecting chains that are shorter than those of common
hydroxamic acid-based inhibitors (TSA, SAHA. . .). Thiol chelating
groups connected via a 5 atom saturated chain to cyclic tetrapep-
tides have also shown potent HDAC inhibitory activities.80,81
In agreement with these precedents, the dimer analogue lacking
the disulfide bond (13) was inactive, which substantiates the pro-
posal that PsA and analogues undergo thiolate exchange reaction
with glutathione by –S  S– bond cleavage.82 Interestingly, Wang
et al. have shown that glutathione-depleted cells were not sensi-
tive to PsA, implying that the reducing environment of the cells
triggered the conversion of the disulfide of 1 to the corresponding
thiol,79 which would be the species responsible for the HDAC
inhibitory activity of psammaplin A after uptake into the cells.
Based on the reported crystal structure, the HDAC8Zn2+thiol
22 complex was constructed with the thiol group chelating the
metal ion, and then refined using energy minimization. The dy-
namic behaviour of the complex using unrestrained molecular
dynamics confirmed the feasibility of the proposed binding orien-
tation and the mutual adaptation between HDAC8 and the ligand.
The linker occupies the narrow channel whereas the bromophenol
interacts with Tyr100 and Phe152 at the rim of the active site en-
trance, a pose that facilitates the formation of a robust hydrogen
bond between the oxime group and Asp101 (Fig. 5).
Our results using alcohol 16, ether 15b and most importantly
dimer 13 confirm the earlier findings with FK22878 and suggest
that psammaplin A 1 acts as a stable pro-drug83 that is activated
upon uptake by the reductive environment of the cells to afford
thiol 22, which then chelates the Zn2+ ion in the active site of the
HDAC metalloenzymes.
5. Conclusion
PsA 1, a natural product with a disulfide bond derived from the
condensation of modified cystamine and tyrosine moieties, has
been reported to display dual HDAC and DNMT epigenetic inhibi-
tory activities. The intriguing ability to target simultaneously more
than one member of the epigenetic machinery (epigenetic multiple
ligands),84 prompted us to synthesize a series of PsA analogues in
an effort to determine the structural determinants for their epige-
netic profile. We have analyzed the effects of the natural-product
inspired collection on the human leukaemia U937 cell cycle, mea-
suring induction of apoptosis and differentiation, induction of
p21WAF1 and tubulin acetylation levels and total histone H3, and
also examined their HDAC1 enzyme-based inhibition profile. From
the results it is concluded that Nature has optimized the design of
the PsA scaffold to fulfil this epigenetic role, since only closely re-
lated synthetic derivatives (with modifications at the bromotyro-
sine ring) exhibited comparable or greater potency than the
natural product. Modifications of the connecting chain, oxime bond
and disulfide unit afforded either inactive or considerable less po-
tent analogues. Exploring the possibility that PsA and derivatives
might display additional epigenetic activities we have also tested
them as inhibitors of DNMT1, DNMT3A, SIRT1 and a peptide con-
taining the p300/CBP HAT domain, but the values measured were
very low. Since epigenetic signalling by PsA appears to be re-
stricted to inhibition of metalloproteinase HDACs, a model for
the interaction of HDAC8 with the thiol derived from PsA 1 (by a
presumed in vivo disulfide cleavage) was computed. The thiol
binds the Zn2+ ion in the active site and the complex is additionally
stabilized by a hydrogen bond interaction between the oxime
group and the Asp101 residue located at the active site entrance.
As with FK228, this bioactivation mechanism illustrates the inge-
nious solution adopted by Nature to protect the reactive zinc-bind-
ing thiol as a disulfide pro-drug with higher bioavailability. The
increased levels of disulfide reductants (i.e., glutathione, thiore-
doxin and thioredoxin reductase) found in many cancer cells ren-
der such cells particularly susceptible to the action of PsA 1.
Despite the failure to greatly improve the epigenetic inhibitory
profile of PsA through the modifications reported, more significant
skeletal alterations of the PsA structure might provide more potent
derivatives, thus lending further support to the important role of
natural products as inspiration85 for the development of designed
multiple ligands50,51 as new anticancer drugs.86,87
6. Experimental section
6.1. General
Solvents were dried according to published methods and dis-
tilled before use. HPLC grade solvents were used for the HPLC puri-
fication. All other reagents were commercial compounds of the
highest purity available. All reactions were carried out under argon
atmosphere, and those not involving aqueous reagents were car-
ried out in oven-dried glassware. Analytical thin layer chromatog-
raphy (TLC) was performed on aluminium plates with Merck
Kieselgel 60F254 and visualized by UV irradiation (254 nm) or by
staining with a solution of phosphomolibdic acid. Flash column
chromatography was carried out using Merck Kieselgel 60 (230–
400 mesh) under pressure. Infrared spectra were obtained on JAS-
CO FTIR 4200 spectrophotometer, from a thin film deposited onto a
NaCl glass. 1H NMR spectra were recorded in CDCl3, CD3OD, DMSO-
d6 and (CD3)2CO at ambient temperature on a Bruker AMX-400
spectrometer at 400 MHz with residual protic solvent as the inter-
nal reference (CDCl3, dH = 7.26 ppm; (CD3)2CO, dH = 2.05 ppm;
CD3OD, dH = 3.31 ppm; DMSO-d6, dH = 2.50 ppm); chemical shifts
(d) are given in parts per million (ppm), and coupling constants
(J) are given in Hertz (Hz). The proton spectra are reported as fol-
lows: d (multiplicity, coupling constant J, number of protons,
assignment). 13C NMR spectra were recorded in CDCl3 CD3OD,
DMSO-d6 and (CD3)2CO at ambient temperature on the same spec-
trometer at 100 MHz, with the central peak of CDCl3
(dC = 77.0 ppm), CD3OD (dC = 49.0 ppm), DMSO-d6 (dC = 39.4 ppm)
or (CD3)2CO (dC = 30.8 ppm) as the internal reference. The DEPT135
sequence was used to aid in the assignment of signals on the 13C
NMR spectra. Melting points were determined on a Stuart SMP10
apparatus. Elemental analyses were determined on a Carlo Erba
EA 1108 analyzer. MS experiments were performed on an APEX
III FT-ICR MS (Bruker Daltonics, Billerica, MA), equipped with a
7T actively shielded magnet. Ions were generated using an Apollo
API electrospray ionization (ESI) source (Bruker Daltonics, Billerica,
MA), with a voltage between 1800 and 2200 V (to optimize ionisa-
tion efficiency) applied to the needle, and a counter voltage of
450 V applied to the capillary. Samples were prepared by adding
a spray solution of 70:29.9:0.1 (v/v/v) methanol/water/formic acid
to a solution of the sample at a v/v ratio of 1–5% to give the best
signal-to-noise ratio. Data acquisition and data processing were
performed using the XMASS software, version 6.1.2 (Bruker
Daltonics). FAB experiments were performed on a VG AutoSpec
instrument, using 3-nitrobenzylalcohol or glycerol as matrix.
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6.2. General procedure for the oxidation of amines with Na2WO4
To a solution of amine (18.0 mmol) in EtOH (40 mL) at 0 °C were
added Na2WO42H2O (18 mmol), 30% H2O2 (16 mL) and H2O
(30 mL). The resulting mixture was stirred for 4 h at room temper-
ature and the reaction was quenched with aqueous saturated
NH4Cl and extracted with EtOAc (3). The combined organic
extracts were washed with brine, dried over Na2SO4 and evapo-
rated. The residue was purified by column chromatography on sil-
ica gel as indicated.
6.3. General procedure for the hydrolysis of esters
Lithium hydroxide (15 mmol) was added to a solution of ester
(1 mmol) in a 1:1 THF/H2O (16 mL) mixture. The solution was
stirred at room temperature for 2 h, neutralized with 10% HCl
and extracted with EtOAc (4). The combined organic layers were
washed with brine, dried over Na2SO4, filtered and the solvent was
evaporated in vacuo. Crystallization of the residue provided the de-
sired acid as indicated.
6.4. General procedure for the amidation of tyrosine acid
derivatives with amines
N-Hydroxyphtalimide (1 mmol) and DCC (1 mmol) were added
to a solution of the carboxylic acid (1 mmol) in dioxane (2.5 mL).
After the mixture had been stirred for 2 h at room temperature, a
solution of the amine (0.5 mmol), Et3N (2 mmol) and MeOH
(1 mL) was added. The resulting mixture was stirred for 12 h at
room temperature and the reaction was quenched with H2O and
extracted with EtOAc (3). The combined organic extracts were
washed with brine, dried over Na2SO4 and evaporated. The residue
was dissolved in THF, filtered off and the solvent was evaporated in
vacuo. The resulting residue was then purified by column chroma-
tography on silica gel as indicated.
6.4.1. (E)-Methyl 2-(hydroxyimino)-3-(4-
hydroxyphenyl)propanoate (3)88
Following the general procedure for the oxidation of amines
with Na2WO42H2O, L-tyrosine methyl ester 2 (3.45 g, 17.68 mmol)
gave, after purification by column chromatography (SiO2, 50:50
hexane/EtOAc), 2.24 g (60%) of oxime 3 as a white powder. 1H
NMR (CD3COCD3, 400.13 MHz): d 11.35 (s, 1H, OH), 8.11 (s, 1H,
OH), 7.11 (d, J = 8.5 Hz, 2H, ArH), 6.73 (d, J = 8.5 Hz, 2H, ArH),
3.84 (s, 2H, 2H3), 3.72 (s, 3H, CO2CH3) ppm.
6.4.2. (E)-Methyl 3-(3-bromo-4-hydroxyphenyl)-2-
(hydroxyimino)propanoate (4)61
A solution of NBS (0.49 g, 2.75 mmol) in CH3CN (6 mL) was
added dropwise over 15 min to the solution of the oxime 3
(0.58 g, 2.75 mmol) in CH3CN (6 mL). The reaction mixture was
stirred at room temperature for 5 h, after which time the solvent
was evaporated and the residue was treated with water and
extracted with EtOAc (3). The combined organic extracts were
dried over Na2SO4, filtered, evaporated and the residue was puri-
fied by column chromatography (SiO2, 50:50 hexane/EtOAc) to
afford oxime 4 (0.65 g, 82%) as a yellow powder. 1H NMR
(CD3COCD3, 400.13 MHz): d 11.49 (s, 1H, OH), 8.62 (s, 1H, OH),
7.44 (d, J = 1.6 Hz, 1H, H20), 7.13 (dd, J = 8.3, 1.6 Hz, 1H, H60), 6.90
(d, J = 8.3 Hz, 1H, H50), 3.85 (s, 2H, 2H3), 3.74 (s, 3H, CO2CH3) ppm.
6.4.3. (E)-3-(3-Bromo-4-hydroxyphenyl)-2-
(hydroxyimino)propanoic Acid (5)
In accordance with the general procedure for the hydrolysis of
esters, ester 4 (0.61 g, 2.11 mmol) gave, after purification by col-
umn chromatography (SiO2, 90:10 EtOAc/MeOH), 0.58 g (99%) of
acid 5 as a white powder, mp: 147–148 °C (hexane/CHCl3) (lit.
147–148 °C, dec.).89 1H NMR (CD3COCD3, 400.13 MHz): d 7.45 (s,
1H, H20), 7.14 (d, J = 7.9 Hz, 1H, ArH), 6.90 (d, J = 7.9 Hz, 1H, ArH),
3.84 (s, 2H, 2H3) ppm.
6.4.4. (2E,20E)-N,N0-[2,20-Disulfanediylbis(ethane-2,1-diyl)]bis[3-
(3-bromo-4-hydroxyphenyl)-2-(hydroxyimino)propanamide]
(psammaplin A, 1)56
Following the general procedure for the amidation of tyrosine
acid derivatives with amines, acid 5 (0.16 g, 0.59 mmol) afforded,
after purification by column chromatography (SiO2, gradient from
25:75 hexane/EtOAc to 95:5 CH2Cl2/MeOH), psammaplin A 1
(0.12 g, 60%) as a white foam. 1H NMR (CD3OD, 400.13 MHz) (data
for monomer): d 7.36 (s, 1H, H20), 7.07 (d, J = 8.3 Hz, 1H, ArH), 6.76
(d, J = 8.3 Hz, 1H, ArH), 3.79 (s, 2H, 2H3), 3.52 (t, J = 6.7 Hz, 2H,
2H10 0), 2.81 (t, J = 6.7 Hz, 2H, 2H20 0), 2.15 (br, 2H, OH) ppm.
6.5. Molecular modeling of psammaplin A
6.5.1. Quantum mechanics calculations
The geometry of the thiol derived from psammaplin A was opti-
mized using the ab initio quantum chemistry program Gaussian
0390 and the HF/3-21G* basis set. A set of atom-centred RHF 6-
31G*//3-21G* charges was then obtained by using the RESP meth-
odology91 as implemented in the AMBER suite of programs (http://
amber.scripps.edu/). Covalent and nonbonded parameters for the
inhibitor atoms were assigned, by analogy or through interpola-
tion, from those already present in the AMBER force field92
(parm99) or consistently derived, as explained in more detail
elsewhere.93
6.5.2. Molecular docking
The genetic algorithm94 implemented in AutoDock95 and the
h-HDAC8 (PDB code 1t64)70 as the target protein upon removal
of trichostatin A was used to generate different HDAC-Zn2+-bound
psammaplin A thiol conformers by randomly changing torsion an-
gles and overall orientation of the molecule. A volume for explora-
tion was defined in the shape of a three-dimensional cubic grid
with a spacing of 0.3 Å that enclosed the residues that are known
to make up the inhibitors binding pocket. At each grid point, the
receptor’s atomic affinity potentials for carbon, oxygen, nitrogen,
sulfur, bromine and hydrogen atoms present in the ligand were
precalculated for rapid intra- and intermolecular energy evaluation
of the docking solution.
To obtain additional validation of the proposed binding mode
for the ligands, the program GRID (http://www.moldiscovery.
com/96 was also used to search for sites on the enzyme that could
be complementary to the functional groups present in this inhibi-
tor. For the GRID calculations, a 18  21  21 Å lattice of points
spaced at 0.5 Å was established at the binding site. The probes used
were C1 = (aromatic carbon), N1 (neutral flat NH, eg amide), N:#
(sp nitrogen with lone pair), O (sp2 carbonyl oxygen) and Br
(bromine). The dielectric constants chosen were 4.0 for the macro-
molecule and 80.0 for the bulk water.
6.5.3. Molecular dynamics simulations
Ternary complexes (HDAC8-Zn2+-psammaplin A thiol) repre-
sentative of the most populated solutions were then refined using
the second generation AMBER force field and 3000 steps of steep-
est descent energy minimization and 6000 steps of conjugate
gradient of only the side chain of the protein and those atoms of
the bound ligand. This procedure allowed readjustment of covalent
bonds and van der Waals contacts without changing the overall
conformation of the complex. The HDAC-psammaplin A thiol com-
plex was then neutralized by addition of eight sodium ions97 that
were placed in electrostatically favored positions and immersed
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in rectangular boxes each containing about 450 TIP3P water mole-
cules98 that extended 1 Å away from any solute atom. The cutoff
distance for the non-bonded interactions was 9 Å, and periodic
boundary conditions were applied. Electrostatic interactions were
represented using the smooth particle mesh Ewald method with
a grid spacing of 1 Å. Unrestrained molecular dynamics (MD)
simulations at 300 K and 1 atm were then run for 6 ns using the
SANDERmodule in AMBER 8.99 The coupling constants for the tem-
perature and pressure baths were 1.0 and 0.2 ps, respectively.
SHAKE100 was applied to all bonds involving hydrogens, and an
integration step of 2 fs was used throughout. The nonbonded pair
list was updated every 10 steps. The simulation protocol involving
a series of progressive energy minimizations followed by a 20 ps
heating phase and a 70 ps equilibration period before data collec-
tion. System coordinates were saved every 2 ps for further analysis.
6.5.4. Analysis of the molecular dynamics trajectories
Three-dimensional structures and trajectories were visually in-
spected using the computer graphics program InsightII. The root-
mean-square (rms) deviations from both the initial structures
and the average structures, the inter-atomic distances, and the
snapshot geometries were obtained using the PTRAJ module in
AMBER. Intermolecular van der Waals energies for individual resi-
dues were calculated with the ANAL module, whereas the solvent-
corrected residue-based electrostatic interaction energies were
calculated with DelPhi, following the procedure described.93
All calculations were performed on the SGI R14000 Origin 3800
at CIEMAT (Madrid), on the SGI 1.5 GHz Itanium2 at CESGA (Santi-
ago de Compostela) and locally on SGI R12000 Octane
workstations.
6.6. Biological assays
6.6.1. Cell culture
Human leukaemia cell lines U937, K562 and HL60 were propa-
gated in RPMI medium supplemented with 10% FBS (Foetal bovine
serum; Hyclone) and antibiotics (100 U/mL penicillin, 100 lg/mL
streptomycin and 250 ng/mL amphotericin-B). Cells were kept at
the constant concentration of 200,000 cells per mL of culture
medium.
6.6.2. Ligands and materials
SAHA (Merck) and MS-275 (a kind gift of Bayer-Schering AG)
were dissolved in DMSO and used at 5  10ÿ6 M. All other com-
pounds described were dissolved in DMSO (Sigma-Aldrich) and
used at 5 and 50 lM.
6.6.3. Cell cycle analysis
2.5  105 cells were collected and resuspended in 500 lL of
hypotonic buffer (0.1% Triton X-100, 0.1% sodium citrate, 50 lg/
mL propidium iodide, RNAse A). Cells were incubated in the dark
for 30 min. Samples were acquired on a FACS-Calibur flow cytom-
eter using the Cell Quest software (Becton Dickinson) and analysed
with standard procedures using the Cell Quest software (Becton
Dickinson) and the ModFit LT version 3 Software (Verity) as previ-
ously reported.101,102 Apoptosis was revealed by monitoring nucle-
ar fragmentation (the so-called ‘sub-G1 DNA peak’) by FACS and
analysed by Cell Quest technology.
6.7. Caspase 3 activation assay
Caspase activity was detected in living U937 cells using the BIO-
MOL and B-BRIDGE Kits supplied with cell-permeable fluorescent
substrates. The fluorescent substrate for caspase 3 was FAM-
DEVD-FMK. ca. 1  106 cells were washed twice in cold PBS and
incubated for 1 h in ice with the corresponding substrates as rec-
ommended by the suppliers. The cells were analysed after washing
using the CellQuest software applied to a FACScalibur (BD). Exper-
iments were performed in duplicate and values were expressed as
mean ± SD.
6.7.1. Granulocyte differentiation
Granulocyte differentiation was carried out as previously de-
scribed.103 Briefly, U937 cells were harvested and resuspended in
10 lL phycoerythrin-conjugated CD11c (CD11c-PE). Control sam-
ples were incubated with 10 lL PE conjugated mouse IgG1 for
30 min at 4 °C in the dark, washed in PBS and resuspended in
500 lL PBS containing propidium iodide (0.25 lg/mL). Samples
were analyzed by FACS with Cell Quest technology (Becton Dickin-
son). Propidium iodide (PI) positive cells have been excluded from
the analysis.
6.7.2. Western blot analyses
Western blot analyses were performed according to standard
procedures following suggestions of antibody suppliers. For the
determination of p21WAF1/CIP1 50 lg of total protein extracts were
separated on a 15% polyacrylamide gels and blotted. Western blots
were shown for p21 (Transduction Laboratories, dilution 1:500)
and total ERKs (Santa Cruz) were used to normalize for equal load-
ing. For a-Tubulin acetylation 25 lg of total protein extracts were
separated on a 10% polyacrylamide gels and blotted. Western blots
where shown for acetylated a-tubulin (Sigma, dilution 1:500) and
total ERKs (Santa Cruz) or total tubulin (Sigma) were used to nor-
malise for equal loading.
6.8. Histone extraction protocol
Cells were harvested and washed twice with ice-cold PBS and
lysed in Triton Extraction Buffer (TEB: PBS containing 0.5% Triton
X 100 (v/v), 2 mM phenyl methyl sulfonyl fluoride (PMSF), 0.02%
(w/v) NaN3) at a cellular density of 10
7 cells per mL for 10 min
on ice, with gentle stirring. After a brief centrifugation at
2000 rpm at 4 °C, the supernatant was removed and the pellet
was washed in half the volume of TEB and centrifuged as before.
The pellet was resuspended in 0.2 M HCl at a cell density of
4  107 cells per mL and acid extraction was left to proceed over-
night at 4 °C on a rolling table. Next, the samples were centrifuged
at 2000 rpm for 10 min at 4 °C, the supernatant was removed and
protein content was determined using the Bradford assay.
6.9. Determination of histone H3 specific acetylations
For the histone H3 acetylation in U937 cells, 10 lg of histone
extract was separated on 15% polyacrylamide gels and blotted.
Western blots were shown for pan-acetylated histone H3
(Upstate).
6.10. Fluorimetric human recombinant HDAC1 assays
GST-HDAC1 has been cloned into the pAcG2T baculovirus trans-
fer vector (BD) and purified by using glutathione beads. The BD
BaculoGold transfection system (BD) has been used in Sf9 insect
cells for expression following supplier’s instructions. The HDAC as-
say has been carried out as follows: the HDAC Fluorescent Activity
Assay is based on the Fluor de Lys Substrate and Developer combi-
nation (BioMol) and has been carried out according to supplier’s
instructions. Briefly, the Fluor de Lys Substrate, which comprises
an acetylated lysine side chain, has been incubated with the puri-
fied recombinant HDAC enzymes in presence or absence of the
inhibitors, for 0.5 h at 37 °C. When a different incubation time
has been used, it is specified into the text. Deacetylation of the sub-
strate sensitizes the substrate so that, in the second step, treatment
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with the Developer for 30 min produces a fluorophore. The fluoro-
phore is excited with a 360 nm light and the emitted light
(460 nm) has been quantified with a TECAN Inphinite M200
station.
6.11. Human recombinant Sirt1 assay
Recombinant human Sirt1 was prepared in E. coli BL21 and puri-
fied by affinity chromatography. The enzymatic reaction consisted
of 1 lg of Sirt1 incubated with the acetylated p53 peptide (AA
379–382), 1 mM dithiothreitol, and a range of inhibitor concentra-
tions, as described. Reactions were carried out at 37 °C for 60 min.
Assays were performed in the presence of 200 lM NAD+ for each
inhibitor. Fluorescence was measured with a fluorimetric reader
(TECAN Inphinite M200 fluorescence plate reader) with excitation
set at 360 nm and emission detection set at 450 nm. Results are
expressed as the mean and standard deviation of four independent
experiments as percentage of activity considering the untreated
control as 100.
6.12. Human recombinant CBP assay
The recombinant CBP was prepared in E. coli BL21 and purified
by affinity chromatography. Recombinant CBP fraction corre-
sponded to amino acids 1098–1877. CBP was incubated in HAT
buffer with 10 lg of histone H4 peptide (corresponding to amino
acids 2–24) and 20 lM Acetyl CoA containing 0.5 lCi/mL [3H]-
Acetyl CoA in the presence of inhibitors. After 2 h a 37 °C, 5 lL of
samples were spotted onto Whatman P81 paper (in triplicate).
The paper squares were washed three times in 5% TCA and once
in 100% acetone and then placed into scintillation vials containing
scintillation fluid to allow the DPM reading. The DPM of enzyme
samples was compared to DPM of negative control. Data have been
expressed as percentage of activity considering the control without
treatment as 100.
6.13. Human recombinant DNMT3A radioactive assay
DNMT3A was produced in E. coli BL21 according to standard
procedures. The methyltransferase radioactive assay was per-
formed in a volume of 25 lL/point, using [3H]-adenosyl-L-methio-
nine (1 lCi) as methyl donor and Poly dI-dC (0.1 c) as methyl
acceptor, while 30–50 ng of recombinant DNMT3A protein was
used, depending on enzyme activity, stability and purity. The com-
pounds were tested at 50 lM. After 2 h incubation at 37 °C, 5 lL of
samples were spotted onto Whatman DE81 paper (in triplicate).
The paper squares were washed three times in 5% Na2HPO4 and
once in sterile water and then placed into scintillation vials con-
taining 5 mL of scintillation fluid to allow the DPM reading. The
DPM of enzyme samples was compared to the DPM of negative
control. Data were expressed as a percentage of activity relative
to control.
6.14. Immunoprecipitation of DNMT1 and radioactive assay
The K562 cells were cultured in the experimental conditions re-
ported and lysed in TAP buffer pH 7–7.5 (50 mM Tris pH 7.0,
180 mM NaCl, 0.15% v/v NP40, 10% v/v glycerol, 1.5 mM MgCl2,
1 mM Na2MoO4, 0.5 mM NaF, 1 mM DTT, 0.2 mM PMSF, 0.1 mM
protease inhibitor cocktail) for 10 min in ice and centrifuged at
130,000 rpm for 30 min. 650 lg of extracts were diluted in TAP
buffer up to 1 mL and pre-cleared by incubating with 20 lL A/G
plus agarose (Santa Cruz) for 30 min to 1 h on a rocking table at
4 °C. Supernatant was transferred to a new tube and 3–5 lg of anti-
body against DNMT1 (Abcam) was added. IP was allowed to pro-
ceed overnight at 4 °C on a rocking table. As a negative control
the same amount of protein extracts were immunoprecipitated
with purified IgG rabbit (Santa Cruz). The following day, 50 lL A/
G plus agarose were added and incubation was continued for 2 h.
The beads were recovered by brief centrifugation and washed with
cold TAP buffer several times. After the last washing 20 lL of 2X
concentrated electrophoresis sample buffer (217 mM Tris–HCl pH
8.0, 5.3% SDS, 17.4% glycerol, 8.7% b-mercaptoethanol, 0.026% bro-
mophenol blue) was added and the sample was boiled for 5 min. A
fraction of supernatants was loaded onto an SDS–PAGE gel in order
to check the immunoprecipitation product. 10 lL of resin binding
DNMT1 were used in DNMT radioactive assay (see above) to test
the inhibitory potency of the PsA derivatives.
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